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ABSTRACT 
 
Human immunodeficiency virus (HIV) infected children are at greater risk of 
developing tuberculosis disease, and might benefit from vaccination with 
novel TB vaccines. However, little is known about the effect of HIV-infection 
on function and phenotype of T cell responses to mycobacterial antigens in 
children. This study compares both CD4 and CD8 T cell cytokine expression 
and memory phenotype in children, following in vitro stimulation with 
mycobacterial antigens, also contained in novel anti-TB vaccines that are 
currently undergoing clinical trials. 
 
Blood was collected from 3 groups of children previously vaccinated with 
bacille Calmette-Guérin (BCG): HIV-unexposed healthy children (n=30), HIV-
seronegative children diagnosed with TB - who had been receiving standard 
anti-TB therapy (n=30) and HIV-infected children not on TB treatment (n=30). 
Blood was stimulated with Antigen 85B and TB10.4, purified protein derivative 
or early secretory antigenic target-6. Cytokine production and the memory 
phenotype of antigen-specific CD4 and CD8 T cells were determined by flow 
cytometry. Longitudinal analysis was performed on functional and memory 
phenotypes of HIV-infected children on antiretroviral therapy. Mycobacterial 
growth inhibition was assessed in whole blood from the HIV-infected group 
using a reporter gene tagged strain of Mycobacterium tuberculosis. 
 
Mycobacteria-specific CD4 and CD8 T cell responses were detectable in all 3 
groups. Children receiving TB treatment had significantly higher frequencies 
of antigen-specific CD4 T cells, compared with HIV-infected children 
(p=0.0176). We observed higher frequencies of CD4 T cells, expressing 
interferon-" (IFN-"), interleukin-2 (IL-2) or both, in children with TB, but no 
differences in memory phenotype between children with and without HIV-
infection. No significant differences in magnitude, function or phenotype of 
antigen-specific T cells were observed in HIV-infected children, compared 
with healthy controls. CD4 T cells expressing IFN-", IL-2 or both were of an 
effector memory phenotype. Mycobacteria-specific CD8 T cells expressed 
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mostly IFN-" in all groups; these cells also expressed an effector memory 
phenotype. Longitudinal follow-up of the HIV-infected children during the first 
12 months of antiretroviral therapy (ART) showed early immune restoration in 
total CD4 T cell percentages and naïve T cells. The proportion of effector 
memory cells declined significantly within 3 months of ART. Similarly, 
mycobacteria-specific IFN- " responses decreased within the first 3 months of 
ART. Peripheral blood mycobacterial growth inhibition increased over time in 
HIV-infected children on ART. 
 
Our data provide a detailed functional and phenotypic analysis of 
mycobacteria-specific T cell memory responses in HIV-infected and 
uninfected children, and the impact of ART. 
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CHAPTER 1 
 
Introduction and literature review 
 
1.1 Introduction 
 
Tuberculosis (TB) is an infectious disease, caused by Mycobacterium 
tuberculosis (M. tuberculosis). The current TB vaccine, bacillus Calmette-
Guérin (BCG), does not provide adequate protection against TB disease in 
children. Further, safer more efficacious TB vaccines are needed for children 
with immunodeficiencies such as human immunodeficiency virus (HIV) 
infection – this population is at highest risk of disease. These factors 
contribute to the need for intensified research in the field of TB vaccine 
development. This chapter summarises a comprehensive review of published 
literature. 
 
1.2 Epidemiology of tuberculosis 
 
1.2.1 Global burden of tuberculosis 
 
TB causes the deaths of almost two million people globally per annum. It is 
especially endemic in developing countries (Figure 1.1 A), where HIV 
infection is also most prevalent (Figure 1.1 B). The World Health 
Organisation (WHO) estimated that in 2009 there were 9.4 million incident 
cases of TB in the world (WHO, 2010a). HIV-infection was estimated to occur 
in 12% of the incident cases; 80% of these HIV-positive cases were living in 
Sub-Saharan Africa (WHO, 2010a). The two epidemics fuel each other and 
significantly contribute to mortality from infectious diseases worldwide 
(Sharma et al., 2005). TB is the leading cause of death among people who 
are HIV-positive (Harries et al., 2001). HIV is the single most important factor 
contributing to the increase in incidence of TB in Africa (Figure 1.1 B) (WHO, 
2010a). Sonnenberg et al. showed that the risk of TB doubles within a year of 
infection with HIV in a cohort study in South African gold miners (Sonnenberg 
et al., 2005). 
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The development of M. tuberculosis strains with drug resistance in the 
population heightens concerns of future control of the TB epidemic. In 2008, 
the WHO reported over 440,000 cases of multidrug resistant TB (MDR-TB) 
(WHO, 2010a). MDR strains of M. tuberculosis are resistant to at least the two 
main first-line anti-TB drugs, rifampicin and isoniazid (Palmero et al., 2003) 
Resistance to anti-TB drugs is primarily the consequence of suboptimal TB 
care and control programmes, including weak health systems. The 
contributing factors to this problem include incorrect drug prescribing practices 
by providers (e.g. choice of drugs, dosage, duration of treatment), programme 
factors (e.g. irregular supply of drugs), and most importantly, patient factors 
(e.g. patient non-adherence to drug regimens) (Chaulet et al., 1995). 
Emergence of Extensively Drug Resistant TB (XDR-TB), poses a serious 
threat to TB control (Gandhi et al., 2006). XDR-TB strains are resistant to any 
fluoroquinolone, and at least one of three injectable second-line drugs, 
capreomycin, kanamycin, and amikacin, in addition to rifampicin and isoniazid 
(Shah et al., 2007). These forms of the disease have high mortality, 
particularly in HIV co-infection and are challenging and expensive to treat 
(Gandhi et al., 2006; Shah et al., 2007). 
 
1.2.2 Tuberculosis in South Africa 
 
TB continues to be a scourge in South Africa, with extremely high disease 
burden, incidence rates and HIV co-infection rates (WHO, 2010a). The current 
epidemic is exacerbated by the growing epidemics of MDR-TB and XDR-TB 
(Cohen et al., 2010). South Africa is ranked 3rd in the world for incident 
cases, out of 22 high-burden TB countries. The WHO registered an incidence 
of 970 cases per 100,000 population in 2009, and 60% of these new TB 
cases were HIV-positive (WHO, 2010a). The problem is compounded by the 
legacy of fragmented health services, which are still very poor in many areas, 
in both cities and rural areas. The co-existence of TB and HIV infection has 
led to escalating TB rates in the South African province of KwaZulu-Natal, 
which has overtaken the Western Cape province for the highest rates of TB 
(Abdool Karim et al., 2009; Cohen et al., 2010). Increased drug resistance 
threatens the achievements of TB directly observed treatment strategy 
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(DOTS) programmes and antiretroviral therapy (ART) distribution 
programmes (Abdool Karim et al., 2009). Despite improvement in the TB 
control programme since its introduction in 1996, stringent measures must be 
taken in its implementation to ensure continued improvement in overall TB 
control including, diagnosis, treatment and case finding. 
 
 
 
 
 
Figure 1.1: Tuberculosis burden 
(A) Global picture of tuberculosis – New TB cases per 100, 000 people in 2009. (B) 
Prevalence of HIV in Tuberculosis. Adapted from (WHO, 2010a). 
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1.3 Mycobacterium tuberculosis 
 
More than a century ago Robert Koch identified M. tuberculosis as the 
causative agent of human TB (Koch, 1982). M. tuberculosis can infect a wide 
variety of animals but man is the principal host. Other disease causing 
mycobacteria within the M. tuberculosis complex includes: M. bovis, M. 
africanum, M. canetti and M. microti (Chimara et al., 2004). However, these 
species are less common in the human host. M. tuberculosis is a highly 
aerobic, rod-like, acid-fast bacterium. The high lipid content of the bacterial 
cell wall and the waxy coating of the cell surface (primarily consisting of 
mycolic acid) makes the cell resistant to Gram staining, and acid-fast 
techniques are used instead (Shapiro and Perlmutter, 2008). Figure 1.2 
shows that bacteria retain a bright red colour after staining with carbolfuchsin, 
and are resistant to decolourisation with acid alcohol (hydrochloric acid and 
ethanol), which is known as a Ziehl-Neelsen stain (CDC, 1979). 
 
The mycobacterial genome is a single chromosome in a closed loop. The 
complete genome sequence of the virulent strain, H37Rv, was published in 
1998 (Cole et al., 1998). It consists of 4,411,529 base pairs encoding around 
4000 genes. Several factors make M. tuberculosis a difficult organism to study 
in the laboratory, hindering TB research: the bacteria multiply very slowly, only 
once every 18 to 24 hours, and can take more than a month to form colonies 
in culture. The tubercle bacilli tend to form clumps, making it difficult to 
enumerate numbers of bacilli. Most discouraging, M. tuberculosis is a 
dangerous, airborne organism and can only be studied in laboratories that 
have specialized biosafety level 3 (BSL3), safety equipment and facilities. 
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Figure 1.2: Mycobacterium tuberculosis Ziehl-Neelsen stain 
Sputum smear after Ziehl-Neelsen staining showing acid-fast bacilli (red rods) retain 
bright red dye after washing with acid alcohol. Downloaded from (CDC, 1979). 
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1.4 Pathogenesis 
 
TB is transmitted in the form of aerosol droplets inhaled into the lungs. When 
a person with active lung TB (smear-positive TB) coughs, sneezes, talks or 
even spits, they propel mycobacterium into the air (WHO, 2010d). Pulmonary 
or lung TB is the most common form of the disease and is characterised by a 
cough (with bloody sputum in the advanced stage) lasting more than 3 weeks, 
accompanied by weakness or fatigue, chest pain, weight loss, fever and/or 
night sweats (WHO, 2010b). The infection can also spread via the 
bloodstream, becoming miliary or disseminated TB, and affecting many 
organs including the meninges, the bones, or the internal organs. Once inside 
the respiratory tract, complex interactions occur between the pathogen and 
the host immune system (Schluger and Rom, 1998). The virulence of the 
organism together with the non-specific and specific immune responses of the 
host, determine the clinical outcome. 
 
Infection with the organism can lead to 1) immediate elimination, 2) immediate 
disease (primary TB), 3) indefinite dormancy inside the host (latent infection), 
or 4) disease many years later (secondary TB), often in the context of relative 
or overt immunosuppression (Kaufmann and McMichael, 2005). Figure 1.3 
illustrates the possible outcomes after exposure to M. tuberculosis (Kaufmann 
and McMichael, 2005). The majority of immunocompetent people (90%) will 
not develop TB disease after exposure. These individuals can mount an 
effective immune response to the initial encounter, which limits multiplication 
of the bacilli. Long lasting, albeit partial, immunity is achieved, both to control 
further infection and reactivation of latent bacilli. Only 10% will go on to 
develop pulmonary or non-pulmonary forms of TB. Secondary TB 
(reactivation disease) is usually due to the reactivation of old lesions 
(Lillebaek et al., 2002; Manabe and Bishai, 2000). M. tuberculosis microfoci 
that have remained dormant after primary infection (latent TB) may undergo 
reactivation at a later time leading to secondary TB. Recent evidence 
suggests that exogenous re-infection is responsible for a significant proportion 
of TB observed in high incidence countries. (Caminero et al., 2001). Latent TB 
has recently been described as a broad spectrum of conditions from low 
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grade TB, non-progressing percolating infection, to dormant infection (Barry et 
al., 2009; Lin and Flynn, 2010). 
 
 
 
 
 
 
Figure 1.3: Schematic diagram showing possible outcomes after M. tuberculosis  
exposure 
(A) Spontaneous healing is rare to absent. (B) Primary disease occurs most notably 
in the presence of immunodeficiency (e.g. HIV-infection). (C) Containment of 
infection inside granulomas occurs in 90% of infected individuals. Granulomas 
consist of infected macrophages and dendritic cells, which present mycobacterial 
antigens to CD4 T cells, CD8 T cells, gamma delta (!") T cells and CD1-restricted T 
cells. M. tuberculosis is killed by IFN-! and tumour necrosis factor-# (TNF-#) 
activated macrophages or via perforin and granulysin. (D) Secondary disease due to 
reactivation or reinfection may occur at a later time. Adapted from (Kaufmann and 
McMichael, 2005). 
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1.5 Tuberculosis treatment 
 
Tuberculosis treatment involves daily combination therapy for the duration of 
6 to 12 months, depending on the clinical manifestations of TB. The treatment 
is usually divided into 2 phases: 2 months of 3-4 drugs to rapidly decrease 
bacillary load and then followed by a maintenance phase with 2 drugs for the 
remainder to kill off remaining organisms. The routinely used first line drugs 
include isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E) and 
streptomycin (S). These drugs have high microbicidal effect and an 
acceptable safety profile. The advantages of using combination therapy are 
(1) to prevent emergence of resistant bacilli, (2) drugs like H and R may act 
synergistically, (3) Z is most effective when bacteria are actively replicating in 
the initial stages of therapy, (4) duration of treatment is reduced, and (5) to act 
simultaneously on all subpopulations of M. tuberculosis (faster and slower 
growing organisms) (Marais et al., 2006). Second line drugs are only used in 
instances of drug resistance to the first line drugs, which have lower anti-TB 
effect, higher toxicity or both. The WHO recommends the same regimen and 
duration of treatment in HIV-infected individuals as in HIV negative 
individuals. Drug susceptibility testing is now recommended at initiation of 
therapy in previously treated TB patients as well as TB/HIV co-infected 
patients (WHO, 2010c). 
 
1.6 Childhood tuberculosis 
 
1.6.1 Tuberculosis in the immunocompetent child 
 
Approximately one million children are estimated to develop TB globally every 
year (Nelson and Wells, 2004; Walls and Shingadia, 2004; Newton et al., 
2008). The source of transmission of M. tuberculosis to children most often is 
a household source case, usually a parent or other adult family member 
(Shah et al., 2006). Other adults in the community may also be a source of 
childhood TB (Schaaf et al., 2003). Children rarely transmit bacilli to each 
other because of lower bacterial loads. Infants and young children are at 
much higher risk of developing disseminated infection after primary 
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tuberculosis and particularly tuberculosis meningitis, which has the highest 
mortality (Marais et al., 2006). HIV infection markedly increases this risk 
(Lawn and Churchyard, 2009) and infected children have increased mortality 
(Madhi et al., 2000) compared with HIV-negative children (Swaminathan, 
2004). 
 
The diagnosis of childhood TB is more difficult than adult TB. Children have 
nonspecific symptoms, chest x rays are less specific, it is difficult to obtain 
sputum samples from children and their lower bacterial loads in sputum 
makes smear and culture less effective (Marais et al., 2006). Improved 
diagnostic methods are urgently required for childhood disease. Development 
of drug resistance is less common in children because of their low bacterial 
load (Schaaf et al., 2000). Multidrug resistant tuberculosis is therefore almost 
always acquired from adults (Schaaf, 2007). The continued increase in 
childhood cases of TB represents ongoing transmission of M. tuberculosis in 
the community. 
 
1.6.2 Tuberculosis in the HIV-infected child 
 
Immune suppression, most commonly due to HIV infection, greatly enhances 
the risk of primary or latent infection progressing to active TB (Cantwell and 
Binkin, 1997; Jeena et al., 2002; Lawn and Churchyard, 2009). Although most 
HIV-related TB is due to reactivation of latent infection in adults, primary 
disease of all clinical types also occurs, particularly in children (Mukadi et al., 
1997). HIV-related TB differs from the classical types in that, as immune 
responses are suppressed, there is limited walling-off of the lesions. This 
encourages local spread as well as widespread dissemination of disease. 
More specifically, HIV-infection results in the loss of CD4 T cells. This 
includes mycobacteria-specific CD4-T cells, and comprehensive disturbances 
of all areas of immune function, from antigen-presentation to adaptive 
responses, driven by T cells. Increases in HIV viral load in serum and 
macrophages (Mø) following M. tuberculosis infection has been observed, as 
well as a switch from Th1 to Th2 dominance via alterations in IL-10, regulatory 
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T cells, IL-12, IL-4, and TNF, leading to loss of granuloma integrity, and 
progression to active TB (Djoba Siawaya et al., 2007). 
 
The hallmark of HIV-infection is the ongoing loss of CD4 T lymphocytes. If 
untreated, this ultimately promotes the development of Acquired 
Immunodeficiency Syndrome (AIDS) and increased susceptibility to 
opportunistic infections. HIV infection and AIDS also complicate diagnosis of 
TB markedly. The Mantoux test, which measures sensitisation to 
mycobacterial antigens and is considered one of the mainstays of TB 
diagnosis in childhood, is significantly less sensitive in HIV infection. A 
retrospective study by Jeeana et al. showed Mantoux positivity in 18% of 
TB/HIV co-infected children compared with 48% in a group of non-HIV-
infected TB infected children (Jeena et al., 2002). Both groups of children 
were recruited from the same public hospital that receives referrals from a 
population of 3–4 million children. Hence, it has been proposed that 5 mm 
induration on Mantoux testing instead of 10 mm can be used as the cut-off for 
positive result in HIV-infected individuals and AIDS patients. HIV-infected 
individuals and AIDS patients receive the same TB treatment as HIV negative 
TB patients. Strict follow-up with chest radiographs and follow-up cultures for 
M. tuberculosis is highly recommended. 
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1.7 Immunity to tuberculosis 
 
1.7.1 Host response to Mycobacterium tuberculosis 
 
After inhalation of circulating aerosol droplets containing infective 
mycobacteria, initial infection is established in resting Mø lining the alveolar 
spaces of the lungs (Henderson et al., 1963). Recognition and uptake of 
microbial products is facilitated by pattern recognition receptors (PRR) (Akira 
et al., 2006). These receptors recognise conserved pathogen associated 
molecular patterns (PAMPs) on microbes, such as lipoarabinomannan (LAM), 
lipopolysaccharide (LPS) and bacterial lipoteichoic acid (Medzhitov and 
Janeway, 2000; Medzhitov, 2007). Individual PRRs have distinct expression 
patterns, bind to specific ligands (PAMPs), activate signaling pathways and 
trigger anti-pathogen host responses, such as activation of proinflammatory 
cytokines (e.g. TNF, and interleukin IL-12, co-stimulatory molecules, or type I 
IFN) (Akira et al., 2006). PRRs are surface or cytosolic molecules, and include 
complement receptors, mannose receptors (Schlesinger, 1993; Ernst, 1998), 
scavenger receptors (Ernst, 1998), Toll-like receptors (TLRs) (Thoma-
Uszynski et al., 2001) and nucleotide-binding oligomerisation domain (NOD)–
like receptors (NLRs) (Ferwerda et al., 2005; Fritz et al., 2006). 
 
The first line of defence after inhalation of M. tuberculosis is represented by 
Mø, dendritic cells (DC) and possibly neutrophils, which may destroy the 
intracellular bacteria using microbicidal properties (van Crevel et al., 2002; 
Kisich et al., 2002; Eum et al.). Mø are equipped with machinery to kill and 
degrade ingested microorganisms. In the mouse macrophage the oxidative 
burst leads to production of highly microbicidal reactive oxygen intermediates 
(ROI) and reactive nitrogen intermediates (RNI) (Ding et al., 1988; Akaki et 
al., 2000). Lysosomal enzymes may also degrade pathogens in an acidic 
environment after phagolysosomal fusion (Schaible et al., 1998). However, M. 
tuberculosis has co-evolved with the human host and has developed multiple 
strategies to evade destruction by Mø. Described mechanisms include the 
prevention of acidification of the phagosome and prevention of 
phagosome/lysosome fusion (Deretic et al., 2006; Vandal et al., 2009). 
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Armstrong and Hart cultured mouse macrophage monolayers containing 
Ferritin-labelled lysozymes with a viable or gamma irradiated (inactivated), 
virulent strain of M. tuberculosis (H37Rv) (Armstrong and Hart, 1971). 
Electron microscopy revealed a marked tendency for the phagosomes 
containing viable bacilli not to have fused with ferritin-marked lysosomes 
compared with the inactivated bacilli. This allowed the viable bacilli to survive 
and multiply within the infected cell. Phagolysosomes are characteristically 
acidic (below pH 5.5) and are rich in hydrolytic enzymes. The low pH 
enhances host defenses by inhibiting microbial growth and enhancing the 
activity of degrading enzymes. Thus by preventing phagosome/lysosome 
fusion the bacilli avoid direct exposure to the toxic contents of these 
organelles. 
 
When Mø fail to destroy the mycobacteria, the host's immune system second 
line of defence is to limit mycobacterial growth inside granulomas (Figure 
1.4), the hallmark of TB pathology (Ulrichs and Kaufmann, 2006). The host’s 
innate immune response is crucial for the initial stages of defence (van Crevel 
et al., 2002; Bhatt and Salgame, 2007). However, it is the adaptive immune 
response that is required when infection persists. Monocytes, Mø, epitheloid 
cells, neutrophils, T cells and natural killer cells are recruited to the site of 
infection. These cells form a granulomatous wall around the infected Mø 
(Figure 1.4) (Ulrichs and Kaufmann, 2006). Infected epitheloid cells fuse to 
form multinucleated Langerhans cells. The centre of the granuloma is 
sometimes characterized by caseation necrosis, more especially in 
progressive disease. IFN-! producing antigen-specific CD4 T cells activate, 
infected Mø to kill mycobacteria (Chan et al., 1992). CD8 T cells are also 
important in chronic infection (van Pinxteren et al., 2000). A less than optimal 
cell-mediated host immune response leads to poor granuloma formation, 
characterized by uncontrolled M. tuberculosis replication within phagocytic 
cells and subsequent development of TB disease. The exact immune factors 
and mechanisms that lead to the successful or unsuccessful immune 
response to M. tuberculosis infection are poorly understood. Comprehension 
of these factors and mechanisms would greatly accelerate the process of 
developing more effective TB vaccines. 
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Figure 1.4: Host response and granuloma formation 
Macrophages (Mø) and epitheloid cells are at the centre of the granuloma. The latter 
fuse to form giant Langerhans cells. These infected cells present antigens to T cells. 
CD4 T cells are activated to produce cytokines such as IFN-! and chemokines. IFN-! 
activated antigen-presenting cells kill the intracellular bacteria via reactive oxygen 
intermediates (ROI) or reactive nitrogen intermediates (RNI). Lymphocytes are 
recruited from blood and migrate to the site of infection in response to chemokines 
CD4+ T cells and Mø produce TNF-" and lymphotoxin-" 3 (LT" 3), which are 
required for formation of the wall surrounding the granuloma. In the centre of the 
granuloma, low oxygen forms a hostile environment for mycobacteria. Activated 
CD8+ T cells kill mycobacteria by means of granulysin and perforin. Adapted from 
(Ulrichs and Kaufmann, 2006). 
 
 
1.7.2 Innate responses against mycobacteria 
 
Innate immunity is described as the first step of host responses following 
antigen exposure. It is described as rapid, lacks antigen-specific qualities and 
does not create immunological memory. The contribution of the innate 
response to TB is beyond the scope of this literature review and is only briefly 
addressed. M. tuberculosis first encounters obstacles of innate immunity such 
as antimicrobial peptides (e.g. defensins, cathelicidins) and proteins (e.g. 
lactoferrin, lysozyme) in airway secretions with both bactericidal and 
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immunomodulatory effects (Ganz, 2002). These peptides and proteins are 
produced by multiple cell types; including neutrophils, monocytes, Mø, T cells 
and epithelial cells (Ganz, 2002; Yang et al., 2001). They are present in the 
airways from the early neonatal period, however their role in paediatric TB is 
yet to be established (Yoshio et al., 2004; Zasloff, 2003). 
 
M. tuberculosis infects human alveolar epithelial cells (Bermudez and 
Goodman, 1996) and induces production of $-defensins, which participate in 
bacillary killing (Rivas-Santiago et al., 2006). Mø acquire human neutrophil #-
defensins (HNPs) released from apoptotic neutrophils upon ingestion of these 
cells, which results in killing of the intracellular bacilli (Tan et al., 2006). TNF-# 
secreted by Mø, in turn, can stimulate neutrophil antimicrobial activity (Kisich 
et al., 2002). Neutrophils are abundant in the BAL fluid of adults with 
pulmonary tuberculosis and frequently contain mycobacteria in an active state 
of division (Eum et al., 2010). When stimulated with mycobacterial antigens, 
neutrophils produce cytokines and chemokines, such as IL-8 and macrophage 
inflammatory protein-l# (MIP-l#) (Kasahara et al., 1998). IL-8 attracts more 
neutrophils and lymphocytes, and (MIP-l#) attracts and activates 
monocytes/Mø. Thus, neutrophils can potentially influence adaptive immune 
responses. These observations suggest a substantial role for neutrophils in 
the control and/or pathogenesis of M. tuberculosis infection. 
 
1.7.3 Initiation of adaptive immunity through antigen processing and 
presentation 
 
Having survived the first obstacles of innate effector mechanisms, M. 
tuberculosis is readily phagocytosed by resident alveolar Mø and DCs (van 
Crevel et al., 2002). DCs are extremely proficient antigen presenting cells 
(APC). They have a crucial role in the initiation of the antigen-specific T cell 
response to pathogen (Banchereau and Steinman, 1998; Henderson et al., 
1997; Giacomini et al., 2001). 
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Researchers have identified DC-specific intercellular adhesion molecule-3 
grabbing nonintegrin (DC-SIGN) as the major receptor for M. tuberculosis 
entry into human DCs, in addition to CR3 and mannose receptor (Geijtenbeek 
et al., 2003; Tailleux et al., 2003; Kaufmann and Schaible, 2003). 
Internalisation of M. tuberculosis is initiated by binding of DC-SIGN to 
mannose-capped lipoarabinomannan (Man-LAM), a major component of the 
mycobacterial cell wall. This process results in activation and maturation of 
the DC and is characterised by upregulation of major histocompatability 
complex (MHC) class I and II molecules, co-stimulatory molecules, CD54, 
CD40, and B7.1 (CD80) and secretion of IL-1, IL-12 and TNF-# (Henderson 
et al., 1997; Giacomini et al., 2001). Activated DCs migrate to the draining 
lymph nodes where they present processed M. tuberculosis antigens on 
surface MHC class II to naïve CD4 T cells and MHC class I to naïve CD8 T 
cells. Cytokines such as IL-12 stimulate the proliferation and differentiation of 
naïve T cells, thereby inducing the adaptive immune response (Hamza T, et 
al., 2010). In addition to the recruitment of CD4 T cells by the action of IL-12 
from Mø and DCs, this cytokine recruits multiple other cell types to the 
locality, such as natural killer (NK) cells and !" T cells, which also secrete 
cytokines to activate infected Mø. 
 
Each MHC class II molecule is composed of a heterodimer of two 
transmembrane glycoproteins, the " and # chains (van Niel et al., 2008). This 
molecule is synthesized in the endoplasmic reticulum (ER) and binds with 
trimers of the invariant chain (Ii). Association of MHC II with the Ii prevents 
MHC-peptide binding in the ER (Roche and Cresswell, 1990; Stumptner and 
Benaroch, 1997). The Ii then facilitates the transport of MHC class II 
molecules from the ER to acidic endosomal compartments (Lamb et al., 
1991). Once in the endosome, lysosomal proteases degrade the Ii chain into 
a smaller fragment known as the class II associated Ii chain peptide (CLIP), 
which remains attached to the MHC-peptide groove (Villadangos, 2001). 
Binding of the MHC-CLIP complex to the human leukocyte antigen (HLA)-DM 
frees the CLIP and allows loading of peptides onto the MHC class II molecule 
(Roche, 1995; Kropshofer et al., 1997). MHC-peptide complexes are then 
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transported to the cell membrane for presentation of these exogenously 
derived antigens to naïve CD4 T cells. 
 
In contrast, MHC class I molecules present peptides to CD8 T cells, 
generated from predominantly endogenous proteins produced in the cytosol 
(Rock and Goldberg, 1999; Pamer and Cresswell, 1998). Intracellular 
organisms such as M. tuberculosis are enclosed within phagosomal 
compartments and this separates bacterial proteins from the cytosol (Deretic 
and Fratti, 1999; Vergne et al., 2004). Despite this, several researchers have 
observed CD8 T cell responses to M. tuberculosis antigens (Serbina and 
Flynn, 1999; Smith et al., 2000). Mechanisms of presentation of these 
mycobacterial peptides to CD8 T cells include cross-presentation and cross-
priming (Figure 1.5) (Kaufmann and Schaible, 2005). 
 
In cross-presentation, mycobacterial proteins such as ESAT-6 and CFP-10 
(with membrane-disrupting properties), escape from the phagosome into the 
cytosol (Figure 1.5 A.i). Escape into the cytosol leads to degradation of these 
mycobacterial proteins by the proteasome (Figure 1.5 A.ii): the classical 
MHC I pathway. Bacterial peptides are then transported back into the 
phagosome by transporters associated with antigen processing (TAP, Figure 
1.5 A.iii), where loading onto MHC class I (Figure 1.5 A.iv) occurs via ER-
mediated phagocytosis (Gagnon et al., 2002; Guermonprez et al., 2003; 
Ackerman et al., 2003; Houde et al., 2003). Cross-priming, at least of 
mycobacterial antigens is proteasome-independent (Schaible et al., 2003). 
This process requires antigen translocation from infected Mø to bystander 
DCs (Kaufmann and Schaible, 2005). This may occur when M. tuberculosis 
infected Mø undergo apoptosis, release apoptotic blebs containing bacterial 
antigens (Figure 1.5 B.i) that are then taken up by DCs (Figure 1.5 B.ii) 
(Schaible et al., 2003; Winau et al., 2004; Winau et al., 2005; Winau et al., 
2006). Apoptotic blebs fuse with lysosomes, bacterial antigens are degraded 
and peptides are transported via TAP into the ER (Figure 1.5 B.iii). These 
peptides are then loaded onto MHC class I (Figure 1.5 B.iv), or CD1 
molecules (Figure 1.5 B.v). DC migrate to the lymph nodes and prime CD8 T 
cells by presenting antigen on MHC class I molecules. 
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Intact antigen processing and presentation machinery are important for 
efficient priming of CD4 and CD8 T cell responses to M. tuberculosis. Efficient 
priming of specific T cell populations is thought to be central for new vaccines 
to be effective. 
 
 
 
Figure 1.5: Bacterial peptide processing and presentation to CD8 T cells 
Priming of CD8 T cells with exogenously derived antigens occurs through 
mechanisms of (A) Cross-presentation and (B) cross-priming on MCH class I 
molecules. In cross presentation, antigens are loaded onto MHC class I molecules 
from the same cell. In cross-priming antigens from infected macrophages are 
translocated to nearby DCs and loaded onto MHC I molecules. Adapted from 
(Kaufmann and Schaible, 2005). 
 
Th1 type cytokines such as IFN-! and TNF-# are critical for effective immunity 
against M. tuberculosis infection (Newport et al., 1996; Keane et al., 2001). IL-
17 a Th17 cytokine, may contribute to inflammation induction of antimicrobial 
peptides and recruitment of Th1 cytokine producing CD4 T cells, resulting in 
inhibition of M. tuberculosis growth in the lungs of mice (Lockhart et al., 2006). 
This suggests a role for the Th17 response in triggering of Th1 cells and 
subsequent macrophage and effector T cell activation at the primary site of 
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TB infection. Th17 cells are a T cell subset with significant proinflammatory 
functions. 
 
In contrast to a Th1/Th17 response, a Th2 response characterised by IL-4, IL-
5 and IL-13 production has been associated with a reduced Th1 response 
(Lienhardt et al., 2002; Rook, 2007). IL-10, an anti-inflamatory cytokine and 
transforming growth factor beta (TGF-$) production by T regulatory cells (Treg) 
inhibit Th1, Th2 and Th17 subsets. TGF-$ is associated with increased 
dissemination of M. tuberculosis (Sharma et al., 2009). However, this remains 
controversial, and may simply reflect a response to the inflammation driven by 
the pathogen. 
 
1.7.4 Cell mediated adaptive responses against mycobacteria 
 
An effective immune response to TB requires activation of infected Mø by 
antigen-specific T cells and killing of intracellular tubercle bacilli (Cooper and 
Flynn, 1995). Murine gene knockout experiments have shown that IFN! is a 
crucial activating cytokine (Cooper et al., 1993; Flynn et al., 1993). Human 
studies have shown that antigen-specific CD4 T cells are critical, since 
impairment of CD4 T cell responses, as seen during HIV infection, leads to 
increased susceptibility to TB (Elliott et al., 2004). CD8 T cells may also be 
important for immunity to TB (Derrick et al., 2004; Billeskov et al., 2007; Bruns 
et al., 2009; Chen et al., 2009). TB vaccine induced CD4 and CD8 T cell 
responses have therefore been major read-outs in clinical trials. 
 
1.7.4.1 CD4 T cells 
 
Once primed in the lymph node, MHC class II restricted M. tuberculosis-
specific CD4 T cells are recruited to the site of infection and produce Th1 type 
cytokines such as IFN!, TNF-" and IL-2. IFN! is a crucial effector molecule 
and together with TNF-" activates infected Mø to kill or control intracelluar 
organisms. Both murine and human studies have shown that CD4 T cells 
have an essential role in protective immunity to M. tuberculosis. Mice deficient 
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in MHC II or CD4 T cells demonstrate an impaired ability to control infection 
and succumb to TB (Caruso et al., 1999; Mogues et al., 2001). Orme et al. 
demonstrated that adoptive transfer of CD4 T cells conferred protection 
against M. tuberculosis in T cell deficient mice (Orme and Collins, 1983). 
Human studies in purified protein derivative (PPD) positive individuals showed 
increased recruitment of IFN-! producing antigen-specific CD4 T cells to the 
lung after bronchi challenge with recall antigens (Walrath et al., 2005). 
Although CD8+ T cells also secrete this cytokine, CD4+ T cells constitute the 
major source of this protein. While it is clear that CD4 T cells and Th1 
cytokines are critical in the cell-mediated response to M. tuberculosis, it is 
also apparent that this part of the immune response alone is not enough. 
Improved laboratory assays have allowed the simultaneous measurement of 
T cell populations and cytokines in small blood samples. This has led to the 
discovery that T cell subsets, cytokines, and chemokines may be important in 
immunity to TB. 
 
1.7.4.2 CD8 T cells 
 
CD8 T cells recognise mycobacterial peptides associated with MHC class I 
via cross-presentation or cross-priming mechanisms (Kaufmann and 
Schaible, 2005). Although there are conflicting views on the role of CD8 T 
cells in M. tuberculosis immunity, data supporting their importance is 
increasingly compelling. Chen et al. recently demonstrated a role for CD8 T 
cells in a non-human primate model of TB (Chen et al., 2009). They reported 
that depletion of CD8 T cells in BCG-vaccinated rhesus macaques led to a 
significant decrease in vaccine-induced immunity against tuberculosis. Also, 
depletion of CD8 T cells in macaques previously infected with M. tuberculosis 
and then cured by antibiotic therapy, also resulted in a decrease in control of 
M. tuberculosis re-infection. Work by Bruns et al. demonstrated that treatment 
of autoimmune diseases with anti-TNF antibodies in humans was associated 
with decreased frequencies of CD8 effector memory T cells as well as 
decreased in vitro antimicrobial activity against M. tuberculosis. The in vitro 
antimicrobial activity was recovered when PBMC from patients with anti-TNF 
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therapy were supplemented with CD8+CCR-CD45RA+ effector memory T cells 
(Bruns et al., 2009). 
 
CD4 and CD8 T cells produce cytokines that activate Mø and lead to 
granuloma formation (IFN! and TNF"). Both CD4 and CD8 T cells also have 
direct-cytotoxic activity and express microbicidal molecules (perforin and 
granulysin) (Cho et al., 2000; Murray et al., 2006). Granulysin granules are 
produced by CD8 T cells, NK cells and !" T cells and can kill extra-and 
intracellular mycobacteria, in conjunction with perforin (Stenger et al., 1998; 
Woodworth et al., 2008). M. tuberculosis specific CD8 T cells are expanded in 
adults (Caccamo et al., 2009) and children (Jacobsen et al., 2007) with TB, 
suggesting that CD8 T cells contribute to the protective immune response 
against M. tuberculosis. Carranza et al. have demonstrated that autologous 
CD8 T cells obtained from healthy household contacts of patients with active 
pulmonary tuberculosis significantly increased the capability of infected Mø to 
limit the growth of M. tuberculosis (Carranza et al., 2006). However, more 
research is needed to understand their role in protection against TB more 
comprehensively. 
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1.8 Type 1 cytokines 
 
The majority of people exposed to M. tuberculosis mount a protective immune 
response that controls infection. However, our knowledge about biomarkers, 
which can be used as correlates of protection against tuberculosis remains 
limited (Mittrucker et al., 2007; Wallis et al., 2010). Although no definite 
correlate of protection has been identified, the importance of type 1 cytokines 
such as IFN-!, TNF-# and IL-12 in immunity against M. tuberculosis cannot be 
disputed (Flynn et al., 1993; Flynn et al., 1995; Cooper and Flynn, 1995; 
Ottenhoff et al., 1998). IL-2, a T cell growth factor produced by CD4 T cells is 
required for memory T cell development as well as secondary expansion of 
memory T cells (Schluns and Lefrancois, 2003; Williams et al., 2006; Dooms 
et al., 2007). This is important for proliferation of antigen experienced T cells 
in the defense against Mycobacterium tuberculosis (Kamath et al., 2006). 
 
1.8.1 Interferon gamma (IFN-!) 
 
IFN-! is the most commonly measured cytokine, since it has been shown to 
be critical in control of M. tuberculosis. (Flynn et al., 1993; Orme et al., 1993). 
Mice with a disrupted IFN-! gene are highly susceptible and succumb to M. 
tuberculosis (Cooper et al., 1993; Flynn et al., 1993). These mice are able to 
form granulomas but are unable to produce RNI and to limit mycobacterial 
growth. Humans with genetic defects in the IFN-! (or IL-12) pathways suffer 
from increased susceptibility to mycobacterial disease, which often manifest in 
childhood (Newport et al., 1996; Jouanguy et al., 1996; Ottenhoff et al., 1998; 
Ottenhoff et al., 2000; Ottenhoff et al., 2005). IFN! is critical for optimal 
activation of Mø and hence for protection against TB (Flesch and Kaufmann, 
1987; Ottenhoff et al., 2000). In mice, IFN! mediates its protective effect 
predominantly by the induction of RNI, which are necessary for the killing of 
the intracellular mycobacteria (Raja, 2004). In contrast, the role of RNI in 
human immunity to M. tuberculosis is not completely understood (Aston et al., 
1998). However, nitric oxide synthase 2 (NOS2), expression has been 
observed in human cells, and mutations in the NOS2 gene are associated 
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with susceptibility to developing TB (Velez et al., 2009). 
 
1.8.2 Interleukin-12 (IL-12) 
 
IL-12 is a critical promoter of Th1, cells that produce IFN! (T lymphocytes) 
and is produced by activated Mø and DC on ingestion of M. tuberculosis 
(Okamura et al., 1998; Fulton et al., 1996; Ladel et al., 1997). In a murine 
model of TB, treatment of mice with exogenous IL-12 increased resistance to 
M. tuberculosis (Cooper et al., 1997) Treatment with IL-12 increases the 
accumulation of Mø in infected tissues. IL-12 gene-disrupted mice are unable 
to control M. tuberculosis infection (Cooper et al., 1997) and this is associated 
to the absence of IFN-! production. Humans with defects in the IL-12 receptor 
gene (Altare et al., 1998; de Jong et al., 1998), or the IL-12 gene itself (Altare 
et al., 1998), are highly susceptible to infection with intracellular pathogens 
and in particular mycobacteria (Ottenhoff et al., 1998). 
 
1.8.3 Tumour necrosis factor alpha (TNF-") 
 
TNF-" is a pro-inflammatory cytokine, which activates macrophage 
antimicrobicidal activity and is essential in granuloma formation (Flesch and 
Kaufmann, 1990). Although it has long been considered a crucial component 
of protection in TB, TNF-# also has potent pro-inflammatory activity and acts 
as a mediator of tissue damage during TB. Its expression by Mø, DC and T 
cells can be induced by M. tuberculosis infection (Ladel et al., 1997; 
Henderson et al., 1997; Barnes et al., 1993; Serbina and Flynn, 1999) and 
absence/alteration of TNF-" production or signalling has been shown to 
impair control of mycobacterial infection (Flynn et al., 1995; Bean et al., 1999). 
TNF-#-receptor, gene deficient mice are extremely susceptible to tuberculosis 
(Flynn et al., 1995) and show delayed expression of RNIs. The lack of TNF-# 
mediated effects also resulted in the lack of epitheloid cells within 
granulomas, although it did not affect the total number of granulomas formed 
(Flynn et al., 1995). TNF-# depletion or neutralisation in mice results in 
decreased killing of mycobacteria by Mø, ultimately leading to tissue necrosis 
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and granuloma disintegration (Tufariello et al., 2003; Saunders and Britton, 
2007). In humans the importance of TNF-" was demonstrated in patients who 
receive TNF blockers for treatment of rheumatoid arthritis or Crohn’s disease 
(Keane et al., 2001). These patients subsequently had a much higher 
probability of reactivating latent TB. 
 
TNF-" is first synthesized as a transmembrane precursor protein. The mature 
soluble TNF-" is cleaved from the plasma membrane by matrix 
metalloproteinases such as TNF-" converting enzyme (TACE) (Keane et al., 
2001; Decoster et al., 1995). TNF is biologically activated by the binding of 
TNF-" to TNF receptor 1 or 2 (TNFR1 or TNFR2) on the surface of many cells 
(Vandenabeele et al., 1995). A disintegrin and metalloprotease, (ADAM) 
family proteins can shed the extracellular domain of both TNF receptors 
(Crowe et al., 1995; Mullberg et al., 1995) Soluble TNF receptors (sTNFR) are 
able to bind to both soluble and membrane TNF. Thus they can neutralize 
TNF-mediated activities. 
 
1.8.4 Interleukin 2 (IL-2) 
 
The induction of immunological memory is the primary goal of vaccination. 
Although T cells primed in the absence of IL-2 are able to undergo clonal 
expansion, upon re-stimulation these cells are incapable of effective recall 
responses. Blattman et al. demonstrated that IL-2 therapy administered during 
the contraction phase in a lymphocytic choriomeningitis virus (LCMV) murine 
infection model, resulted in proliferation and prolonged survival of virus-
specific CD8 and CD4 T cells and decreased viral burden (Blattman et al., 
2003). Several studies suggest that administration of IL-2 therapy to patients 
with mycobacterial disease, including TB, may be useful in limiting disease 
(Akuffo et al., 1990; Kaplan et al., 1991; Johnson et al., 1997). Millington et al. 
report an increase of M. tuberculosis-specific IL-2 and IL-2/IFN-! secreting T 
cells in effectively treated TB patients, compared with frequencies of these 
cells in these patients before treatment (Millington et al., 2007). These 
researchers suggest that IL-2 production might be a marker of reduced 
antigen load and could therefore serve as a marker of clinical disease state 
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(Sargentini et al., 2009). However, a clinical trial in patients with TB receiving 
recombinant IL-2 immunotherapy together with standard TB chemotherapy 
did not result in better outcome (Johnson et al., 2003). 
 
1.8.5 Polyfunctional T cells 
 
Polyfunctional T cells are defined as T cells which co-express cytokines such 
as IFN-!, TNF-# and IL-2. Such polyfunctional cells have been associated 
with more effective control of murine intracellular infections (Darrah et al., 
2007), including M. tuberculosis (Forbes et al., 2008; Lindenstrom et al., 
2009). Studies of chronic viral infections in humans associate polyfunctional T 
cells with protective antiviral immunity (Harari et al., 2006). HIV-1-specific T 
cells have been shown to shift from a predominantly single IFN-! producing 
phenotype before treatment to a polyfunctional phenotype after commencing 
ART (Harari et al., 2004). Similar to work first carried out by Betts et al., Owen 
et al. observed polyfunctional responses in individuals who naturally control 
HIV-1 to low levels throughout the course of infection (elite controllers) (Betts 
et al., 2006; Owen et al., 2010). 
 
Since there is no single cytokine that correlates with protection from TB, more 
recently, studies of polyfunctional T cells have been carried out to assess if 
polyfunctionality is associated with increased protection. However, the 
dynamics of these responses are complex. Induction of polyfunctional T cell 
responses by novel vaccines in both mice and humans is currently perceived 
as a desirable outcome (Forbes et al., 2008; Lindenstrom et al., 2009). 
Polyfunctional T cell responses induced by viral-vectored novel TB vaccines 
have been observed in adults (Beveridge et al., 2007; Abel et al., 2010) as 
well as adolescents and children (Scriba et al., 2010). 
 
However, a recent paper from our group demonstrated that there was no 
difference in the percentages of polyfunctional T cells in infants protected from 
TB following BCG vaccination compared with infants who were not protected, 
as they developed TB. This calls into question the association of 
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polyfunctional responses with protection from TB (Kagina et al., 2010). Young 
et al. report increased polyfunctional CD4 and CD8 T cell responses in 
patients with active TB prior to treatment compared to after treatment (Young 
et al., 2002; Young et al.). This is possibly a reflection of antigen load as 
opposed to protective immunity (Millington et al., 2007). Other researchers 
have reported similar observations in TB patients (Caccamo et al., 2010) and 
HIV-infected patients (Sutherland et al., 2010) before and after ART. Further 
studies regarding the mechanism of induction of these polyfunctional T cells 
and their role in immunity to TB are required. 
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1.9 Immune memory 
 
Immunological memory leads to a more rapid and quantitatively greater 
immune response of the host to a repeat exposure to pathogen (Figure 1.6) 
(Kaech and Wherry, 2007). Primary (1°) infection or vaccination induces naïve 
T cells to undergo clonal expansion resulting in increased numbers of antigen-
specific T cells. These expanding cells differentiate into effector T cells with 
more rapid effector function. After antigen clearance, most of the effector T 
cells contract or undergo apoptosis (programmed cell death) and memory 
cells remain. The memory T cells expand faster and with an enhanced 
response to secondary (2°) challenge with pathogen (Kaech et al., 2002; 
Seder and Ahmed, 2003). Several models of memory T cell differentiation 
have been proposed from studies of viral infections in both mice and humans 
(Kaech et al., 2002; Seder and Ahmed, 2003; Appay and Rowland-Jones, 
2004). 
 
 
 
 
Figure 1.6: Memory T Cell Development 
T cells (blue line) expand on pathogen (red line) encounter and differentiate into 
effector T cells, of which most die during a contraction phase, but some persist to 
become long-lived memory T cells. Upon re-infection, memory T cells re-expand and 
control infection faster than with initial encounter with pathogen. Adapted from 
(Kaech et al., 2002). 1°; primary pathogen challenge, 2°; secondary pathogen 
challenge. 
 
 
Memory cells have considerable heterogeneity in phenotype and function. 
CD4 and CD8 T cell cytokine expression has been linked with cell surface 
expression of markers of memory phenotype in viral infections in mice 
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(Sallusto et al., 1999) and humans (Harari et al., 2005). In order to study T cell 
differentiation and key T cell memory populations, it is useful to analyse these 
surface markers (Sallusto et al., 1999). CD45RA (a leukocyte common 
antigen isoform) is lost by T cells upon priming, and can thus be used to 
differentiate naïve from memory (antigen experienced) T cells (Akbar et al., 
1988; Kolber, 2004). However, in some models highly differentiated antigen 
experienced cells can re-express this marker (Hamann et al., 1997; Seder 
and Ahmed, 2003). Dunne et al. suggest that CD45RA-CD45RO+ may better 
represent primed cells (Dunne et al., 2002). 
 
Expression of the chemokine receptor, CCR7 on antigen-experienced cells, 
defines central memory T cells (TCM), which express IL-2 and are able to 
home to lymphoid organs. Although these cells do not express immediate 
effector function, they are long lived and proliferate rapidly upon antigen 
reencounter. By contrast, effector memory T cells (TEM), which lack CCR7 
expression, predominantly express effector cytokines, such as IFN-! (Sallusto 
et al., 1999; Harari et al., 2005). These populations can be further dissected 
according to their degree of differentiation, based on the expression level of 
CD27. This co-stimulatory marker is sequentially lost during T cell 
differentiation (Fritsch et al., 2005). 
 
The differential expression of cell surface markers such as CD45RA, CCR7, 
and CD27 on CD4 and CD8 T cells characterise the heterogeneity of the 
memory T cell response (Figure 1.7 A and B) (Appay et al., 2002; Sallusto et 
al., 2004; Appay et al., 2008). Different effector functions associate with 
distinct intracellular molecules and surface phenotypes. For example antigen 
experienced CCR7-CD45RA+CD27- CD8 T cells express immediate effector 
function when presented with viral antigen and are pre-dominantly IFN-! 
producers (Hamann et al., 1997). IL-2 expression by CCR7+CD45RA-CD27+ 
CD8 T cells can be low to high (Figure 1.7 A). Similarly CD4 T cells can also 
be subdivided into T cell populations showing differential expression of these 
phenotypes with distinct effector functions (Figure 1.7 B). 
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Figure 1.7: CD8 and CD4 T cell maturation in response to antigen 
(A) CD8 and (B) CD4 T cell phenotypic associations to functional attributes. Five 
distinct subsets of circulating T cells are defined according to CD45RA, CCR7, and 
CD27 expression. Adapted from (Appay et al., 2008). 
 
 
The developmental pathway of memory T cell subsets from naive T cells 
remains a subject of debate in humans. The discussion centres, around 
whether the cell differentiation pathway is linear or branched, one-way or 
reversible. A linear differentiation pathway has been described in CD8 T cells 
from murine viral and bacterial infection models and is suggested to be 
progressive, from naïve ! effector ! TEM ! TCM (Seder and Ahmed, 2003; 
Wherry and Ahmed, 2004). In contrast, studies of T cell differentiation in 
human viral infection suggest that TEM-like cells with shorter telomere length 
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compared to TCM are the end point of memory development (Champagne et 
al., 2001; Appay et al., 2002; Gamadia et al., 2003; Papagno et al., 2004). 
Appay et al. propose a progressive model of differentiation of CD4 and CD8 T 
cells from early ! intermediate ! late differentiated subsets (Appay et al., 
2002; Appay and Rowland-Jones, 2004), thus supporting a linear pathway of 
differentiation. 
 
These models of memory development have mostly been studied in viral 
infections of animal models. More human studies of T cell memory 
phenotypes are needed in chronic bacterial infections such as TB. To date, 
there is no clear consensus on the development of memory/effector T cell 
differentiation (Appay et al., 2008; Ahmed et al., 2009), and the terminology of 
effector and memory responses has often been used inconsistently. 
Additional studies would need to better define the lineage factors and 
interplay of the different subsets in a more comprehensive fashion. However, 
the general agreement is that successful vaccination requires long-lived 
immunological memory that confers protection against infection or disease 
(Lambert et al., 2005). In the context of TB vaccine development, the 
generation of memory T cells and thus the characterisation of mycobacteria-
specific T cells is of particular importance, and has not been studied in great 
detail in HIV-infected children. 
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1.10 Effects of human immunodeficiency virus infection on the immune 
system and impact of antiretroviral therapy (ART) 
 
Infection with HIV has a detrimental effect on several parts of the immune 
system, but its primary impact is on the population of CD4 T cells (Mogensen 
et al., 2010). Progression of HIV infection to AIDS is characterised by a 
steady decline of this particular T cell subset, due to (although not limited to) 
preferential infection via certain cell surface receptors, such as CCR5 and 
CXCR4 (Mehandru et al., 2007). The result is a profound defect in T cell 
function and depletion of cells, which places the host at risk of disease caused 
by opportunistic pathogens (Lloyd, 1996; Edgar, 2008; Geldmacher et al., 
2010). M. tuberculosis control requires CD4 T cells, thus HIV-infection is one 
of the most frequently encountered co-infections in areas with a high 
prevalence of TB. Through clinical experience it is now well established that 
the dramatic decline of CD4 T cells increases the risk to contract potentially 
lethal bacterial and viral co-infections (Lloyd, 1996; Wilcox and Saag, 2008). 
 
The aim of anti-retroviral therapy (ART) is to prevent or slow down the 
profound decline of the CD4 T cells as well as delay or prevent onset of 
infections by interfering with the replication of HIV at several life cycle steps. 
The different drugs used in the combination therapy, which is the most 
effective treatment starts often at different stages of the HIV-life cycle in order 
to prevent successful replication (Nielsen et al., 2005). Despite the success of 
protease and reverse transcriptase inhibitors in suppressing HIV-1 replication, 
new drugs are being evaluated. Among these new targets, inhibitors of virus 
attachment to target cells and integration are the most promising candidates 
(Moore and Stevenson, 2000). The aim of ART is to maintain an undetectable 
level of virus in the blood. It is not yet possible to completely eradicate HIV 
once a person is infected, and combination therapy needs to be taken 
continuously to avoid replication and development of viral resistance (Wilcox 
and Saag, 2008). 
 
When to start ART in children was debated until recently, as the advantage of 
rapid viral suppression is potentially offset by the risk associated with very 
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long term use of powerful medication. However, it has now become clear that 
any infant found to be HIV infected should start ART as soon as possible after 
diagnosis, independent of the CD4 count (South African Department of 
Health, 2009). A reliable CD4 count result is not necessarily available in all 
resource poor settings and many children are only monitored clinically (Lloyd, 
1996). As in adults, TB is a leading co-morbidity and ART decreases 
susceptibility. A large number of older children in HIV clinics in South Africa 
have never received ART and are in need of urgent treatment to prevent 
infections and death. The detrimental impact of abnormal function of CD4 T 
cells is easily appreciated from the extensive discussion of the T cell 
populations and their mediators in the above sections. The impaired cellular 
responses to mycobacterial antigens in both adults and children have been 
well characterised in this context, in particular reduced levels of IFN-! (Tena 
et al., 2003; Mansoor et al., 2009), which is of central importance for 
containing mycobacterial infection, as discussed above. IFN-! release assays 
(IFGRAs), used in the diagnosis of TB are promising, however, further 
investigation is needed for their use in high-risk groups such as HIV infected 
adults and children (Mori, 2009; Fujita et al., 2010). 
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1.11 Prevention of tuberculosis through vaccination 
 
1.11.1 BCG vaccine and basis for new vaccine candidates 
 
Bacillus Calmette-Guérin (BCG), developed by two French researches, Albert 
Calmette and Camille Guérin, is still the only licensed vaccine against TB 
(WHO, 2004). It is a live attenuated strain of M. bovis, which is the causative 
agent of TB in cattle. The less virulent BCG vaccine strain was developed 
through serial subculture (231 passages) on slices of potato soaked in a 
glycerol-bile mixture, over a 13-year period (Benevolo-de-Andrade et al., 
2005). It was first given as a vaccine to humans in June 1921 (McKone, 
1948). The vaccinee was a newborn, whose likely caregiver, the infant’s 
grandmother, had TB. The infant’s mother had succumbed to TB shortly after 
childbirth (Benevolo-de-Andrade et al., 2005). Today, only a few countries do 
not use BCG for routine vaccination mostly because TB is relatively rare, for 
example, the USA and the Netherlands (Fine et al., 1999). The BCG vaccine 
is used throughout TB-endemic countries, and is estimated to be administered 
to more than 100 million newborns annually as part of the WHO Expanded 
Programme for Immunization (EPI) (Hussey et al., 2007). 
 
BCG is safe and affords variable and mostly poor protection against 
pulmonary TB. Despite this, it does protect against severe childhood forms of 
TB, such as miliary TB and TB meningitis (Trunz et al., 2006), which are 
associated with high mortality rates. Its efficacy in preventing pulmonary TB in 
adults has varied dramatically in various studies in different parts of the world 
from 80% in the United Kingdom to 0% in Chingleput, India (Fine, 1995). 
Environmental factors may contribute to this difference in efficacy. For 
example, it has been suggested that exposure to environmental mycobacteria 
may interfere with or mask the BCG induced immune response (Brandt et al., 
2002; Black et al., 2002). Many other factors may also contribute to this 
discrepancy including BCG vaccine strain, age, genetic predisposition and 
immunosuppression amongst others. 
 
Because of case reports of disseminated BCG infection (BCGosis) (Hesseling 
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et al., 2007; Hesseling et al., 2009), this vaccine is contraindicated in HIV 
infection according to the revised WHO Vaccine Safety Committee guidelines 
(WHO, 2007). However, in reality, the HIV status of most infants is unknown 
at birth, when the BCG vaccine is routinely administered and many HIV-
infected infants continue to receive it. In addition to BCGosis as a result of 
severe immune deficiency, BCG may also cause immune reconstitution 
syndrome (BCG-IRIS) once combination anti-retroviral therapy (ART) is 
commenced, particularly in children with very low CD4 T cell counts (Smith et 
al., 2009). A more efficacious vaccine that is safe and protective in HIV-
infected children is urgently needed. An increasing effort is being made to 
design better anti-tuberculosis vaccines including viral vectors, recombinant 
BCGs, and the use of M. tuberculosis proteins with an adjuvant (subunit 
vaccines) to induce more optimal immune responses. 
 
1.11.2 Novel anti-TB vaccination strategies in the immunodeficient host 
 
Despite its poor protection against pulmonary TB, BCG has good safety 
records and will continue to be used due to its beneficial effects against 
severe forms of TB. Thus novel TB vaccine development has focused on 
boosting BCG induced immunity using prime-boost vaccination strategies 
(Kaufmann et al., 2006; Kaufmann, 2006; Kaufmann, 2010; Parida and 
Kaufmann, 2010) rather than eliminating the BCG vaccine altogether. Several 
promising vaccine candidates are currently in human clinical trials (McShane 
et al., 2005; Brennan et al., 2007; Hussey et al., 2007; Hoft, 2008; Kaufmann 
et al., 2010). The current development of new anti-TB vaccines centres 
around strategies for the generation of an improved BCG, such as 
recombinant BCG (rBCG) (Horwitz and Harth, 2003; Grode et al., 2005; 
Horwitz et al., 2006), viral vectored vaccines or the use of immunodominant 
antigens in subunit vaccines to boost the BCG prime (Weinrich Olsen et al., 
2001; McShane et al., 2005; Reed and Lobet, 2005; Hoft, 2008). Since 
application of a live replicating vaccine to immunocompromised individuals 
carries the potential risk of dissemination (Hesseling et al., 2003; Hesseling et 
al., 2007; Hesseling et al., 2009), the TB epidemic in HIV-infected populations 
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has urged the development of efficacious, non-replicating TB vaccines that 
are suitable for CD4 T cell deficient hosts such as subunit vaccines. 
 
Novel subunit vaccines currently under development typically carry antigens, 
that are highly immunogenic and recognized by a high proportion of 
individuals infected with M. tuberculosis, or vaccinated with BCG, such as 
ESAT-6, TB10.4 and Ag85B (Brock et al., 2004; Dietrich et al., 2006). The 
coding gene for ESAT-6 is not present in any of the M.bovis BCG vaccine 
strains or in most environmental mycobacteria and consequently, reactivity to 
this antigen is an indication of M. tuberculosis infection. TB10.4 is also a 
member of the ESAT-6 gene family. In contrast to ESAT-6, the gene coding 
for TB10.4 is also present in BCG. Cells isolated from immune competent, 
BCG vaccinated individuals as well as TB patients produced high levels of 
IFN-! after stimulation with TB10.4 (88% and 71% responders, respectively) 
(Skjot et al., 2000). Ag85B is present in both M. bovis BCG, and M. 
tuberculosis and is well described in the literature as another potent IFN-! 
inducer in both M. tuberculosis infected and BCG vaccinated individuals 
(Wiker and Harboe, 1992). 
 
All three antigens have been shown to induce control of M. tuberculosis 
infection in animal models when given as subunit vaccines. Weinrich Olsen et 
al. have shown efficacy of an Ag85B-ESAT-6 fusion protein in both mice 
(Weinrich Olsen et al., 2001) and guinea pig models (Olsen et al., 2004). 
Langermans et al. also showed protection against M. tuberculosis in a non-
human primate model (Langermans et al., 2005). Further, Dietrich et al. have 
found even better control of infection with a fusion protein containing Ag85B 
and TB10.4 in a murine model (Dietrich et al., 2005). The subunit vaccine has 
been formulated with the adjuvant IC31, which promotes a strong Th1 
response (Aagaard et al., 2009). This novel construct represents another new 
promising vaccine candidate against TB. 
 
A successful vaccine needs to induce protective immune responses by 
generating immunological memory. However, in HIV-infected individuals, 
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profound T cell defects might prevent successful vaccination, as antigen-
experienced (memory) T cell populations are depleted and or dysfunctional. 
For example, immune responses to Influenza A and measles vaccination are 
impaired in HIV-infected children (Obaro et al., 2004; Lyall et al., 1997). ART 
results in strong and sustained inhibition of viral replication and is associated 
with a rapid rise in CD4 T cells in patients with advanced disease. In contrast 
to adults, the rise in CD4 T cells in children in response to ART is 
predominantly within CD45RA+ cells. Thymic output of T cells is recognised to 
be greater in children, and thymic rearrangement excision circle (TREC) 
assays confirm that a high proportion of naïve cells are recent thymic 
emigrants (De Rossi et al., 2002). It remains to be determined whether this 
higher proportion of naïve cells results in broader functional immune 
reconstitution in children as opposed to adults. In adults receiving ART, 
reconstitution of antigen-specific cellular immune responses has been 
demonstrated in vitro, but more importantly, in vivo studies show that 
susceptibility to TB is significantly reduced (Badri et al., 2002). This reduced 
susceptibility to TB was highest in symptomatic patients and those with 
advanced immune suppression. Despite this the overall susceptibility still 
remains well above that of HIV-negative individuals. The question whether it 
could be further reduced by vaccination remains unanswered in both adults 
and children. 
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1.12 Whole blood assays used to study mycobacteria-specific 
responses 
 
1.12.1 Whole blood intracellular cytokine staining (ICS) assay 
 
Whole blood assays are attractive as a tool to study immune responses to M. 
tuberculosis as all relevant cell types as well as humoral factors are present 
and can contribute to the interaction with mycobacteria (van Crevel et al., 
1999). In contrast to conventional assays using peripheral blood mononuclear 
cells (PBMCs), the whole blood intracellular cytokine-staining (ICS) assay 
uses smaller blood volumes without the need for sophisticated processing of 
blood (Hanekom et al., 2004). This is particularly relevant when studying 
paediatric populations and for the laboratory set up of many developing 
countries. The ICS assay allows the study of antigen-specific T cell 
responses, giving a snapshot of the immune response at the time of blood 
sampling. Whole blood is stimulated with mitogen, and pathogen-specific 
antigens. Surface and intracellular molecules such as cytokines are then 
detected using flow cytometry in a stimulated sample and compared with an 
unstimulated control sample. In this thesis we used an ICS assay to measure 
intracellular production of IFN-! and IL-2 and characterised surface phenotype 
of CD4 and CD8 T cells after stimulation of whole blood with mycobacterial 
antigens, as detailed in chapter 2. 
 
1.12.2 Basic principles of multiparameter flow cytometry 
 
Flow cytometry allows detailed characterisation of multiple parameters on a 
single cell level as cells flowing in a fluid stream are interrogated by a series 
of lasers (Shapiro, 2003). Light scattered in the forward direction (forward 
scatter, FSC), gives information about the cell size, and light scattered at a 
90° angle (side scatter, SSC) gives information about the internal complexity 
or granularity of the cell, Surface and intracellular markers of interest, stained 
with fluorescent molecules (e.g. fluorochrome-conjugated monoclonal 
antibodies), allow detailed characterisation of specific cell populations. These 
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fluorescent molecules are excited by the lasers and emit light at longer 
wavelengths. The intensity of the emitted fluorescence is proportional to the 
number of binding sites on the cell of interest. The scattered light and emitted 
fluorescence are collected by detectors and converted to digital signals, which 
are displayed for analysis in one and two dimensional plots, such as 
histograms and dot plots, respectively. 
 
1.12.3 Tools to study mycobacteria-specific responses 
 
The purpose of any assay in the context of vaccine evaluation is to provide an 
in vitro measure of the vaccine-specific immune response (immunogenicity or 
vaccine take). In TB vaccine research most of the assays used evaluate the 
magnitude and quality of the vaccine-specific memory T cell response. These 
assays measure a recall response after stimulation of whole blood or PBMCs 
with vaccine antigens in vitro. These assays measure antigen-induced host 
responses through levels of secreted or expressed key cytokines using 
enzyme-linked immunosorbent assay (ELISA) (Hasan et al., 2009), enzyme-
linked immunosorbent spot (Elispot) assay (Hughes et al., 2005), ribonucleic 
acid (RNA) assay (Hasan et al., 2009), or frequencies of T cell responses 
using flow cytometry (Hanekom et al., 2004; McShane et al., 2005; Horton et 
al., 2007; Scriba et al., 2010; Abel et al., 2010). Bactericidal assays, which 
enumerate mycobacteria in cell culture systems before and after host-
pathogen interactions are also used in vaccine evaluation. 
 
1.12.3.1 Cytokine assays 
 
Although studies of single or multiple cytokines have provided important 
insights into the pathophysiology of tuberculosis infection and disease, 
correlation of cytokine levels with outcome have been poor. This is mainly a 
consequence of the wide inter- and intra-individual variability and reflects the 
complexity of the host-pathogen interactions. As a consequence, to date, no 
validated biomarkers exist that accurately predict progression from TB 
infection to TB disease. In TB vaccine assessment, several immunogenicity 
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markers, such as production of IFN-! in response to vaccine antigens are 
currently being evaluated, but there is obvious heterogeneity. The assays 
used may vary in duration depending on the nature of the question being 
addressed as well as what is practical. The different types of assays include 
(1) the short term assay which is less than 24 hours, (2) the medium term 
assay is between 1 to three days and (3) the long term assay can be four to 
five days or more (Hanekom et al., 2008). Each type of assay has distinct 
advantages and disadvantages and assay selection depends on what is 
practical within the study settings as well as what part of the immune 
response is investigated. Regardless, optimization of the chosen assay 
system is key in generating reliable immunological data. Resource permitting, 
performing a combination of short, medium and long term assays would be 
more informative. The data in this thesis was generated with a short term ICS 
whole blood assay as well as a 96-hour bactericidal assay, which are both 
practical in paediatric studies. 
 
1.12.3.2 Bactericidal assays 
 
Bactericidal assays in the context of tuberculosis vaccine research are well 
established in animal models, where they are applied to screen potentially 
promising vaccine candidates (Weinrich Olsen et al., 2001; Langermans et al., 
2005; Dietrich et al., 2005). Reduction of bacterial load in various organs 
functions as the main read-out of efficacy. The first generation of human 
bactericidal assays, were designed using Mø infected with M. tuberculosis 
(Silver et al., 1998). Freshly harvested peripheral blood lymphocytes (PBL) 
were added to infected Mø (primary lymphocyte-dependent inhibition) and 
lymphocytes added subsequently. Co-cultures were lysed and viable 
mycobacteria counted by CFU plating. Worku et al. used T cells expanded 
from peripheral blood and stimulated with specific mycobacterial antigens 
prior to adding them to antigen-presenting cells in vitro (secondary 
lymphocyte-dependent inhibition) (Worku and Hoft, 2000). 
 
One of the main impediments of work with M. tuberculosis in bactericidal 
assays is the need for containment facilities and the fact that bacterial 
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quantification is only available after weeks of incubation. To facilitate more 
rapid read-outs, new assays were designed which measure metabolic activity 
as a correlate of mycobacterial numbers. Two different systems have been 
designed: reporter–gene tagged mycobacteria (Kampmann et al., 2000) or a 
radiometric detection system using BacTec bottles (Cheon et al., 2002). 
These assays were adapted for whole blood rather than PBMC (whole blood 
inhibition assays). Whole blood assays require considerably smaller volumes 
of blood compared with PBMC based assays, making them more suitable 
under field conditions, especially when children are studied. Some 
investigators have used BCG rather than virulent M. tuberculosis to avoid the 
requirement for BSL3 conditions. However validation with virulent strains is 
important and has been carried out (Al-Attiyah et al., 2006; Martineau et al., 
2007). 
 
The mycobactericidal assay used in this thesis utilises diluted whole blood 
and reporter-gene tagged mycobacteria (M. tuberculosis H37Rv). The 
reporter-gene (lux AB) is carried on a plasmid (pSMT1) under the control of 
the inactivated heat-shock promoter (hsp60) (Snewin et al., 1999). Metabolic 
activity, which is the viability marker of the bacteria, is measured by recording 
the emitting bioluminescence signal as relative light units (RLU). The 
bioluminescence signal is induced by adding, an exogenous substrate, n-
decyl-aldehyde. Bioluminescence, the biological production of light, is ATP-
dependent and only viable bacteria emit light. It is a marker of mycobacterial 
viability, which was shown to correlate directly and consistently with 
mycobacterial quantification by counting CFU (Snewin et al., 1999). Figure 
1.8 shows a schematic representation of the whole blood luminescence 
assay. 
 
In this thesis, we used the reporter-gene tagged mycobacterial assay 
developed by Kampmann et al. to complement and correlate the data 
gathered by ICS whole blood cytokine assays with a functional read-out. 
(Kampmann et al., 2000). 
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Figure 1.8: Schematic of the whole blood growth inhibition assay 
Reporter-gene tagged mycobacteria (M. tuberculosis H37Rv or BCG) were 
transformed with the plasmid (pSMT1). This plasmid carries the reporter-gene 
luciferase A and B (lux AB) genes, under the control of an inactivated heat-shock 
promoter (hsp60). Heparinised whole blood diluted 1:2 with RPMI and inoculated 
with luminescent bacteria is incubated at 37°C for 96 hours on a rocking platform. 
Supernatants are removed and frozen for future cytokine analysis. The growth ratio 
is determined by dividing the RLU reading at 96 hours (T96hrs)/ by the reading at 
baseline (T0hrs). Schematic obtained from B Kampmann. 
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1.13 Aims of the study 
 
ART has completely transformed both life expectancy and quality of life for 
HIV-infected individuals in developed countries and the introduction of ART 
into sub-Saharan Africa is now a major world health priority. In the coming 
years, increasing numbers of children with HIV will be treated in sub-Saharan 
Africa, but despite extensive therapy with ART, a large number of these 
children will subsequently succumb to TB, as they reside in an environment 
highly endemic for TB. Protection from TB must therefore rank as a 
fundamental component of health care delivery in these countries. Apart from 
providing long-term preventative anti-TB therapy with its potential 
complications, vaccination of this vulnerable group must remain an alternative 
option. Most of the novel TB vaccines aim to boost BCG immunity through a 
heterologous prime-boost vaccination strategy. Whether vaccination could 
successfully boost anti-mycobacterial immunity in HIV-infected children 
receiving ART remains unanswered. There are presently no data on baseline 
mycobacteria-specific T cell memory responses in paediatric HIV infection 
that could be boosted with an anti-TB vaccine. This study will address the 
fundamental question whether ART will enable the reconstitution of 
mycobacteria-specific immune responses to antigens contained in novel anti-
TB vaccines, in HIV-infected children receiving ART. 
 
Hypothesis: 
 
Our hypothesis is that T cells from children with previous BCG vaccination, 
with or without HIV infection, can recognize mycobacterial antigens that are 
under investigation for inclusion into novel anti-TB vaccines. 
We hypothesize that mycobacteria-specific memory CD4 and CD8 T cell 
responses are lower in HIV-infected children before ART, compared with non-
HIV-infected children, but are reconstituted during the course of ART. 
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Objective: 
Our objective is to describe effector and memory responses to selected 
mycobacterial antigens in African children with and without HIV infection and 
to study the impact of ART on such responses in the HIV-infected group. 
 
Specific Aims: 
 
 1. To develop and optimise an 8-colour flow cytometry panel to functionally 
and phenotypically characterise memory sub-populations of mycobacteria-
specific CD4 and CD8 T cells. 
 2. To quantify the frequency and memory phenotype of mycobacteria-
specific T cells in children with and without HIV-infection. 
 3. To quantify the frequency and memory phenotype of mycobacteria-
specific T cells in HIV-infected children during the course of ART. 
 4. To determine mycobacterial growth inhibition in whole blood of HIV-
infected children before and during the course of ART. 
 5. To determine the association between data obtained by ICS and whole 
blood growth inhibition assays. 
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Materials and methods 
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2.1 Introduction 
 
In this chapter the general methods and reagents used in the project are 
described in detail. 
 
2.2 Materials and methods 
 
2.2.1 Study design 
 
This prospective study addressed three aims: 1) to develop and optimize an 
8-colour flow cytometry antibody panel to study T cell responses, 2) cross-
sectional analysis of T cell responses in HIV+ children and control groups, and 
3) longitudinal analysis of T cells in HIV-infected cohort during 12 months of 
therapy. The aim of this study was to compare the function and phenotype of 
T cell responses in children, in order to characterise the type of responses 
that might be observed in children of different immunocompetence in 
response to antigens currently included in novel candidate TB vaccines. To 
accomplish this, memory T cell responses in small volumes of whole blood 
were evaluated. 
 
2.2.2 Study participants 
 
Ethical approval for the study was obtained from the Research Ethics 
Committees of the University of Cape Town, South Africa (REC 081/2006), 
and of Imperial College London, UK (02/GB/23E). Healthy adult volunteers 
and three groups of children, who had all received BCG vaccination at birth, 
were targeted for enrolment. Adults were enrolled following informed consent. 
Legal guardians of children gave informed consent. All children were recruited 
and followed up by the same dedicated research nurse. Demographic 
characteristics of all children are tabulated and described in chapter 4. 
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2.2.2.1 Healthy adult volunteers 
 
Development and optimisation of multiparameter flow cytometry panels were 
completed using whole blood from healthy adults. The volunteers were 
recruited at the Institute of Infectious Disease and Molecular Medicine 
(IIDMM) at the University of Cape Town (UCT). Only individuals over the age 
of 18, of ideal weight and with good general health were recruited. None of 
the volunteers were taking medication for chronic illness. 
 
2.2.2.2 Healthy children 
 
Healthy children (HC), under 15 years of age, of normal weight for age and 
born to HIV-negative mothers, were recruited from community clinics, routine 
immunisation clinics and pre-booking clinics for planned surgery at Red Cross 
Children’s Hospital, Cape Town. Any children, who had reported prior 
exposure to an active TB case, children with a past history of TB, children 
treated for LTBI or any evidence of acute or chronic health problems were 
excluded. This group served to determine the nature of T cell responses to 
mycobacterial antigens in BCG-vaccinated, but HIV and TB-negative 
population of healthy children. 
 
2.2.2.3 HIV-seronegative children diagnosed with TB 
 
HIV-seronegative children, under 15 years of age, diagnosed with TB, and 
had been receiving standard anti-TB therapy (rifampicin, isoniazid and 
pyrazinamide) for a minimum of 2 months, were recruited from TB clinics. TB 
diagnosis was either by culture confirmation (definite TB) or by a combination 
of suggestive signs and symptoms, a history of TB exposure, abnormal chest 
radiology, positive tuberculin skin test (TST) response (>10 mm) and 
response to TB therapy (probable TB). This group served to determine T cell 
responses to mycobacterial antigens in immunocompetent children who were 
expected to have M. tuberculosis-specific immunological memory. Any 
children who were acutely unwell, malnourished or on immunosuppressive 
medication were excluded. 
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2.2.2.4 HIV-infected children 
 
Children above the age of 3 months, with perinatally acquired HIV-1 infection, 
about to start triple combination antiretroviral therapy (ART) were identified by 
clinicians and/or the research nurse at HIV-community clinics, at pre-
treatment meetings or at the Red Cross Children’s Hospital. All children were 
receiving regular follow-up and fulfilled either clinical or immunological criteria 
for starting ART according to WHO guidelines. However, children under 12 
months were started on ART regardless of their clinical or immunological 
status in line with the new guidelines (WHO, 2008). None of the children had 
previously received ART or treatment for TB. Any children, who had prior 
reported exposure to an active TB case, children who were acutely unwell or 
had signs/symptoms of TB or other opportunistic infections, were excluded. 
Children with a history of rapidly progressing HIV disease, such as 
opportunistic infections, recurrent severe bacterial infections, specific 
encephalopathy and wasting syndrome were excluded. Children with a CD4 
count of less than 50 cells/µl, who required multiple hospital admissions for 
opportunistic infections or other complications of HIV disease, were excluded. 
 
2.2.3 Tissue culture 
 
Throughout all tissue culture procedures, sterile conditions were maintained. 
 
2.2.3.1 Blood sample collection 
 
A total of 10 ml heparinised venous blood was collected into vacuum 
collection tubes (BD Biosciences), from all children. All bloods were 
processed within two hours of blood draw. In the healthy and TB groups blood 
samples were used to prepare duplicate antigen stimulations of whole blood 
for intracellular cytokine staining (ICS) assay. In HIV-infected children 5 ml of 
blood was used for the ICS assay and 5 ml was used for the mycobacterial 
growth inhibition assay (see section 2.2.4 and 2.2.5, respectively). A further 2 
ml of ethylenediaminetetraacetic acid (EDTA) blood was collected from HIV-
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infected children: 500 µl blood was sent for determination of CD4 count, 500 
µl for full blood count and differential count as well as 1 ml for HIV-viral load 
determination. 
 
2.2.3.2 Stimulations 
 
A whole blood ICS assay, which allows characterisation of T cell responses to 
specific antigens in relatively small volumes of blood, was used to identify the 
memory phenotype and cytokine expression of mycobacteria-specific T cells 
(Hanekom et al., 2004). Whole blood was stimulated with the recombinant 
proteins, Ag85B (Rv1886c) and TB10.4 (Rv0288) (added together due to 
limited blood volumes, at 10 µg/ml each), M. tuberculosis purified protein 
derivative (PPD, at 20 µg/ml,) or early secretary antigenic target-6 (ESAT-6) 
peptides, (Rv3875) at 10 µg/ml. All antigens were kindly provided by P. 
Andersen, Staten Serum Institute, Denmark. Unstimulated blood served as 
negative control and blood incubated with staphylococcal enterotoxin B (SEB, 
at 10 µg/ml, Sigma) as positive control. 1 ml of whole blood was incubated 
with antigens in 2 ml polypropylene tubes (Sarstedt) for a total of 7 hours in a 
programmable water bath at 37°C. Brefeldin A (Sigma, 10 µg/ml) was added 
after the first 2 hours of incubation, to trap cytokines intracellularly. The water 
bath was programmed to cool down to room temperature after a further 5 
hours at 37°C. 
 
Cells were harvested within 20 hours of start of incubation, and incubated with 
2 mM EDTA (Sigma) for 15 minutes at room temperature to reduce cell 
clumping. To lyse red blood cells and fix white blood cells, the sample was 
transferred into 15 ml conical Falcon tubes containing 9 ml FACS lysing 
solution (BD Biosciences), and incubated at room temperature for 10 minutes. 
Cells were centrifuged at 300 x g for 7 minutes at room temperature. 
Supernatants were decanted and the remaining cells resuspended in a 
cryopreservation solution consisting of 500 µl RPMI 1640 medium with L 
glutamine (Sigma) and 500 µl 20% dimethyl sulfoxide (DMSO, Sigma) in heat 
inactivated fetal calf serum (FCS, Gibco, Invitrogen). Resuspended cells were 
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transferred into cryovials (Corning) and placed in Mr. Frosty’s (Merck) 
containing isopropanol (Sigma), which allows gradual freezing at a rate of -
1°C/min. Mr Frosty’s were placed at -80°C. Cells were transferred to liquid 
nitrogen for longer term storage the following morning. 
 
2.2.4 Intracellular cytokine staining (ICS) assay 
 
Optimisation of this assay is described in detail in chapter 3. 
 
2.2.4.1 Antibodies 
 
The following combination of surface antibodies was used: anti-CD3 Pacific 
Blue (UCHT1), anti-CD8 PerCP-Cy5.5 (SK1), anti-CD27 PE (MT271), anti-
CD45RA PE-Cy7 (L48), all from BD Biosciences, anti-CD4 QD605 (S3.5, 
Invitrogen) and anti-CCR7 APC (150503, R&D Systems). Anti-IFN-! 
AlexaFluor700 (B27) and anti-IL-2 FITC (5344.111, both from BD 
Biosciences) were used for intracellular cytokine staining. 
 
2.2.4.2 Intracellular cytokine staining assay 
 
T cell functional and phenotypic profiles were measured using a two-step 
staining method: cells were permeabilised, stained first for surface markers 
followed by staining for intracellular cytokines. The cryopreserved cells were 
rapidly thawed in a water bath at 37°C. Thawed cells were transferred into 5 
ml 2054 Falcon tubes (BD Biosciences) containing 2 ml 1% bovine serum 
albumin (BSA, Sigma) in 1 X Dulbecco’s phosphate buffered saline (PBS, 
BioWhittaker), washed twice at 300 x g for 7 minutes. The cells were 
transferred to a 96 well plate (Nunc) and permeabilised using 200 µl 
1XPerm/Wash Solution (BD Biosciences) for 10min at 4°C. Cells were then 
pelleted at 1800 x g for 3 minutes at 4°C in a refrigerated centrifuge. The cells 
were resuspended in 50 µl 1XPerm/Wash and then stained at 4°C, first with 
surface antibodies for 30 minutes - after a wash step using 180 µl 
1XPerm/Wash, the cells were stained with intracellular antibodies for 1 hour at 
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4°C in the dark in the remaining 50 µl Perm/Wash. After intracellular staining, 
the cells were washed with 180 µl 1XPerm/Wash and again pelleted at 4°C 
for 3 minutes at 1800 x g, resuspended in 100 µl 1XPerm/Wash and 
transferred to 5ml 2054 Falcon tubes. 
 
2.2.4.3 Multiparameter flow cytometry 
 
Stained samples were acquired on the same day on a LSRII flow cytometer. 
The details of the LSRII instrument configuration, flow cytometry panel 
optimisation, data acquisition and analysis are described in chapter 3. 
 
2.2.4.4 Data analysis 
 
All flow cytometry data were analyzed using FlowJo v8.8.2 (Tree Star), Pestle 
(v1.6.1) and Spice (v4.9) (Mario Roederer, Vaccine Research Center, 
National Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health (NIH) (Roederer et al., 2011). Results were expressed as 
the frequency of positive events, of the stimulated sample, above those of the 
negative control, the unstimulated sample. Memory phenotypes of cytokine 
producing, mycobacteria-specific T cells were only analysed if at least 40 
cytokine+ (specific) cells were detected, and if this response was at least 
double that from the unstimulated control. 
 
2.2.5 Mycobacterial growth inhibition assay 
 
The mycobacterial species used in this study was the virulent M. tuberculosis 
H37Rv lux strain, provided by Dr Kampmann, Imperial College London. All 
work with the virulent strain was done in a BSL3, containment facility. 
 
2.2.5.1 Mycobacterial media 
 
7H9 broth: 4.7 g of powdered 7H9 broth (Middlebrook, BD, Difco) was 
dissolved in 900 ml dH20 (containing 2 ml glycerol, BDH, Merck) and 500 µl 
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Tween 80 (Sigma). The broth was autoclaved for 15 min at 121°C. The 
prepared media was supplemented with 10% (20 ml) ADC enrichment 
(Middlebrook, BD, Difco) and 10 mg hygromycin B (200 µl of 50 mg/ml stock, 
Boehringer Mannheim, Roche Diagnostics) before use as liquid growth 
medium for MTB lux and stored at 4°C. 
 
7H11 agar: 10.5 g of powdered 7H11 agar (Middlebrook, BD, Difco) in 450 ml 
dH20 (containing 2.5 ml glycerol) was boiled to dissolve completely. The agar 
was then sterilized by autoclaving for 15 min at 121°C.  The prepared media 
was supplemented with 10% (50 ml) OADC enrichment (Middlebrook, BD, 
Difco), 10 mg of amphotericin B (50 mg/ml stock) and 25 mg hygromycin B 
(500 µl of 50 mg/ml stock) before use as solid growth medium for MTB lux. 
The medium was then poured into plates under sterile conditions and left to 
set. Plates were stored at 4°C until use. 
 
2.2.5.2 Preparation and storage of mycobacteria 
 
Recombinant mycobacteria (MTB lux) were grown into the logarithmic phase 
over 72 hours in a shaking incubator at 37°C in 7H9/ADC/Tween 
80/hygromycin medium. Logarithmic growth of MTB lux was initially detected 
by plating 100 µl aliquots of serial dilutions of MTB lux culture on solid media 
and counting colony-forming units (CFU) after 4 weeks of incubation at 37°C. 
Subsequently, mycobacterial growth was determined by measuring relative 
light units (1 CFU = 10 RLU). The culture was dispensed into 1 ml vials; 
glycerol (Sigma) was added to a final concentration of 25% and the vials 
frozen at -80°C. Each vial was shown to contain 1.8 x 107 RLU/ml viable 
mycobacteria. 
 
2.2.5.3 Preparation of mycobacterial culture for inoculation into whole blood 
 
Prior to each experiment, a vial of stored MTB lux was thawed, added to 15 
ml of 7H9/ADC/ Tween 80/hygromycin medium in a sterile disposable 250 ml 
Erlenmeyer flask (Corning) and incubated with shaking at 120 rev/min in a 
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37°C incubator for 72 hours. The mycobacteria were then resuspended in 
sterile PBS to a concentration of 4-5 x 106 RLU/ml prior to inoculation. 
 
2.2.5.4 Mycobacterial growth inhibition assay protocol 
 
A whole blood luminescence assay, as previously described (Kampmann et 
al., 2000), was performed. 5 ml of heparinised whole blood was diluted 1 in 2 
with RPMI 1640 medium (Sigma). 900 µl volumes of blood were then 
aliquoted into 7 ml screw top, endotoxin-free tubes (Sterilin, Merck), and 
inoculated with 100 µl luciferase-labelled M. tuberculosis H37Rv (MTB lux) at 
4-5 x 106 RLU/ml to give a final volume of 1 ml per tube. Cells were inoculated 
in triplicate with MTB lux at two time points: 0 and 96 hours to measure 
mycobacterial growth. A 24-hour lux sample was also set up in duplicate for 
supernatant analysis. An unstimulated control sample was also set up at each 
time point with blood and RPMI only. The sampl s were then incubated at 
37°C (no CO2) on a platform shaker (Merck, Stuart Scientific, STR6) set at 20 
rev/min. The 0 hour time point samples were analysed immediately after 
inoculation, on the day of blood collection. 
 
To harvest, samples were centrifuged for 10 minutes at 2000 x g and 400 µl 
supernatant was collected from each tube and filtered before storage at -80°C 
for future cytokine measurement. To readjust the volume, 400 µl of sterile 
PBS was added to the samples, before transferring to 25 ml Sterilin universal 
tubes and adding 10 ml dH2O to lyse the red blood cells. The samples were 
incubated for 10 minutes at room temperature and centrifuged for 10 minutes 
2000 x g to recover the MTB lux. The supernatant was discarded and the 
pellet was vortexed to disperse the MTB lux, and resuspended in 1 ml of 
sterile PBS. Samples were diluted 10-fold in duplicate (to minimise any 
reduction of luminescence in opaque samples [quenching]) prior to 
luminescence measurement. 
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2.2.5.5 Bioluminescence detection 
 
Luminescence was measured using a single tube luminometer (Turner Design 
20/20, Germany). This design uses an injectable port to inject 100 µl of the 
substrate, 1% n-decyl aldehyde, (Sigma) in ethanol into each luminometer 
tube (Sarstedt). Measurements were collected over 20 seconds from each 
tube and reported as a mean. Duplicate measurements were reported for 
each sample prepared in triplicate. An unstimulated control sample incubated 
with whole blood and RPMI only was included at each time point. Growth of 
MTB lux in mycobacterial culture medium only was also measured after 96h. 
Luminescence was measured in units of relative light units and results were 
expressed as a calculated growth ratio (GR), which relates the RLU reading at 
96 hours, to the RLU reading of the inoculum (0 hours), using the following 
formula: 
 
RLU of MTB lux at T96 
 Growth ratio =   
RLU of MTB lux at T0 
 
2.2.6 CD4 and differential count and viral load determination 
 
The full blood count (cells/µl and percentages), differential count (cells/µl and 
percentages) and viral load (log10 RNA copies/ml) determinations were 
routinely done at the National Health Laboratory Services (NHLS) and results 
were accessible to treating clinicians in the HIV clinic. CD4 T cell enumeration 
and viral load measurements were performed at enrolment and then at 3 
monthly intervals up to 12 months by the clinical laboratory services. The 
lower limit of detection for the viral load assay is <1.7 log10 RNA copies/ml. 
 
2.2.7 Statistical Analysis 
 
Statistical analysis was performed using GraphPad Prism version 5.0 for Mac 
OS X. Differences between groups were calculated first with a Kruskal Wallis 
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test, then Mann-Whitney or Wilcoxon matched pairs test. Correlations were 
calculated by non-parametric Spearman test. All tests were two-tailed, and a 
value of p <0.05 was considered significant. 
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CHAPTER 3 
 
Optimisation of an 8-colour flow cytometry panel to study 
mycobacteria-specific T cell populations 
 
3.1 Introduction 
 
3.2 Methods 
3.2.1 Immunofluorescence staining 
3.2.2 Antibody titration 
3.2.3 Effects of fixation on surface marker resolution 
3.2.4 Fluorescence minus one 
 
3.3 Antibody panel design and optimisation results 
3.3.1 Selecting markers of Interest 
3.3.2 Instrumentation 
3.3.2.1 Instrument Configuration: Laser and Detector considerations 
3.3.2.2 Instrument quality control and performance tracking 
3.3.3 Assignment of antibody-fluorochrome combinations 
3.3.3.1 Antigen density and antibody brightness 
3.3.3.2 Spectral overlap considerations and compensation 
3.3.4 Empirical process of final antibody selection 
3.3.4.1 Antibody titration 
3.3.4.2 Effects of fixation on surface marker resolution 
3.3.4.3 Staining protocol optimization for the analysis of surface markers 
3.3.5 Final antibody panel performance 
3.3.6 Experimental set up 
3.3.6.1 Sample size calculation for rare event analysis 
3.3.6.2 Intra-assay variability 
3.3.6.3 Gating strategy & Data Analysis of multiparameter data sets 
 
3.4 Discussion 
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3.1 Introduction 
 
Flow cytometry is a sensitive technique that allows detailed characterisation of 
immune responses at the single cell level (Appay et al., 2000; Betts et al., 
2003; Betts et al., 2006). Polychromatic flow cytometry (PFC), also called 
multiparameter flow cytometry, has evolved to allow measurement of more 
than 4 colours plus two physical characteristics; forward scatter (FSC) and 
side scatter (SSC) (Roederer et al., 1996; Roederer et al., 1997; De Rosa et 
al., 2003; Perfetto et al., 2004; De Rosa et al., 2004). These recent advances 
have greatly increased our understanding of the complexity of the immune 
system. Recent advances in flow cytometry instrumentation, software and 
reagents has shown increased application of this technique, especially in the 
field of T cell immunology (Harari et al., 2004; Betts et al., 2006; Darrah et al., 
2007) and vaccine development (Seder et al., 2008). 
 
This chapter describes the methods and systematic approach that were 
employed in this study, to develop an optimal antibody panel for measuring 
intracellular cytokine expression by multiparameter flow cytometry. To this 
end, an 8-colour antibody panel was developed and optimised to characterise 
function and memory phenotype of mycobacteria-specific CD4 and CD8 T 
cells. Optimisation of flow cytometry based polychromatic assays becomes 
more complex and time consuming as more parameters are included 
(Mahnke and Roederer, 2007). However, the wealth of information gained 
usually justifies the technical challenges. It is important for each researcher to 
titrate flow cytometry reagents and optimise the combinations of antibody-
fluorochromes in flow cytometry panels. Before the final flow cytometry assay 
was adopted in this study a large number of optimisation experiments were 
performed. The optimised panel was used to address the aims of this project, 
as stated in chapters 4 and 5. 
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3.2 Methods 
 
3.2.1 Immunofluorescence staining 
 
Optimisation experiments were performed using a single staining step when 
staining for surface markers only or the two-step staining method described in 
chapter 2 for ICS (section 2.2.4.2) on samples obtained from healthy adults. 
 
3.2.2 Antibody titration 
 
Each antibody was individually titrated by serial dilution to determine optimal 
antibody titre and staining performance. Titrations were performed on 
samples that had under gone the same treatment as the experimental 
staining, since temperature, light exposure and staining buffer might influence 
staining and antibody performance. To ensure antigen saturation twice the 
concentration recommended by the manufacture was selected as the starting 
titre. At least 10 two-fold serial dilutions were completed per antibody in 100 µl 
volumes. 
 
3.2.3 Effects of fixation on surface marker resolution 
 
Since all whole blood samples used in this study were fixed prior to staining 
with antibodies, the effects of fixation on the resolution of surface markers 
was assessed. A 1 ml fresh blood sample was ether stained immediately prior 
to fixing or 1 ml blood was add to 9 ml FACS lysing solution, vortexed and 
incubated at room temperature for 15 min, to lyse red blood cells. Cells were 
pelleted and stained with surface antibodies. 
 
3.2.4 Fluorescence minus one 
 
For fluorescence minus one, (FMO) experiments, one antibody was omitted at 
a time to assess potential false positives or spectral overlap issues, which 
could arise from interactions between fluorochromes in large antibody panels. 
A sample was stained with all the antibodies in the complete panel and 
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compared with a series of samples stained with the same panel while omitting 
one antibody in consecutive samples. FMO experiments were performed 
under the same conditions as the final experimental set-up. Data was 
analysed using the same gating strategy applied to the experimental samples. 
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3.3 Antibody panel design and optimisation results 
 
3.3.1 Selecting markers of Interest 
 
Markers of interest were included in the final panel by considering (1) the 
research question and (2) the ability to detect the markers of interest with the 
proposed assay system. The markers of interest characterised in this thesis 
include markers of T lymphocyte lineage (CD3, CD4, CD8), phenotype (e.g. 
CD45RA, CCR7, CD27) and function (IFN-!, IL2). The aim was to 
characterise antigen experienced CD4 and CD8 T lymphocytes (CD3+ T cells) 
in peripheral blood from children and healthy adult controls using 
multiparameter flow cytometry. Multiparameter flow cytometry allows 
integrated measurement of functional and phenotypic parameters relevant to 
TB immunity in limited volumes of paediatric blood samples. 
 
The rationale for inclusion of the markers selected in this study is reviewed in 
detail in chapter 1. CD4 and CD8 T, cell type 1 cytokine responses are known 
to be important in the immune response against M. tuberculosis (Schluger 
and Rom, 1998). This kind of immunity is therefore the most commonly 
measured when evaluating mycobacterial immunity. The memory T cell 
compartment is important in the context of successful vaccination and 
consists of both CD4 and CD8 T cells that can rapidly acquire effector 
functions to kill infected cells and/or secrete inflammatory cytokines that inhibit 
replication of the pathogen. Sallusto et al., have characterised memory T-cells 
into effector memory (CD27-, CD62L-, CCR7-) and central memory T cells 
(CD27+, CD62L+, CCR7+), with different functions and migratory properties 
(Sallusto et al., 1999). 
 
CD4 and CD8 T cell populations in this thesis were analysed for memory 
markers (e.g. CD45RA and CCR7), differentiation markers (e.g. CD27), as 
well as markers of cellular function (e.g. IFN-!). 
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3.3.2 Instrumentation 
 
3.3.2.1 Instrument Configuration: Laser and Detector considerations 
 
In order to design and optimise ICS panels the type of flow cytometry 
instrumentation that is available for sample acquisition must first be identified. 
The antibody-fluorochrome combinations discussed in the following sections 
was guided by the choice of instrument configuration (laser and detector: 
mirror/filter combinations) of the South African Tuberculosis Vaccine Initiative 
(SATVI) laboratory BD LSR II. Table 3.1 illustrates the configuration of the 
SATVI laboratory BD LSR II instrument, which is equipped with three different 
excitation light sources (lasers). 
 
The three lasers excite particles at distinct wavelengths: 488nm (blue), 405nm 
(violet) and 633nm (red). Detectors/photomultiplier tubes (PMTs) arranged in 
an octagon-shaped array collect light from the blue laser (Figure 3.1 A) and 
those in two trigon-shaped arrays collect light from the violet and red lasers 
(Figure 3.1 B and C, respectively) The blue laser PMT arrays measure up to 
seven parameters and those for the violet and red lasers up to three 
parameters each. Fluorescent emission wavelengths detected by the PMTs 
are based on filter combinations placed in front of each PMT. The LSR II is 
equipped with two types of filters: dichroic long pass (DCLP) and band pass 
(BP) filters (Perfetto et al., 2004). LP filters allow light above a specified 
wavelength to pass through the filter to be detected by the PMT. All light 
below this wavelength is reflected to the following PMT. The BP filter, in turn, 
only transmits light within a specified wavelength range to be detected by the 
following PMT. Any wavelengths, which fall outside this range, are not 
measured. 
 
For example, in Table 3.2, for the blue laser, wavelengths of light longer than 
735 nm are transmitted through a 735 LP filter and shorter wavelengths are 
reflected. The wavelengths are then passed through a 780/60 band pass (BP) 
filter that allows transmission of wavelengths longer than 750 and shorter than 
810 nm. This cascade of light culminates in measurement of the PE-Cy7 
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maximal emission (Em) wavelength (785nm) in PMT A. The wavelengths 
shorter than 735 nm are reflected to the next PMT (PerCP-Cy5.5). The 
instrument configuration thus dictates which types of fluorochrome reagents 
can be used with the available configuration (Baumgarth and Roederer, 2000; 
Perfetto et al., 2004; Mahnke and Roederer, 2007). 
 
 
Laser (%) 
Mirror 
LP (nm) 
Filter 
BP (nm) 
PMT 
Possible 
Fluorochromes 
Blue (488nm) 735 780/60 A PE-Cy7 
 685 695/40 B PerCP-Cy5.5 
 635 670/14 C PE-Cy5, PerCP 
 600 610/20 D PE-Texas Red 
 550 576/26 E PE 
 505 530/30 F FITC, AlexaFluor 488 
 Blank 488/10 G SSC 
 Blank Blank H  
     
Violet 
(405nm) 
630 655/8 A Quantum Dot 655 
 505 605/12 B Quantum Dot 605 
 Blank 440/40 C Pacific Blue 
     
Red (633nm) 735 780/60 A APC-Cy7 
 690 720/40 B AlexaFluor 700 
 Blank 660/20 C APC 
 
Table 3.1: Optical configuration of the SATVI Laboratory BD LSR II instrument 
%: wavelength, LP: long pass, BP: band pass, FSC: forward scatter, SSC: side 
scatter 
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Figure 3.1: Representation of photomultiplier tubes arranged in octagon and trigon  
arrays with fluorochromes selected for an for an 8-colour panel 
(A) Blue laser octagon array of PMTs and filters that can detect side scatter (SSC) 
and up to six fluorescence signals. (B) Violet laser trigon and (C) Red laser trigon 
array of PMTs and filters that can detect up to three fluorescent signals. From the BD 
Biosciences flow cytometry manual 2003. 
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3.3.2.2 Instrument quality control and performance tracking 
 
At the start of the study, instrument settings were optimised to ensure 
reproducible and reliable longitudinal experiments. Instrument baseline 
settings were established using Cytometer Setting and Tracking (CST) beads, 
(BD Biosciences). The LSR II used for this analysis was calibrated each day 
prior to sample acquisition using the CST beads. This procedure ensured that 
PMT voltages were adjusted to set fluorescence target values for each 
experiment and that flow cytometer instrument variation would be 
independent of this parameter. 
 
Validation of PMT voltages incorporates the CV, signal to noise ratio and PMT 
linearity curves. A tolerance target range was established for each channel 
and daily quality control (QC) standardization (performance checking) of the 
LSR II involved adjustment of PMT voltages within the target range in addition 
to laser alignment check. A daily QC ensures that any variation noted 
between different samples, within or between experiments is independent of 
the performance of the cytometer. 
 
Following this procedure, baseline PMT voltages for the flow cytometry 
antibody panel used in this study were established and target values were 
recorded for the baseline settings. These were saved as application settings 
and were applied to all subsequent acquisition sessions. 
 
3.3.3 Assignment of antibody-fluorochrome combinations 
 
In order to describe the desired aspects of T cell function and memory 
phenotype it was necessary to combine 8 different markers. Fluorescently 
labelled monoclonal antibodies specific for these markers of interest were 
selected for an 8-colour flow cytometry panel. Assignment of antibody-
fluorochrome combinations was an empirical and integrated process. 
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The following considerations were taken into account when designing the 
multiparameter panel: antibody brightness and antigen density, spectral 
overlap and compensation requirements. This process was further 
constrained by the available instrument configuration (lasers and PMTs) as 
well as the commercial availability of antibody conjugates. Because many of 
the antibody-fluorochrome combinations were already established in the 
SATVI laboratory, we established the study panel based on the following 
combinations: anti-CD3 Pacific Blue, anti-CD4 PerCP-Cy5.5, anti-CD4 
QD605, anti-CD8 Pacific Orange, anti-CD8 PerCP-Cy5.5, anti-CD45RA PE-
Cy7, anti-CCR7 APC, anti-CD27 PE, anti-IFN-! AlexaFluor700 and anti-IL-2 
FITC. 
 
3.3.3.1 Antigen density and antibody brightness 
 
Table 3.2 illustrates the fluorochromes, which were investigated for inclusion 
in the 8-colour staining panel. CD3/4/8 are abundantly expressed proteins, 
which identify major lineages of cells. Antibodies to these markers stain cells 
very brightly. This allows good resolution between negatively and positively 
staining cell populations resulting in a bimodal distribution. The expression 
pattern of CD45RA and CCR7 is often a continuum, resulting in less distinct 
resolution between negatively and positively staining cell populations. 
 
It is important to assign the brightest fluorochromes to dim markers, and vice 
versa (Baumgarth and Roederer, 2000; Maecker and Trotter, 2009). However, 
care must be taken to avoid spillover from bright cell populations into 
channels requiring high sensitivity for those populations (Baumgarth and 
Roederer, 2000; Maecker and Trotter, 2009). Following convention, dim 
markers were assigned to bright colours with little compensation spread and 
markers that are present at high density were assigned to dimmer 
fluorochromes (Table 3.2). 
 
The staining index (SI) of a fluorochrome gives a measure of the brightness of 
the fluorochrome relative to its level of noise in unstained cells (Baumgarth 
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and Roederer, 2000; Maecker and Trotter, 2009). Fluorochromes with high SI 
allow clear discrimination between positive and negative populations and 
were, therefore, assigned to dim markers. Markers with high expression were 
assigned to fluorochromes with lower SI. For example, a bright fluorochrome, 
such as PE-Cy7, was chosen for CD45RA, while a dimmer fluorochrome, like 
Pacific Blue, was used for CD3. 
 
 
 Marker Fluorochromes tested 
CD3 Pacific Blue 
CD4 PerCP-Cy5.5, Quantum Dot 605 
CD8 Pacific Orange, PerCP-Cy5.5 
CD45RA PE-Cy7 
CCR7 APC 
P
he
no
ty
pe
 
CD27 PE 
IFN-! AlexaFluor700 
Fu
nc
tio
n 
IL-2 FITC 
 
Table 3.2: Fluorochromes investigated for inclusion into the 8-colour staining panel 
 
 
3.3.3.2 Spectral overlap considerations and compensation 
 
Fluorochromes emit light over a wide wavelength range. This can lead to 
spectral overlap between dyes that emit light at similar wavelengths and are 
detected in more than one detector (Figure 3.2) (Baumgarth and Roederer, 
2000; BDBiosciences, 2010). For example in (Figure 3.2), FITC emits in the 
FITC channel (primary fluorochrome) as well as in the PE channel (secondary 
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fluorochrome). This spectral overlap is accounted for by compensation 
(Bagwell and Adams, 1993; Roederer et al., 1997; Roederer, 2001). This 
subtracts light of the primary fluorochrome from the signal in the secondary 
fluorochrome. It is best to choose fluorochromes that do not require too much 
compensation (i.e. have little fluorescence overlap), but with multicolour 
experiments this becomes unavoidable (Baumgarth and Roederer, 2000). 
 
 
 
Figure 3.2: Fluorescence spectra showing overlap between closely emitting  
fluorochromes 
The spectral emission wavelength of FITC overl ps into the PE detector channel. 
Adapted from (BDBiosciences, 2010). 
 
We used anti-mouse immunoglobulin (Ig) kappa (&) CompBeads (BD 
Biosciences), to calculate compensation for each flow cytometry experiment, 
(Figure 3.3 A-D). The CompBeads provide distinct negative (background 
fluorescence) and positive stained bead populations and sufficient numbers of 
positive events to allow calculation of accurate compensation 
(BDBiosciences, 2009a). They consist of two populations of microparticles: 
the positive control anti-mouse Ig & CompBeads bind any mouse Ig, while the 
negative control CompBeads do not bind Ig (BDBiosciences, 2009b). The 
CompBeads were stained with a single antibody-fluorochrome conjugate 
(single stain compensation control) for all fluorochromes included in an 
experiment. 
 
Compensation aligns the median of the negative and positive cell populations 
(Figure 3.3 B and D) (Bagwell and Adams, 1993; Herzenberg et al., 2006). 
Figure 3.3 B and D illustrates that individual cells fall above or below the 
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median (e.g. when plotting FITC against PE or PerCP-Cy5.5 against 
Alexafluor700), resulting in data spread. This apparent broadening of the data 
is a result of applying compensation, when the correction or subtraction of 
fluorescence is the result of two relatively large numbers (i.e. the statistical 
variance of the fluorescence measurements increases with the correction 
applied) (Herzenberg et al., 2006). Data spread can give false positives with 
brightly stained cells. Therefore, care must be applied when choosing 
fluorochrome combinations and gating strategies should be optimised. 
 
 
 
Figure 3.3: Compensating for spillover and data spread 
(A) Uncompensated cells stained with FITC fluoresce in the PE channel. (B) After 
compensation the median of the negative population is aligned with the positive 
population. (C) Prior to compensation CD8 cells stained with PerCP-Cy5-5 fluoresce 
in the AlexaFluor700 channel. (D) Compensation correctly aligns the negative and 
positive populations. 
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3.3.4 Empirical process of final antibody selection 
 
We initially investigated the use of a Pacific Orange conjugated antibody (CD8 
Pacific Orange) to detect CD8 T cells. However, because of the poor 
resolution between the CD8 negative and positive populations with this 
antibody as shown in Figure 3.4 A, this antibody was excluded from the 
panel. CD8 PerCP-Cy5.5 showed a better resolution between the positive and 
negative CD8 populations, and was used instead for the final panel (Figure 
3.4 B). We then investigated inclusion of a relatively new fluorochrome, 
Quantum Dot 605 (QD605), which has relatively narrow emission spectra 
(Chattopadhyay et al., 2006) and therefore, less compensation requirements. 
Initially, QDot605 was only available as a biotinylated antibody, requiring a 
two-step staining method. The cells were first stained with CD4 biotin for 30 
minutes, followed by a 30 minute staining step with streptavidin QDot605. We 
elected to change to the directly conjugated antibody when it became 
commercially available, to avoid the two-step labeling. 
 
 
 
Figure 3.4: Histograms showing whole blood staining of C3+CD8 T cells with two  
different fluorochrome-conjugated antibodies 
(A) CD8 Pacific Orange-conjugated antibody shows decreased resolution between 
negative and positive population in the 8-colour panel.  (B) CD8 PerCP-Cy5.5-
conjugated antibody shows optimal resolution of negative and positive populations in 
the 8-colour panel. 
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3.3.4.1 Antibody titration 
 
It was important to determine the optimal concentration for each antibody as 
this allows the identification of the lowest titer that could be used while 
allowing near maximal staining and achieving good resolution between the 
positive and negative cell populations. This is referred to as the signal-to-
noise (S/N) ratio. The CCR7 APC titration illustrates this point: the optimal titer 
for CCR7 APC was chosen by identifying the positive and negative cell 
populations for CCR7 and, for each of these, the median fluorescence 
intensity (MFI) was calculated. The ratio between the MFI of the positive and 
negative cells was then calculated and plotted along with the frequency of the 
positively staining cell population for each antibody volume. Figure 3.5 A and 
B illustrates the optimal titer chosen for CCR7 APC. The optimal titre lies on 
the plateau of a titration curve indicating maximal staining of the positive 
staining cells (saturation point). The saturation point was reached at 2.5 µl of 
CCR7 APC antibody (Figure 3.5 B). The best resolution of positive and 
negative staining cells (highest S/N ratio) was reached at 5 µl. To achieve 
better resolution between the positive and negative cell populations of CCR7 
APC the 5 µl volume was chosen, especially, since the expression pattern of 
CCR7 is often a continuum. More coluors mean more spillover issues, with 
loss of resolution sensitivity in affected detectors. The optimal staining 
volume/concentration was titrated for each fluorochrome-conjugated antibody. 
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Figure 3.5: Titration of APC conjugated CCR7 antibody 
(A) The gates represent the CD3+ CCR7+ and CD3+ CCR7- populations displayed as 
contour plots after stimulation of whole blood with Ag85B/TB10.4. The antibody was 
titrated by serial dilution from a volume of 20µl to 0.039µl in 100µl. (B) The 
frequencies of CD3+ CCR7+ cells and signal-to-noise ratios in relation to antibody 
volume. 
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3.3.4.2 Effects of fixation on surface marker resolution 
 
To determine the effects of fixation on surface marker staining and antibody 
performance, fresh whole blood was stained with antibodies before fixing the 
cells and compared with whole blood stained after fixation with FACS lysing 
solution. Figure 3.6 illustrates that resolution between positive and negative 
staining cells was maintained for CD45RA PE-Cy7 after fixation and results 
were comparable to freshly stained samples. Similarly, CCR7 APC and CD27 
PE maintained reliable resolution after fixation between positive and negative 
staining cells (data not shown). 
 
 
 
 
 
Figure 3.6: Effect of fixation with FACS lysing solution on surface marker staining 
CD4 (red shading) and CD8 (blue line) T cell histogram overlays illustrating 
resolution of positive and negative CD45RA populations in (A) fresh and (B) fixed 
whole blood. 
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3.3.4.3 Staining protocol optimization for the analysis of surface markers 
 
The effect of the staining technique on the resolution of surface markers and 
on antibody performance was determined by staining with staining buffer and 
compared with Perm/Wash buffer. Figure 3.7 illustrates that better resolution 
of positive and negative populations of CCR7 was achieved for both CD4 and 
CD8 T cells when staining with Perm/Wash buffer compared with 1% BSA 
(staining buffer). Good resolution was achieved for all other surface markers 
when staining with Perm/Wash buffer. 
 
 
 
 
Figure 3. 7: Staining protocol for the analysis of surface markers 
CCR7 APC staining in (A) Staining buffer and (B) Perm/Wash buffer. 
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3.3.5 Final antibody panel performance 
 
To test for fluorescence spillover effects in the 8-colour panel as well as 
overall performance of the 8-colour panel the fluorescence minus one (FMO) 
experiment was performed, where cells are stained with all antibodies except 
one. Figure 3.8 shows an example of a FMO experiment where all antibodies 
were included except CD4 QDot 605. This method allows detection of 
fluorescence signal caused by any of the other fluorochromes in the QDot 605 
detector (false positive). The spectral overlap was assessed by recording the 
frequencies of cells expressing each marker on cells with or without each 
antibody on cells within the lymphocyte gate. Table 3.3 shows the frequencies 
obtained when each antibody fluorochrome was excluded. No significant false 
fluorescence signal was detected in any of the channels (Table 3.3). Table 
3.4 illustrates the final optimal staining panel and optimal staining volumes. 
 
 
 
 
Figure 3.8: Example of fluorescence minus one experiment missing CD4 Qdot605 
Density plots weree gated on CD3+ T cells except for CD3 Pacific Blue, which is 
gated on lymphocytes. 
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Antibody Fluorochrome Clone 
Optimal volume  
(µl) 
CD3 Pacific Blue UCHT1 1 
CD4 Quantum Dot 605 S3.5 0.5 
CD8 PerCP-Cy5.5 SK1 5 
CD45RA PE-Cy7 L48 5 
CCR7 APC 150503 5 
CD27 PE MT271 10 
IFN-! AlexaFluor700 B27 1 
IL-2 FITC 5344.111 5 µl 
 
Table 3.4: Final 8-colour panel and antibody titers 
 
3.3.6 Experimental set up 
 
3.3.6.1 Sample size calculation for rare event analysis 
 
When assessing antigen specific responses relatively small frequencies are 
expected (<5%). The power calculator developed by Holden Maecker was 
used to determine the number of events required to obtain a power of 90%, 
p<0.05, (downloaded from http://maeckerlab.typepad.com). Table 3.5 shows 
the number of events of CD4 and CD8 T cells required for acquisition for 
reliable rare event analysis. The median levels for backgrounds and Ag85B-
TB10.4-specific responses for IFN-! and IL-2 were calculated from a whole-
blood experiment performed on six adult volunteers. The analysis revealed 
that approximately 152000 CD4 T cells and about 687000 CD8 T cells were 
required to allow reliable detection of IFN-! IL-2 expressing cells over 
background. The power calculator was used as a tool/guide to predict the 
necessary sample size/number of cells to be acquired to be confident to have 
enough positive events above background in any given marker/cell sub-
population. However, due to small numbers of possible events, especially in 
HIV infection the entire sample was acquired. 
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 CD4 CD8 
Cytokine IFN-! IL-2 IFN-! IL-2 
Frequency of cells in unstimulated 
control (% Background) 
0.02 0.02 0.01 0.02 
Frequency of cells in stimulated 
sample (% Positive events) 
0.08 0.04 0.02 0.03 
Number of events required 23877 128961 257961 429893 
 
Table 3.5: Sample size required for rare event analysis 
The power calculator developed by Holden Maecker was used to determine the 
number of events to acquire when assessing cytokine production. Downlaoded from 
(http://maeckerlab.typepad.com). 
 
3.3.6.2 Intra-assay variability 
 
To assess intra-assay variability of the ICS assay, six identical samples from 
the same adult volunteer were simultaneously stained with the 8-colour panel 
shown in Table 3.4. Table 3.6 shows the coefficient of variation (CV) 
calculated for the six experiments. The CVs were calculated using the mean 
percentage of cytokine positive cells (IFN-!+ or IL-2+) for both CD4 and CD8 T 
cells and standard deviation. The CVs for cytokine positive CD4 (IFN-!+ or IL-
2+) and for IFN-!+CD8 T cells were <10%. However, the CV increased to 
>20% at very low frequencies of positive cells as seen with IL-2+CD8 T cells. 
The reliability of significant differences becomes questionable at these very 
low values. 
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Table 3.6: Intra assay variability: coefficient of variation of cytokine positive T cells 
 
3.3.6.3 Gating strategy & Data Analysis of multiparameter data sets 
 
We started by excluding doublets from the analysis by gating on forward-
scatter (FSC)-height vs. FSC-area. Doublet events may either be the 
consequence of two cells sticking together, or two cells have passed through 
the laser beam so close to each other that they have been interpreted as a 
single event. When this involves two different cell types the flow cytometer will 
record that a cell displaying the characteristics of both cell-types was present 
in the sample (double-positive). This can be highly misleading, especially 
when evaluating a rare marker. 
 
Small lymphocytes were selected by gating on SSC-Area and FSC-Area. T 
lymphocytes were selected by gating on the CD3+ cells, which were 
subsequently differentiated into CD4 and CD8 T cells. Backgating confirmed 
that the cytokine expressing cells were found at the centre of the lymphocyte 
gate (i.e. within the mid fluorescent range). Intracellular cytokine expression 
was analysed in the predefined CD4 and CD8 T cell populations by using 
Boolean gating to determine the combination of cytokines produced. 
 
 CD4 CD8 
 IFN-! IL-2 IFN-! IL-2 
Minimum (%) 0.301 0.154 0.097 0.028 
Median (%) 0.366 0.174 0.106 0.048 
Maximum (%) 0.383 0.199 0.119 0.055 
Mean (%) 0.355 0.174 0.106 0.046 
Std. Deviation 0.03 0.02 0.01 0.01 
Coefficient of variation (%) 8.47 9.65 8.28 22.23 
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Figure 3.9 illustrates the performance of the final panel and the gating 
strategy that was used to characterize cytokine producing CD4 and CD8 T 
cell populations. This gating strategy was used to analyse both the cross-
sectional and the longitudinal data, in chapter 4 and 5, respectively. 
 
To account for background or spontaneous cytokine production frequencies of 
cytokine expressing cells in the negative control (unstimulated sample) were 
subtracted from frequencies measured in the stimulated samples. Participants 
were excluded from the analysis for any of the following reasons: (1) a 
positive control (SEB) response less than the median plus 3 median absolute 
deviations (MAD) above median background of the negative control, (2) less 
than 40 positive events in the stimulated sample for phenotypic analysis. All 
values of zero were adjusted to 0.001 for plotting on the logarithmic scale. 
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Figure 3.9: Final performance of the panel used to identify mycobacteria-specific  
CD4 and CD8 T cells 
(A) Representative density plots showing the gating strategy used to identify CD4 
and CD8 T cells from whole blood. From left to right, cell doublets were excluded 
using forward scatter-area and forward scatter-height parameters. Small lymphocytes 
were then selected. T cells were selected by gating on CD3+ cells and this was then 
followed by selection of CD4 and CD8 T cells. (B) Representative plots showing IFN-
! and IL-2 expression by unstimulated (Nil), SEB, ESAT-6, Ag85B/TB10.4, or PPD, 
stimulated CD4 or (C) CD8 T cells. 
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3.4 Discussion 
 
In the present chapter the key points in the optimisation process were titration 
of individual fluorochrome conjugated antibodies, spectral overlap 
considerations and control of compensation. Establishing a multi-parameter 8-
colour panel to simultaneously assess phenotypic and functional T cell 
markers has presented technical challenges, but these were overcome by a 
meticulous, step-wise approach to assess all variables that may influence 
outcome. We have confirmed that the following steps or considerations should 
be adhered to when starting up a flow cytometry panel: 1) select 
fluorochromes for brightness and least spillover, 2) optimize antibody panels 
by taking into account reagent brightness and data spread, 3) Standardise 
longitudinal experiments with proper QC, 4) put systems into place to allow 
streamlined and reproducible analysis. Optimisation experiments give 
valuable knowledge on the strengths and weaknesses of an assay, thereby 
aiding the extraction of meaningful information from complex data sets. 
 
We were successful in the development and optimization of an 8-colour flow 
cytometry panel to comprehensively and reliably assess mycobacteria-
specific T cell cytokine expression combined with the ability to phenotype the 
memory T cells in small whole blood samples collected from paediatric 
populations. Relevant markers were selected to address the research 
questions in this study allowing the characterisation of functional profiles and 
memory subsets of CD4 and CD8 T cells. Various antibody-fluorochrome 
combinations were assessed and suboptimal or poorly performing reagents 
were excluded from the final antibody panel. 
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CHAPTER 4 
 
CD4 and CD8 T cell responses to mycobacterial antigens 
 
4.1 Introduction 
 
4.2 Methods 
 
4.3 Results 
4.3.1 Participant recruitment and demographics 
4.3.2 Mycobacteria-specific CD4 and CD8 T cell frequencies were detectable 
in all groups of children 
4.3.3 Frequencies and proportions of polyfunctional CD4 and CD8 T cells 
4.3.4 Co-variants of the Ag85B/TB10.4-specific CD4 and CD8 T cell response 
4.3.5 Antigen-specific CD4 and CD8 T cells express an effector memory 
phenotype 
4.3.6 T cell memory phenotypes are comparable in healthy and diseased 
children 
 
4.4. Discussion 
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4.1 Introduction 
 
Children are known to have a much higher risk of severe disease from 
tuberculosis (TB) than adults and better protection from TB has been 
identified as an international health and research priority in both adults and 
children (Nelson and Wells, 2004; Lienhardt et al., 2003). As part of the World 
Health Organisation (WHO) expanded program of immunisation (EPI), the 
only licensed vaccine against TB, bacille Calmette-Guérin (BCG), is given to 
more infants worldwide than any other childhood vaccine. However, it is well 
established that BCG has limited value in curbing the global TB epidemic, as 
it affords variable and mostly poor protection against pulmonary TB (Trunz et 
al., 2006). HIV infection is a major contributor to the TB epidemic, as 
associated immune compromise dramatically increases the risk of TB disease 
(Lawn and Churchyard, 2009; Abdool Karim et al., 2009). HIV-infected 
children are more susceptible to TB than HIV-uninfected children. Mortality in 
children with concomitant HIV infection has been reported to be as high as 
13% in HIV-infected children compared with 1.5% in HIV-uninfected children 
in a South African study in children (Madhi et al., 2000). 
 
Currently, there is no evidence to suggest that BCG confers protection against 
TB in HIV-infected infants and children (WHO, 2004), but might in fact be 
potentially harmful by causing dissemination, resulting in BCGosis (Hesseling 
et al., 2007; Hesseling et al., 2009). The HIV status of most infants is 
unknown at birth, when the BCG vaccine is routinely administered, especially 
in resource poor settings where there is lack of public health infrastructure to 
assess HIV status of the mother. Many infants with HIV infection therefore 
continue to receive the vaccine. BCG-related disease may also manifest as 
an immune reconstitution syndrome (BCG-IRIS) once antiretroviral therapy 
(ART) is commenced, particularly in children with very low CD4 T cell counts 
(Smith et al., 2009). A more efficacious vaccine that is safe in 
immunocompromised persons and confers protection to HIV-infected 
individuals is therefore urgently needed (Newton et al., 2008). 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 82 
Any successful vaccine is required to generate long-lived immunological 
memory and induce protective immune responses. However, despite 
longstanding research efforts, the “correlates of protection”, i.e. markers that 
can be measured in peripheral blood to reflect protective immune responses 
against TB, continue to be ill defined. Animal and human studies have shown 
that antigen-specific CD4 T cells are critical, (Mogues et al., 2001; Saunders 
et al., 2002; Havlir and Barnes, 1999), since impairment of CD4 T cell 
responses, such as in HIV, lead to dramatic increase in TB susceptibility, 
partially reversible by treatment with ART. CD8 T cells also appear important 
for protection (Behar et al., 1999; Derrick et al., 2004; Billeskov et al., 2007; 
Bruns et al., 2009; Chen et al., 2009). The generation of antigen-specific 
memory/effector T cell populations by a given TB vaccine candidate has 
therefore been the focus of immunological read-outs for novel TB vaccines. 
These immune responses have not been studied in great detail in HIV 
infected patients (Wilkinson et al., 2009), particularly not in children. 
 
Since human studies have demonstrated disease susceptibility to intracellular 
pathogens in persons with genetic defects in the IFN-! and IL-12 pathways 
(Flynn et al., 1993; Orme et al., 1993; Newport et al., 1996; Ottenhoff et al., 
1998; Ottenhoff et al., 2005), it is widely accepted that “protective” T cells 
should express T helper type 1 (Th1) cytokines, such as IFN-!, IL-2 and TNF-
". IL-2 is required for secondary expansion of memory T cells (Williams et al., 
2006; Dooms et al., 2007). Further, polyfunctional T cells, which co-express 
two or more cytokines, have been associated with more effective control of 
murine intracellular infections (Darrah et al., 2007), including M. tuberculosis 
(Forbes et al., 2008), but convincing human data are currently lacking. 
 
T cell cytokine expression has been linked with cell surface expression of 
markers of memory phenotype in viral infections in mice (Sallusto et al., 1999) 
and humans (Harari et al., 2005). CD45RA, which is lost by T cells upon 
priming, differentiates naïve and memory (antigen-experienced) T cells. 
However, this marker can be re-expressed, in some more extensively 
differentiated populations. Within the antigen-experienced population, 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 83 
expression of CCR7 defines central memory T cells (TCM) which classically 
express IL-2 and are able to home to lymphoid organs. Although these cells 
are thought to lack immediate effector function, they are long lived and 
proliferate rapidly upon antigen reencounter. By contrast, effector memory T 
cells (TEM), which lack CCR7 expression, predominantly express effector 
cytokines, such as IFN-! (Sallusto et al., 1999; Harari et al., 2005). These 
populations can be further dissected according to their degree of 
differentiation, based on the expression level of CD27. This co-stimulatory 
marker is sequentially lost during T cell differentiation (Fritsch et al., 2005). 
 
To date, very few studies have analyzed mycobacteria-specific T cell 
immunity in detail in children beyond infancy (Tena et al., 2003). It is unknown 
whether HIV-infected children can mount similar T cell responses to healthy 
children upon vaccination with novel TB vaccines. In this cross-sectional study 
we aimed to delineate the type of T cell responses that may be boosted by 
new TB vaccines in three groups of children. To achieve this aim the function 
and memory phenotype of mycobacteria-specific T cells were characterised in 
African children with and without HIV-infection. 
 
4.2 Methods 
 
Whole blood was collected from 3 groups of BCG-vaccinated children: HIV 
unexposed healthy children (n=30), HIV-seronegative children receiving TB 
treatment (n=30) and HIV-infected children without TB (n=30). Blood was 
stimulated with specific mycobacterial antigens for a total of 7 hours as 
described in chapter 2. T cell cytokine production by CD4 and CD8 T cells as 
well as the memory phenotype of these antigen specific T cells was 
determined using an 8-colour flow cytometry panel as detailed in chapter 3. 
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4.3 Results 
 
4.3.1 Participant recruitment and demographics 
 
Children were recruited at clinics in African communities from TB endemic 
areas in the Western Cape region, as described in chapter 2, in section 2.2.2. 
The demographic characteristics of all children are summarised in Table 4.1. 
 
We enrolled 30 children of similar age into each of the three study groups 
(overall median age: 3 years, interquartile (IQR) range: 1-5 years). All children 
had routinely received BCG vaccination at birth, as part of the Expanded 
Programme on Immunisation (EPI) in South Africa. All children (n=30) 
enrolled into the healthy control group (HC) were clinically well, had normal 
full blood count and C-reactive protein (CRP) levels and no other signs of any 
ongoing infection or inflammation. 
 
All children enrolled into the TB group (TB) were receiving standard treatment 
for TB with isoniazid, rifampicin and pyrazinamide for a median of 4 months 
(range: 2-6 months). Twenty-nine children had pulmonary TB, 1 child had TB 
of the spine. In 7 cases, TB had been microbiologically confirmed by positive 
culture. In the other 23 cases TB was diagnosed based on epidemiological 
history, signs and symptoms consistent with TB, abnormal chest X-ray, a 
positive tuberculin skin test (induration > 10mm) and clinical improvement 
after start of TB treatment. 
 
All HIV-infected children had perinatally acquired HIV infection and had 
advanced HIV disease, fulfilling clinical and/or immunological criteria for 
starting antiretroviral therapy (ART), according to WHO guidelines (WHO, 
2008). The CD4 percentages of these HIV-infected children are well below 
percentages reported for age-matched healthy African children from Uganda 
(IQR: 18.8%–45.8%) (Lugada et al., 2004). Any children with reported 
exposure to an active TB case in their household were excluded from the HC 
and HIV groups. 
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Healthy 
Controls 
(n=30) 
TB Diseased 
(n=30) 
HIV-Infected 
(n=30) 
Male/female  
 
17/13 
 
17/13 
 
15/15 
Ethnicity    
Black 27 27 26 
Mixed race 1 3 4 
White 2 0 0 
Age in years, median (IQR) 3.5 (1-5) 3 (1-4) 3.5 (1-6) 
<1 2 4 6 
1 - 5 23 22 16 
6 - 12 5 3 8 
>12 0 1 0 
CD4 absolute count 
(cells/µl), median (IQR) 
N/A N/A 531 (284-1259) 
CD4 percentage, median 
(IQR) 
N/A N/A 
17.85 (12.93-
21.45) 
Viral load (log10 RNA 
copies/ml), median (IQR) 
N/A N/A 4.8 (4.30-5.76) 
 
Table 4.1: Study participant demographic characteristics 
IQR; interquartile range, N/A; not available 
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4.3.2 Mycobacteria-specific CD4 and CD8 T cell frequencies were detectable 
in all groups of children 
 
We used flow cytometry to evaluate the frequency of CD4 and CD8 T cells 
expressing IFN-! and IL-2 in whole blood from the three groups of children 
after antigen stimulation (Figure 4.1). Cytokine expression in unstimulated 
samples was very low and mostly undetected. All groups of children 
responded to the positive control (SEB). There were no significant differences 
in response to the positive control between any of the different study groups 
(data not shown). When blood was stimulated with Ag85B/TB10.4, CD4 T 
cells typically expressed IFN-! and/or IL2 (Figure 4.1 B), whereas CD8 T cells 
expressed mostly IFN-!. 
 
 
 
Figure 4.1: Functional characterisation of Ag-specific T cell cytokine expression by  
intracellular cytokine staining and flow cytometry 
(A) Representative density plots, from a single healthy child, showing the gating 
strategy used to identify cytokine expressing CD4 and CD8 T cells from whole blood. 
From left to right, cell doublets were excluded using forward scatter-area and forward 
scatter-height parameters. Small lymphocytes were then selected. T cells were 
selected by gating on CD3+ cells, followed by selection of CD4 and CD8 T cells. (B 
and C) Representative plots showing IFN-! and IL-2 expression in unstimulated (Nil), 
SEB and Ag85B/TB10.4 stimulated CD4 (B) or CD8 (C) T cells. 
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Although fewer CD3+ cells were available for analysis from HIV-infected 
children (median (IQR): 154,670 (104,156–294,199)), compared with the 
number of CD3+ T cells from HC children (median (IQR): 254,468 (165,733–
345,048); p=0.026) and non-HIV-infected children with TB (median (IQR): 
247,026 (165,000–393,612); p=0.036), mycobacteria-specific CD4 and CD8 T 
cells were readily detectable, even in HIV-infected children. Frequencies of 
these specific cells were observed in a remarkably broad range, between 0 
and 10.36% in all three groups (Figure 4.2). 
 
Total cytokine-expressing (IFN-!+ and/or IL-2+), total IFN-! or total IL-2 
Ag85B/TB10.4-specific CD4 T cell frequencies were significantly lower in HIV-
infected children, compared with the TB group (Figure 4.2 A-C). There were 
no differences in Ag85B/TB10.4-specific CD4 T cell frequencies between HIV-
infected children and children in the HC group. Frequencies of PPD-specific 
CD4 T cells, expressing total cytokine, or IFN-! or IL-2 were also significantly 
higher in the TB group, compared with both the HC and HIV-infected groups 
(Figure 4.3 A-C). Similarly, ESAT-6-specific CD4 T cells were detectable in 
all three groups of children, although mostly at very low frequencies. Again, 
total cytokine-expressing or total IFN-! ESAT-6-specific CD4 T cell 
frequencies were significantly lower in the HIV-infected children, compared 
with the TB group (Figure 4.4 A-C). 
 
There was no difference in frequencies of total cytokine or total IFN-!-
expressing Ag85B/TB10.4-specific CD8 T cells between the 3 groups (Figure 
4.5 A-C). Total IL-2-expressing Ag85B/TB10.4-specific CD8 T cells were 
significantly lower in HIV-infected children, compared with both the TB and 
HC groups (Figure 4.5 C). However, the validity of this difference was 
questionable since the Ag85B/TB10.4-specific IL-2-expressing CD8 T cell 
frequencies were very low. Peptide antigens are perceived to be more optimal 
for stimulating CD8 T cell responses as these antigens would require less 
processing and are better recognized by CD8 T cells. However, as our own 
data confirm, strong CD8 responses can also be elicited using protein 
antigens. Concentrations and type of antigen and time-course are likely to 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 88 
play a role in the quality and quantity of such responses. However, control 
experiments using peptides of the same antigens revealed highly correlated 
results (data not shown). Frequencies of PPD-specific CD8 T cells were low in 
all groups of children and no differences between groups were observed (data 
not shown). Similarly, no difference in total cytokine, total IFN-! or total IL-2 
expression by ESAT-6-specific CD8 T cells was observed (data not shown). 
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Figure 4.2: Ag85B/TB10.4-specific CD4 T cell responses measured by intracellular  
cytokine  
staining and flow cytometry in whole blood from the three groups of children 
Each symbol represents an individual and for each plot, the median is represented by 
the horizontal line. (A) Frequencies of Ag85B/TB10.4-specific, total cytokine+ (IFN-!+ 
and/or IL-2+) CD4 T cells (B) total IFN-!+ or (C) total IL-2+ CD4 T cells after 
incubation with recombinant proteins. Differences between any two groups were 
calculated using the Mann Whitney U test. HC, healthy controls; TB, children with TB; 
HIV, children with HIV-1 infection. 
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Figure 4.3: PPD-specific CD4 T cell responses in the three groups of children 
Each symbol represents an individual and for each plot, the median is represented by 
the horizontal line. (A) Frequencies of PPD-specific, total cytokine+ (IFN-!+ and/or IL-
2+) CD4 T cells (B) total IFN-!+ or (C) total IL-2+ CD4 T cells. Differences between 
any two groups were calculated using the Mann Whitney U test. HC, healthy controls; 
TB, children with TB; HIV, children with HIV-1 infection. 
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Figure 4.4: ESAT-6-specific CD4 T cell responses 
Each symbol represents an individual and for each plot, the median is represented by 
the horizontal line. (A) Frequencies of ESAT-6-specific, total cytokine+ (IFN-!+ and/or 
IL-2+) CD4 T cells (B) total IFN-!+ or (C) total IL-2+ CD4 T cells. Differences between 
any two groups were calculated using the Mann Whitney U test. HC, healthy controls; 
TB, children with TB; HIV, children with HIV-1 infection. 
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Figure 4.5: Ag85B/TB10.4-specific CD8 T cell responses in the three groups of  
children 
(A) Frequencies of Ag85B/TB10.4-specific, total cytokine+ (IFN-!+ and/or IL-2+) CD8 
T cells. Each symbol represents an individual and for each plot, the median is 
represented by the horizontal line. (B) total IFN-!+ or (C) total IL-2+ CD8 T cells. 
Differences between any two groups were calculated using the Mann Whitney U test. 
HC, healthy controls; TB, children with TB; HIV, children with HIV-1 infection. 
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4.3.3 Frequencies and proportions of polyfunctional CD4 and CD8 T cells 
 
Cells that co-express cytokines have been suggested to provide better 
protection against intracellular infections than cells that express only a single 
cytokine (Darrah et al., 2007). We compared the frequencies of cytokine co-
expressing cells between the 3 groups of children. HIV-infected children had 
significantly lower frequencies of Ag85B/TB10.4-specific CD4 T cells co-
expressing IFN-! and IL-2 than children with TB (p=0.002, Figure 4.6 A). 
Ag85B/TB10.4-specific CD4 T cells expressing IFN-! alone were also 
significantly less frequent in HIV-infected children, compared with children 
with TB (p=0.029). 
Frequencies of bi-functional expressing PPD-specific CD4 T cells were 
significantly lower in HIV-infected and HC groups compared to children with 
TB (p=0.002 and p=0.004, respectively; Figure 4.7 A). This was also true for 
mono-functional IFN-!-expressing CD4 T cells in HIV-infected and HC groups 
compared to the TB group (p=0.028 and p=0.014, respectively). 
Similarly, ESAT-6-specific bi-functional CD4 T cells were significantly lower in 
HIV-infected compared with children with TB (p=0.0003, Figure 4.8 A). 
Healthy children appeared to have lower ESAT-6-specific bi-functional CD4 T 
cells, but this was not significant (p=0.05). 
 
Despite the low frequencies of Ag85B/TB10.4-specific CD8 T cells producing 
IL-2 alone or co-expressing IFN-! and IL-2 in all three groups of children, 
these subsets were significantly less frequent in HIV-infected children, 
compared with the TB group (p=0.024 and p=0.040, respectively; Figure 4.9 
A). IL-2 expressing mono-functional CD8 T cell frequencies were also lower in 
the HIV-infected group compared with healthy controls (p=0.01, Figure 4.9 
A). 
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Figure 4.6: Analysis of the quality of Ag85B/TB10.4-specific CD4 T cells in the three  
groups of children 
(A) Frequencies of bifunctional or monofunctional specific CD4 T cells. Each symbol 
represents an individual and for each plot the median is represented by the horizontal 
line. (B) Pie charts represent the mean proportions of cells co-expressing IFN-! 
and/or IL-2, among the total CD4 T cell response, after stimulation with 
Ag85B/TB10.4. Differences between any two groups were calculated using the Mann 
Whitney U test. HC, healthy controls; TB, children with TB; HIV, children with HIV-1 
infection. 
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Figure 4.7: Analysis of the quality of PPD-specific CD4 T cells 
(A) Frequencies of bifunctional or monofunctional specific CD4 T cells. Each symbol 
represents an individual and for each plot, the median is represented by the 
horizontal line. (B) Pie charts represent the mean proportions of cells co-expressing 
IFN-! and/or IL-2, among the total CD4 T cell response, after stimulation with PPD. 
Differences between any two groups were calculated using the Mann Whitney U test. 
HC, healthy controls; TB, children with TB; HIV, children with HIV-1 infection. 
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Figure 4.8: Analysis of the quality of ESAT-6-specific CD4 T cells in the three groups  
of children 
(A) Frequencies of bifunctional or monofunctional specific CD4 T cells. Each symbol 
represents an individual and for each plot, the median, is represented by the 
horizontal line. (B) Pie charts represent the mean proportions of cells co-expressing 
IFN-! and/or IL-2, among the total CD4 T cell response, after stimulation with ESAT-
6. Differences between any two groups were calculated using the Mann Whitney U 
test. HC, healthy controls; TB, children with TB; HIV, children with HIV-1 infection. 
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Figure 4.9: Analysis of the quality of Ag85B/TB10.4-specific CD8 T cells in whole  
blood from three groups of children 
(A) Frequencies of bifunctional or monofunctional specific CD8 T cells. Each symbol 
represents an individual and for each plot, the median, is represented by the 
horizontal line. (B) Pie charts represent the mean proportions of cells co-expressing 
IFN-! and/or IL-2, among the total CD8 T cell response, after stimulation with 
Ag85B/TB10.4. Differences between any two groups were calculated using the Mann 
Whitney U test. HC, healthy controls; TB, children with TB; HIV, children with HIV-1 
infection. 
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To further characterise the quality of the T cell response, we assessed 
combinations of cytokine expression among antigen-specific T cells. Overall, 
Ag85B/TB10.4-specific cells expressing IL-2 alone comprised the 
predominant subset of specific CD4 T cells in all groups of children (Figure 
4.6 B), whereas cells expressing IFN-! alone or in combination with IL-2 
comprised similarly sized subsets. 
PPD-specific CD4 T cells were more polyfunctional, with IFN-!/IL-2 co-
expressing cells comprising approximately 50% of the total response in the 
TB and healthy control groups (Figure 4.7 B). 
Both the HC and the HIV-infected groups had lower proportions of 
polyfunctional CD4 T cells after stimulation with ESAT-6 compared to the TB 
group. IFN-!/IL-2 co-expressing cells comprised 30-40% in the TB group 
compared to approximately10% in the HC and HIV-infected groups (Figure 
4.8 B). 
 
By contrast, CD8 T cells expressed almost exclusively IFN-! after stimulation 
with Ag85B/TB10.4 (Figure 4.9 B). PPD- and ESAT-6-specfic CD8 T cells 
also predomiminantly expressed IFN-! (data not shown). The PPD- and 
ESAT-6-specific CD8 T cell response was too low to further reliably 
characterise polyfunctionality (data not shown). 
 
4.3.4 Co-variants of the Ag85B/TB10.4-specific CD4 and CD8 T cell response 
 
Frequencies of the antigen-specific CD4 and CD8 T cell response were highly 
correlated. Total cytokine-producing Ag85B/TB10.4-specific CD4 T cell 
frequencies in all groups of children correlated with cytokine-producing CD8 T 
cell frequencies (Figure 4.10 A-C). In HIV-positive children, the routinely 
conducted CD4 counts (measured as absolute number/µl or in percentage) 
did not correlate with viral load (r=0.15, p=0.453; Figure 4.11). Viral load and 
CD4 percentages also did not correlate with the total cytokine-producing 
Ag85B/TB10.4-specific CD4 or CD8 T cell frequencies (data not shown). We 
also investigated the relationships between age or time on TB treatment with 
the frequencies of specific T cells. We observed an inverse correlation 
between age and the magnitude of the total Ag85B/TB10.4-specific CD4 T 
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cell response in healthy children (Figure 4.12 A). This was not observed in 
the TB group (r=-0.18, p=0.353) or the HIV-infected children (r=-0.34, p=0.07, 
data not shown). Frequencies of specific CD8 T cells also did not correlate 
with age in the 3 groups. Time on TB treatment did not correlate with the 
magnitude of CD4 or CD8 T cells (Figure 4.12 B and C, respectively). 
 
Similar trends were observed in co-variants after stimulation with PPD and 
ESAT-6 (data not shown). 
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Figure 4.10: Relationship between the total Ag85B/TB10.4-specific CD4 and CD8 T  
cell response in (A) healthy children, (B) children with TB and (C) HIV-Infected  
children 
Correlations were calculated by nonparametric Spearman test. 
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Figure 4.11: Percentage CD4 T cell counts compared to plasma viral load in HIV- 
infected children at enrollment 
Correlations were calculated by nonparametric Spearman test. 
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Figure 4.12: Relationship between Ag85B/TB10.4-specific CD4 or CD8 T cell  
response, age, and time on TB treatment 
(A) Frequencies of total cytokine+ CD4 T cells against age in healthy children. (B) 
Ag85B/TB10.4-specific CD4 T cell responses or (C) specific CD8 T cell responses 
were compared to months on TB treatment in the TB group. Correlations were 
calculated by nonparametric Spearman test. 
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4.3.5 Antigen-specific CD4 and CD8 T cells express an effector memory 
phenotype 
 
To examine the link between T cell cytokine expression profile and memory 
phenotype, we analysed the expression of the phenotypic markers, CD45RA, 
CD27 and CCR7, on mycobacteria-specific T cells. Figure 4.13 illustrates the 
memory phenotype marker co-expression pattern by Ag85B/TB10.4-specific 
IFN-!+ or IL-2+ CD4 T cells, relative to the total CD4 T cell population, 
following stimulation of whole blood from a healthy child. 
 
 
 
 
 
Figure 4.13: Flow cytometric analysis of CCR7, CD45RA and CD27 expression on 
total CD4 T cells (red background) or Ag85B/TB10.4-specific CD4 T cells, expressing 
IFN-! (black dots, upper plots) or IL-2 (black dots, lower plots) 
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CD4 T cells producing IFN-!, or IFN-! and IL-2, were predominantly of a 
CD45RA–CCR7– effector memory phenotype. Both presence and absence of 
the differentiation marker, CD27, was observed on these effector memory 
cells (Figure 4.14). A larger proportion of IFN-!+IL-2+ (p=0.02) and IFN-!+ 
(p=0.01) CD4 T cells expressed the effector memory phenotype CD45RA–
CCR7–CD27–, compared with IL-2+ CD4 T cells. IL-2-producing T cells were 
significantly more likely to be of a CD45RA+CCR7+CD27+ central memory 
phenotype compared with IFN-!+IL-2+ (p=0.0002) or IFN-!+ (p=0.0046) 
producing CD4 T cells. 
 
Significantly higher proportions of IFN-!+IL-2+ antigen-specific CD4 T cells 
belonged to an effector memory phenotype (CD45RA-CCR7-CD27+/-), 
compared with the non-cytokine- producing total CD4 T cell subset (p<0.0001, 
Figure 4.12). A small subset of Ag85B/TB10.4-specific CD4 T cells also 
expressed a CD45RA+CCR7–CD27- phenotype, which in CD8 cells specific 
for chronic viruses has been termed terminally differentiated effector memory 
cells (Brenchley et al., 2003). Similar trends were observed after stimulation 
with PPD or ESAT-6 in CD4 T cells (data not shown). 
 
 
Figure 4.14: Memory phenotype of Ag85B/TB10.4-specific CD4 T cells in healthy  
children 
Relative proportions of memory phenotype marker co-expression by the indicated 
cytokine-producing specific CD4 T cell populations, or the total CD4 T cell population. 
For each plot, the median is represented by the horizontal line, the interquartile range 
by the box and the range by the whiskers. Differences were calculated with the 
Kruskal–Wallis test, followed by the Mann–Whitney U test (p-values not shown). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 105 
In antigen-specific IFN-!+ CD8 T cells this CD45RA+CCR7–CD27- terminally 
differentiated phenotype predominated (Figure 4.15). The non-cytokine 
producing, total CD8 T cell population were more likely to express a 
CD45RA+CCR7+CD27+ phenotype compared with IFN-!+ CD8 T cells. These 
cells comprised a significantly higher proportion of the total CD8 population, 
compared with antigen-specific IFN-!+ CD8 T cells (p<0.0001, Figure 4.15). 
Specific CD8 T cells also expressed a CD45RA-CCR7- phenotype, 
characteristic of effector memory T cells. However, more specific CD8 T cells 
expressed the CD45RA+CCR7- phenotype than non-cytokine producing CD8 
T cells (Figure 4.15). Approximately half of these IFN-!- producing effector 
memory cells expressed CD27. Similar trends were observed after stimulation 
with PPD or ESAT-6 in CD4 T cells (data not shown). 
 
 
 
 
 
Figure 4.15: Memory phenotype of Ag85B/TB10.4-specific CD8 T cells in healthy  
children 
Relative proportions of memory phenotype marker co-expression by IFN-!+ CD8 T 
cells, or the total CD8 T cell population. Differences were calculated with the 
Kruskal–Wallis test, followed by the Mann–Whitney U test (p-values not shown). 
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4.3.6 T cell memory phenotypes are comparable in healthy and diseased 
children 
 
In order to analyse whether HIV infection or TB disease might affect the 
memory phenotypes of mycobacteria-specific cells, we compared the 
phenotypes of mycobacteria-specific CD4 and CD8 T cells between all three 
groups (Figure 4.16). No significant differences in memory phenotype were 
observed amongst Ag85B/TB10.4-specific CD4 cells expressing IFN-! (Figure 
4.16 A) or IL-2 (Figure 4.16 B) between the three groups. Similarly, the 
memory phenotypes of IFN-!-expressing CD8 T cells were also not different 
between the three groups (Figure 4.16 C). There was also no difference in 
CD4 and CD8 T cell memory phenotypes between the groups of children after 
PPD and ESAT-6 stimulation (data not shown). 
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Figure 4.16: Comparison of Ag85B/TB10.4-specific T cell memory phenotype  
between the three groups of children 
Relative proportions of memory phenotype marker co-expression by (A) IFN-!+ CD4 
T cells or (B) IL-2+ CD4 T cells (C) Relative proportions of memory phenotype 
marker co-expression by IFN-!+ CD8 T cells. No significant differences were 
observed (p-values not shown). HC, healthy controls; TB, children with TB; HIV, 
children with HIV-1 infection. Differences between any two groups were calculated 
with the Mann-Whitney U test. 
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4.4. Discussion 
 
Very little is known about the adaptive immune response to Mycobacterium 
tuberculosis in children from a setting of very high TB incidence. We 
characterised and compared mycobacteria-specific CD4 and CD8 T cell 
responses in healthy children, children with TB and anti-retroviral naïve, HIV-
1-infected children. Five major points emerged: 1. mycobacterial antigens, 
which are included in novel TB vaccines were found to be highly recognised 
as recall antigens in our populations; 2. mycobacteria-specific CD4 and CD8 
T cells were readily detected at surprisingly high magnitudes in children from 
all groups; 3. the frequencies of observed specific T cell responses covered a 
remarkably broad range; 4. no significant differences in magnitude, function or 
phenotype of specific T cells were observed in HIV-infected children, 
compared with healthy controls, but evidence of active TB significantly 
enhances the magnitude of the responses; 5. mycobacteria- specific CD4 and 
CD8 T cells were of an effector memory phenotype. 
 
We detected mycobacteria-specific CD4 and CD8 T cell responses at high 
frequencies in children from all 3 groups, even in the HIV-infected group. 
These responses covered a remarkably broad range, extending from 0% up 
to 10%. Whether a high magnitude of T cell responses is associated with 
enhanced protection is not clear. Transfer of ESAT-6-specific memory Th1 
cells to recipient mice before M. tuberculosis challenge showed that higher 
numbers of specific T cells confer better protection than lower numbers 
(Gallegos et al., 2008). However, numerous other animal and human studies 
have shown that the CD4 T cell IFN-! response does not necessarily correlate 
with protection, but may rather reflect bacterial load or degree of inflammation 
(Forbes et al., 2008; Wolf et al., 2008; Bennekov et al., 2006; Mittrucker et al., 
2007; Tchilian et al., 2009; Majlessi et al., 2006; Kagina et al., 2010). This is 
also consistent with our finding of the highest T cell responses in TB-affected 
children. Our data show that a substantial proportion of children have 
mycobacteria-specific T cell populations, expressing IFN-! and/or IL-2, which 
may be enhanced by heterologous boosting vaccines. Whether such 
responses correlate with protection from TB disease remains to be further 
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validated in the human host. 
 
We chose TB10.4 and Ag85B as mycobacterial recall antigens for the T-cell 
assays in our study. These antigens have recently been incorporated into a 
subunit vaccine in the form of a fusion protein, Ag85B-TB10.4, formulated with 
the adjuvant IC31 (Aagaard et al., 2009). TB10.4 and Ag85B are expressed in 
a wide range of mycobacterial species and are commonly recognized in M. 
tuberculosis– infected and BCG-vaccinated individuals (Skjot et al., 2000). 
Our data suggest these antigens may be immunodominant in children, 
including children with HIV infection, for the first time. We were surprised by 
the high frequencies of the responses in some children. To validate our 
findings, we conducted control experiments using peptides of the same 
antigens, which revealed highly correlated results (data not shown). We 
therefore concluded that our findings are not prone to experimental artifact, 
but reflect real antigen-specific T cell magnitudes. 
 
Furthermore, although these antigens have previously been shown to induce 
high levels of CD8 responses in animal models the high magnitude of CD8 
responses also surprised us (Elvang et al., 2009). Our findings are 
encouraging news for the formulation of vaccines incorporating these 
antigens, because they appear to be able to induce both CD4 and CD8 
responses. Detection of CD8 responses using recombinant proteins as recall 
antigens was most likely a result of cross-priming, also observed in the 
context of BCG vaccination of infants (Soares et al., 2008). 
 
Vaccine boosting may have different outcomes in BCG-primed, 
M.tuberculosis uninfected and latently infected children. To date, few data are 
available on the character of T cell responses in older children, who are more 
likely to have been exposed to TB. Most studies in children have been 
performed following BCG vaccination in infants (Soares et al., 2008; Kagina et 
al., 2009; Lalor et al., 2010). These studies report lower frequencies of 
specific CD4 and also CD8 T cells in infants to those observed here in older 
children. This could reflect a less differentiated infant immune system. Naïve 
T cells constitute a larger proportion of the T cell compartment in infants, 
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compared with older children (Shearer et al., 2003). Since the readout for 
intracellular cytokine assays is a frequency of T cells, the larger proportion of 
naïve cells may serve to lower the proportion of specific memory cells. 
Additionally, the differences between our results and the infant studies may 
also reflect the use of different antigens. Further, it is possible that the wide 
age range in our study may have confounded our results, although children 
were age-matched between the groups. 
 
The finding that frequencies of mycobacteria-specific T-cell responses in HIV-
infected and -uninfected children were not significantly different was 
unexpected. Lower mycobacteria- specific CD4 T-cell responses have been 
observed in HIV- infected adults when compared with HIV-uninfected control 
subjects (Elliott et al., 1999; Sutherland et al., 2006). We recently also showed 
that BCG-specific T-cell responses were markedly impaired in HIV-infected 
infants during the first year of life (Mansoor et al., 2009). Further, blood of 
children with HIV was more permissive to mycobacterial growth in vitro and 
associated with lower levels of IFN-! compared with HIV-negative children 
(Tena et al., 2003). The reason for the similar frequencies between HIV-
negative and HIV-positive children observed here is currently unclear. 
However, given the high rate of mortality in untreated, HIV-infected children in 
Africa—35% in children in the first year of life and 52.5% up to 2 years of age 
(Newell et al., 2004)—our inclusion of HIV-infected children, with a mean age 
of 3.7 years, may have introduced a selection bias for children with slower 
HIV progression and better-preserved immune function. The wide range of 
responses observed in our study may also have led to less statistical power 
for detecting differences between the groups. Regardless, our data suggest 
that heterologous vaccine boosting may enhance T-cell responses in at least 
a proportion of HIV-infected children. Development of vaccines that augment 
T-cell immunity in this vulnerable group is particularly important. 
 
We found that children with TB had significantly higher mycobacteria-specific 
CD4 and CD8 T-cell responses compared with HIV-infected children but not 
compared with the healthy control subjects. This is likely to reflect disease-
associated inflammation and/or high levels of antigen exposure. This 
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contrasts with work showing that T-cell responses in patients with active 
pulmonary TB express lower levels of Th1 cytokines, such as IFN-! and IL-2 
(Hirsch et al., 1999). However, these previously published studies did not 
examine cytokine production at the single-cell level. 
 
The wide age range of participants in our study groups presents a study 
limitation. Because it is known that different ages are associated with 
differences in T-cell maturation and differentiation (Shearer et al., 2003), this 
is likely to be an important contributor to the large range of mycobacteria-
specific T-cell frequencies we observed. Ideally, a larger sample size would 
have allowed stratification of children by age, but this was beyond the scope 
of this study. We observed an inverse correlation between age and the 
magnitude of the CD4 T-cell response in healthy children. Multiple factors 
may affect the magnitude of response, including time since BCG vaccination 
(Weir et al., 2008). Additional studies are required to understand this 
association. 
 
Another caveat in our study was the variation in time on treatment and time 
since diagnosis of children in the TB group; however, there was no correlation 
with frequency of cytokine-producing T cells. Based on studies of culture 
conversion under treatment and longitudinal observations of immune 
responses using IFN-! release assays (Herrmann et al., 2009), we reasoned 
that a significant decline in antigenic load occurs during the early phase of TB 
treatment with more inherent variability than at later stages and that the 
longevity of effector responses is yet to be better defined. We therefore 
decided to enroll into the TB group those children who were already well 
established on their course of treatment. Another limitation was the unknown 
M. tuberculosis infection status in the HIV-infected and healthy control groups. 
Latent infection may have a marked effect on the magnitude and phenotype of 
T cell responses and analysis of infection status, as a covariate could have 
been additionally informative. 
 
The aim of vaccination is the induction of immunological memory. It is 
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therefore essential to better understand memory profiles in children with and 
without co-morbidity who might receive such vaccines. We chose to 
extensively investigate the memory profiles of antigen-specific T cells, 
because such data in older children are lacking. Central memory T cells, 
along with IL-2 expression, are believed to be the optimal phenotype for long-
lived protective immunity after infection or vaccination (Sallusto et al., 1999). 
We report here that the Ag85B/TB10.4-specific T cell response was 
characterized by an effector memory phenotype. This is in agreement with 
memory phenotypes reported previously on mycobacteria-specific T cells in 
adults (Scriba et al., 2008), children (Mueller et al., 2008) and infants (Soares 
et al., 2008; Kagina et al., 2009). 
 
Both presence and absence of the differentiation marker, CD27, was 
observed on these effector memory CD4 and CD8 T cells, suggesting an 
intermediate to an advanced stage of differentiation. This consistently 
observed effector memory phenotype may suggest high levels of exposure to 
mycobacterial antigens, as seen in chronic viral infections (Harari et al., 
2005), either through exposure to environmental mycobacteria, M. 
tuberculosis or, less likely, persistent antigen after BCG vaccination. 
Alternatively, mycobacteria-specific T cells may exhibit alternative 
differentiation or maturation pathways to those defined in chronic viral models 
(Harari et al., 2005) Along these lines, a considerable proportion of 
mycobacteria-specific T cells express Th1 cytokines, but show a “naïve” 
CD45RA+CCR7+ phenotype. Such T cell phenotypes have previously been 
reported in other studies of anti-mycobacterial T cells by us and others 
(Soares et al., 2008; Kagina et al., 2009; Scriba et al., 2008; Caccamo et al., 
2006). We previously suggested that this CD45RA+CCR7+ population reflects 
early differentiation into Ag-specific cells, before loosing CD45RA expression 
(Soares et al., 2008). However, this phenotype is not observed in human viral 
infections (Harari et al., 2005). Additional studies are required to investigate 
this further. 
 
In summary, we report substantial frequencies of mycobacteria-specific 
effector CD4 and CD8 T cell responses, which may be augmented by boost 
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vaccines, even in HIV- infected children. These findings are encouraging in 
the context of ongoing trials of novel TB vaccines. 
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CHAPTER 5 
 
Reconstitution of T cell immunity In HIV-Infected children 
receiving ART 
 
5.1 Introduction 
 
5.2 Methods 
 
5.3 Results 
5.3.1 HIV cohort follow-up and clinical outcome 
5.3.2. Mycobacteria-specific CD4 and CD8 T cell responses during ART 
5.3.3 Polyfunctional CD4 T cell response during ART 
5.3.4 Memory T cell phenotype during ART 
 
5.4.Discussion 
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5.1 Introduction 
 
HIV infection is associated with increased risk of TB disease and death (Wood 
et al., 2007; Corbett et al., 2003; WHO, 2010a). Progressive loss of function 
and numbers of CD4 T cells are observed in infected individuals (Hazenberg 
et al., 2000). In the absence of treatment, this eventually leads to the 
development of the Acquired Immunodeficiency Syndrome (AIDS), increasing 
the risk for developing opportunistic infections. 
 
Antiretroviral therapy (ART) results in strong and sustained inhibition of viral 
replication and is associated with a rise in CD4 T cell numbers (Collier et al., 
1996; Autran et al., 1997). This results in partial immune restoration of the 
immune deficiency (Autran et al., 1997; Connick et al., 2000; Li et al., 1998). 
For the most part this improvement in the immune system protects people 
from opportunistic infections (Kaplan et al., 2000). However, it is less clear 
whether functional immune responses can be fully restored, particularly in 
persons with advanced stages of HIV infection (Lange et al., 2002; Lange et 
al., 2003; Lederman et al., 2003; Lawn et al., 2005). In adults receiving ART, 
reconstitution of antigen-specific cellular immune responses has been 
demonstrated to opportunistic pathogens such as cytomegalovirus (CMV), M. 
avium complex (MAC), Toxoplasma gondii and Candida albicans (Li et al., 
1998; Komanduri et al., 1998; Rinaldo et al., 1999; Connick et al., 2000; Havlir 
et al., 2000; Fournier et al., 2001). In contrast, Weinberg et al. observed 
inconsistent recovery of cytomegalovirus CMV-specific CMI in HIV-infected 
patients receiving ART (Weinberg et al., 2001). Recurrences in CMV disease 
have been observed in HIV–Infected patients despite potent ART and 
apparent immune reconstitution (Johnson et al., 2001). 
 
Clinical susceptibility to TB is significantly reduced in HIV-infected individuals 
on ART (Ledergerber et al., 1999; Girardi et al., 2000; Kirk et al., 2000; Jones 
et al., 2000; Santoro-Lopes et al., 2002; Badri et al., 2002). Benefit of ART is 
significant across all WHO stages and CD4 cell counts. However, the overall 
susceptibility to develop TB in ART treated individuals does not return to that 
of HIV-negative individuals (Lawn et al., 2005; Komati et al., 2010). Thus 
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partial immune restoration of the immune deficiency is observed in HIV 
infection (Autran et al., 1997; Connick et al., 2000). Timing of ART initiation is 
suggested as a deciding factor of the capability of the immune system to 
reconstitute. 
 
CD4 T cells are essential in the immune response to M. tuberculosis (Mogues 
et al., 2001; Saunders et al., 2002; Havlir and Barnes, 1999). HIV may disrupt 
the TB-specific responses by directly or indirectly causing the death of the 
CD4 T cells that most effectively respond to the mycobacterium. CD8 T cells 
are also important in the M. tuberculosis-specific response (Behar et al., 1999; 
Derrick et al., 2004; Billeskov et al., 2007; Bruns et al., 2009; Chen et al., 
2009). Early initiation of ART during acute infection might reduce the damage 
caused by HIV, allowing better development of early CD4 and CD8 T cell M. 
tuberculosis-specific responses. 
 
It remains to be determined whether the effects of ART may influence broader 
functional immune reconstitution in children as opposed to adults. No studies 
have been conducted in children to analyse to what degree mycobacteria-
specific T cell memory responses form part of this reconstitution. The 
objective of this part of the study was to characterise how mycobacteria-
specific CD4 and CD8 T cell responses change in HIV-infected children once 
ART is commenced. To address this we performed a longitudinal follow-up of 
HIV-infected children prior to and during the first year of ART, and assessed 
changes to anti-mycobacterial specific T cell responses. 
 
5.2 Methods 
 
The cohort of HIV-infected children (described in chapter 4) was followed up 
at 3-monthly intervals for a total of one year, as described in chapter 2. 
Venous blood was collected at baseline (before commencing ART). Whole 
blood stimulations with mycobacterial antigens for a total of 7 hours were 
carried out as described in chapter 2. Cytokine expression profiles and 
memory phenotype of mycobacteria-specific CD4 and CD8 T cells were 
characterised by multi-parameter flow cytometry as described in chapter 3. 
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5.3 Results 
 
5.3.1 HIV cohort follow-up and clinical outcome 
 
A total of 30 HIV-infected children were enrolled into the study and followed-
up at their regular visits to the HIV clinic at Red Cross Children’s Hospital in 
Cape Town. None of the children had reported exposure to an adult with 
active TB in their household at baseline, or during the first 12 months of ART. 
All children who completed follow-up were compliant with their ART during 
their first 12 months of therapy. None of the children developed signs or 
symptoms of TB during the course of the study. 
 
At 3 months, the cohort on ART comprised 28 children: 2 children were lost to 
follow-up, as one defaulted ART and the other relocated outside Cape Town. 
By 6 months, three further children were lost to follow-up; two children had 
relocated outside Cape Town and one child had died (of sepsis), a day prior 
to the 6 month visit. Twenty-five out of 30 children thus completed the 12 
months study. 
 
The median CD4 cell percentage at baseline was 17.85% (IQR: 12.93-
21.45%) and the median absolute CD4 cell count was 531 cells/µl (IQR: 284-
1249). The median log10 viral load RNA copies/ml at baseline was 4.88 (IQR 
range: 4.30-5.76). There were no significant differences in baseline CD4 cell 
counts between the children who completed 12 months follow-up compared 
with children who dropped out for the above reasons (median CD4 cell 
percentage: 18.10% (IQR: 13.35-23.95%) and 14.85% (IQR: 11.55-18.00%), 
respectively, p=0.221). The baseline log10 viral load RNA copies/ml were, 
however, significantly greater in the children who did not complete the study 
compared with the group that completed the study (median log10 viral load 
RNA copies/ml: 6.38 (IQR: 6.01-7.68 log10 RNA copies/ml) and 4.79 (IQR: 
4.15-5.00 log10 RNA copies/ml), respectively, p=0.003). 
 
By 3 months the CD4 cell percentage had already increased significantly 
(p=0.001) above baseline levels and continued to rise in the subsequent 6 
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months (p<0.0001, Figure 5.1 A). The median CD4 cell percentage remained 
significantly higher at 12 months of ART compared with percentages prior to 
ART. The median log10 viral load RNA copies /ml decreased significantly to 
below the detectable limit by 3months (p<0.0001, Figure 5.1 B) and the 
subsequent months up to 12 months. The overall decrease in viral load RNA 
copies /ml was significant with a p value of less than 0.0001. Twenty-two of 
the 25 children had fully suppressed viral loads by 12 months of therapy 
(Figure 5.1 B). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 119 
 
 
 
Figure 5.1: Changes in CD4 T cell percentages and viral load in the first 12 months  
of ART 
(A) The CD4 T cell percentage and (B) log RNA copies/ml viral load were measured 
in HIV-infected children aged 0.33-12 years, at the time of enrolment into the study 
(T0), and at 3 monthly intervals in the first 12 months of ART. The changes over time 
are illustrated. A significant increase in percentage CD4 T cells was observed after 
the initiation of ART (p=0.001) and sustained throughout the study period. Data of all 
30 patients are shown. The Kruskal-Wallis test (solid line) was used to analyse the 
overall change. Differences between time-points were analysed with the Wilcoxon 
matched pairs test (dashed line). 
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5.3.2. Mycobacteria-specific CD4 and CD8 T cell responses during ART 
 
Cytokine expression profiles of mycobacteria-specific T cells were measured 
as described in chapter 3. The frequency of mycobacteria-specific IFN-! 
and/or IL-2 producing CD4 and CD8 T cells was assessed before and during 
12 months of ART. SEB was used as a positive control at all time-points. Four 
participants, two at 6 months and the other two at 12 months, had SEB 
responses < 3 median absolute deviations above median background 
(unstimulated). Flow cytometry data obtained for these participants at these 
time-points were excluded from analysis for all antigens. The median 
background of unstimulated cells was above the detection limit of the SATVI 
flow cytometer (0.01%). For this reason backgrounds were subtracted for 
each individual at all time-points. Reported data have been corrected for 
background except for data on memory phenotypes. The frequency of cells in 
the unstimulated samples remained low at all time-points, thus allowing 
sensitive detection of low expressed cytokines. The median background for 
cytokine+ CD4 T cells was 0.02% (IQR, 0.01-0.06) before ART and 0.01% 
(IQR, 0.003-0.02) at 12 months of ART (data not shown). The median 
background for cytokine+ CD8 T cells was 0.02% (IQR, 0.01-0.03) before ART 
and 0.01% (IQR, 0.002-0.02) at 12 months of ART (data not shown). There 
were no differences in response to the positive control at all time-points for 
both CD4 and CD8 T cells (Figure 5.2, data shown for CD4 T cells only). 
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Figure 5.2: Cytokine producing CD4 T cells stimulated with SEB 
Whole blood from HIV-infected children was stimulated with SEB and frequencies of 
cytokine+ CD4 T cells were determined by flow cytometry at 0, 3, 6, 9 and 12 months 
of ART. Overall there were differences in frequencies of cytokine+ CD4 T cells over 
the first year of therapy. Four individuals (coloured lines) were excluded from the 
analysis, since they had no response to SEB: two at 6 months and the other two at 
12 months. 
 
 
The overall frequency of total cytokine-expressing (IFN-!+ and/or IL-2+) 
Ag85B/TB10.4-specific CD4 T cells decreased during ART (p=0.016, Figure 
5.3 A). The median frequency of Ag85B/TB10.4-specific total cytokine 
producing CD4 T cells was low before of ART and decreased to below the 
sensitivity level of the assay at 12 months of ART (p=0.017, Figure 5.3 A). 
Ag85B/TB10.4-specific total IFN-!+ CD4 T cells also decreased during 12 
months of ART (p=0.028, Figure 5.3 B). The frequencies of Ag85B/TB10.4-
specific total IL-2+ CD4 T cells did not change throughout the 12 months 
(Figure 5.3 C). 
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PPD-specific total cytokine producing, total IFN-!+ or total IL-2+ CD4 T cells 
showed no change in the first 12 months of ART (Figure 5.4 A, data only 
shown for total cytokine+ cells). The median frequencies of ESAT-6-specific 
total cytokine producing CD4 T cells were very low throughout the first 12 
months of ART (Figure 5.4 B). Total IFN-!+ and total IL-2+ ESAT-6-specific 
CD4 T cells were also low and did not change 12 months into ART (data not 
shown). 
 
The median frequencies of Ag85B/TB10.4-specific total cytokine producing or 
total IFN-!+ CD8 T cells were low at the start of ART and declined during 12 
months of ART (p=0,003 and p=0.001, respectively; Figure 5.5 A and B). 
Ag85B/TB10.4-specific total IL-2+ CD8 T cells were very low throughout 12 
months of ART and the validity of the significance difference in frequencies is 
questionable (p=0.009, Figure 5.5 C). The median frequencies of PPD-
specific total cytokine producing CD8 T cells were low before ART and did not 
change by 12 months of ART (Figure 5.6 A). ESAT-6-specific total cytokine 
producing CD8 T cells also remained very low throughout the first 12 months 
of ART (Figure 5.6 B). Similar trends as with PPD or ESAT-6-specifc total 
cytokine+ CD8 were observed for both total IFN-!+ and IL-2+ CD8 T cells after 
stimulation with PPD or ESAT-6 (data not shown). 
 
Overall, some children showed a dramatic decrease in frequencies of 
mycobacteria-specific responses over the first three months of ART. These 
children all had responses to the positive control and were all included in the 
analysis. The majority of the children showed a steady decline in the 
frequency of mycobacteria-specific responses during ART (Figure 5.7 A and 
B). Similar patterns of individual changes in cytokine responses were 
obtained for both PPD and ESAT-6-specific CD4 and CD8 T cells. 
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Figure 5.3: Ag85B/TB10.4-specific cytokine producing CD4 T cells during the first  
year of ART 
(A) Total cytokine producing (B) total IFN-! and (C) total IL-2 CD4 T cells, detected 
using an intracellular cytokine staining assay, following stimulation of whole blood 
with Ag85B/TB10.4. Box and whisker plots with horizontal lines indicating the median 
%, the whiskers the minimum and maximum values, and the boxes the inter-quartile 
range. Kruskal-Wallis test (solid line) was used to analyse the overall change. 
Differences between time-points were analysed with the Wilcoxon matched pairs test 
(dashed line). A p<0.05 indicates significance. 
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Figure 5.4: PPD and ESAT-6-specific CD4 T cells over the first year of ART 
Frequencies of total cytokine producing CD4 T cells were assessed after stimulation 
of whole blood with either (A) PPD or (B) ESAT-6. Box and whisker plots with 
horizontal lines indicating the median %, the whiskers the minimum and maximum 
values, and the boxes the inter-quartile range. Kruskal-Wallis test (solid line) was 
used to analyse the overall change. Differences between time-points were analysed 
with the Wilcoxon matched pairs test (dashed line). A p<0.05 indicates significance. 
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Figure 5.5: Ag85B/TB10.4-specific cytokine producing CD8 T cells during the first  
year of ART 
(A) Total cytokine producing (B) total IFN-! and (C) total IL-2 CD8 T cells, detected 
using an intracellular cytokine staining assay, following stimulation of whole blood 
with Ag85B/TB10.4. Box and whisker plots with horizontal lines indicating the median 
%, the whiskers the minimum and maximum values, and the boxes the inter-quartile 
range. Kruskal-Wallis test (solid line) was used to analyse the overall change. 
Differences between time-points were analysed with the Wilcoxon matched pairs test 
(dashed line). A p<0.05 indicates significance. 
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Figure 5.6: PPD and ESAT-6-specific CD8 T cells over the first year of ART 
Frequencies of total cytokine producing CD8 T cells were assessed after stimulation 
of whole blood with either (A) PPD or (B) ESAT-6. Box and whisker plots with 
horizontal lines indicating the median %, the whiskers the minimum and maximum 
values, and the boxes the inter-quartile range. Kruskal-Wallis test (solid line) was 
used to analyse the overall change. Differences between time-points were analysed 
with the Wilcoxon matched pairs test (dashed line). A p<0.05 indicates significance. 
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Figure 5.7: Representative graphs showing individual changes in CD4 and CD8 
T cell cytokine frequencies during the first year of ART 
Frequencies of Ag85B/TB10.4 total cytokine producing (A) CD4 T and (B) CD8 T 
cells at 0, 3, 6, 9 and 12 months of ART. Dots indicate individual frequencies for each 
time-point. All values of zero were adjusted to 0.001 for plotting on the logarithmic 
scale. 
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5.3.3 Polyfunctional CD4 T cell response during ART 
 
Cells that co-express cytokines have been suggested to provide better 
protection against intracellular infections than cells that express only a single 
cytokine (Darrah et al., 2007). We investigated the cytokine co-expression 
patterns in the children while on ART. The frequency of Ag85B/TB10.4-
specific polyfunctional IFN-!+IL-2+ CD4 T cells were low and did not change in 
the first 12 months of ART (Figure 5.8 A). CD4 T cells stimulated with PPD 
expressed high frequencies of IFN-!+IL-2+ (Figure 5.8 B). However, these did 
not change during 12 months of ART. Frequencies of ESAT-6-specific IFN-
!+IL-2+ CD4 T cells were very low and no difference was observed during ART 
(Figure 5.8 C). 
Frequencies of specific polyfunctional IFN-!+IL-2+ CD8 T cells were too low to 
characterise further for all antigens (data not shown). 
 
We next assessed the proportions of CD4 T cells expressing a polyfunctional 
profile at 3, 6, 9 and 12 months of ART using pie charts (Figure 5.9). The 
Ag85B/TB10.4-specific CD4 T cell response was dominated by a subset 
expressing only IL-2 before and during ART (Figure 5.9). The Ag85B/TB10.4-
specific IL-2 producing subset appeared to decrease from approximately 60% 
at baseline to 50% at 3 months of ART, but returned to approximately 60-70% 
at 6 months and persisted at this level up to 12 months of ART. The IFN-! and 
IL-2 co-expressing cells dominated the PPD-specific CD4 T cell response 
(Figure 5.9), before ART and persisted over 12 months of therapy. In ESAT-
6-specific cells the IL-2-only producing cells remained at approximately 60-
70% during 12 months of ART. Proportions of IFN-!-only producing cells 
decreased from about 20% before ART to 10-15% in 12 months of therapy, 
after Ag85B/TB10.4 or ESAT-6 stimulation. 
 
Proportions of CD8 T cells were too low for reliable longitudinal analysis of 
polyfunctionality for all antigens. IFN-! continued to be the predominant 
cytokine expressed by specific CD8 T cells for all antigens (data not shown). 
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Median fluorescence intensity (MFI) of a functional parameter indicates the 
intensity of staining for the particular intracellular cytokine. This may reflect 
the amount of cytokine expressed by cells (Darrah et al., 2007; Duvall et al., 
2008). Polyfunctional cells appear to produce considerably more cytokine 
from each cell (Figure 5.10 A-F). The MFI of Ag85B/TB10.4-specific IFN-!+ 
CD4 T cells was significantly higher in the dual positive cells compared with 
the single positive IFN-!+ CD4 T cells (Figure 5.10 A) before ART. This was 
also true for IL-2+ CD4 T cells and IFN-!+ CD8 T cells (Figure 5.10 B and C, 
respectively). IL-2+ CD8 T cells showed no difference in staining intensity 
whether dual positive or single positive (Figure 5.10 D). 
This trend of higher MFIs of IFN-!+ and IL-2+ CD4 T cells or IFN-!+ CD8 T 
cells was also observed for PPD or ESAT-6 stimulated cells (data not shown). 
Again there was no association between polyfunctionality and MFI for IL-2+ 
CD8 T cells for both, PPD or ESAT-6 stimulations (data not shown). 
 
To further characterize the quality of the polyfunctional response we 
calculated the MFI of the polyfunctional cells during ART. No major changes 
in MFIs were observed during ART for all antigens for CD4 T cells (Figure 
5.11 A-F). 
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Figure 5.8: IFN-!+IL-2+ CD4 T cell responses during ART 
Whole blood from HIV-infected children receiving ART was stimulated with (A) 
Ag85B/TB10.4, (B) PPD and (C) ESAT-6. After staining for intracellular cytokines 
CD4 T cells were assessed for differences in frequencies of IFN-!+IL-2+ cells at 0, 3, 
6, 9 and 12 months. The Kruskal-Wallis test (solid line) was used to analyse the 
overall change. Differences between time-points were analysed with the Wilcoxon 
matched pairs test (dashed line). A p<0.05 indicates significance. 
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Figure 5.9: Analysis of the quality of mycobacteria-specific CD4 T cells in HIV-1  
infected children 
Pie charts represent the mean proportions of cells producing IFN-!+IL-2+ cells (red), 
IFN-!+ only (green) and IL-2+ only (blue) of the total cytokine CD4 T cell response at 
baseline (T0), 3, 6, 9 and 12 months of ART. Whole blood was stimulated with 
Ag85B/TB10.4, PPD or ESAT-6. 
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Figure 5.10: Median fluorescence intensity (MFI) for intracellular cytokines of  
Ag85B/TB10.4-specific CD4 and CD8 T cells 
MFI for (A) IFN-! was calculated for Ag85B/TB10.4-specific CD4+ T cells. IFN-! MFI 
for each functional population is shown as a histogram and color-coded according to 
the number of positive functions. Representative data from a single HIV-infected child 
are shown. MFIs are shown for CD4 T cells producing (B) IFN-! (purple) or (C) IL-2 
(pink). IFN-! MFI for Ag85B/TB10.4-specific CD8+ T cell responses is shown as a 
histogram in a single HIV-infected child. MFI for (D) Ag85B/TB10.4-CD8 T cells 
producing  (E) IFN-! (purple) or (F) IL-2 (pink) are also shown. 
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Figure 5.11: Longitudinal changes in MFIs for intracellular cytokines of  
mycobacteria-specific CD4 T cells 
Changes in MFI for IFN-! or IL-2 of polyfunctional cells at 0, 3, 6, 9 and 12 months 
after stimulation with (A and B) Ag85B/TB10.4, (C and D) PPD or (E and F) ESAT-6. 
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5.3.4 Memory T cell phenotype during ART 
 
ART is known to restore the production of naïve T cells by the thymus and 
reduce antigen load and is therefore likely to have effects on the overall 
phenotypic distribution of the circulating T cell population (Vigano et al., 2000; 
Ometto et al., 2002). We assessed changes in memory phenotype of 
Ag85B/TB10.4-specific T cells, during the course of ART. Expression of the 
phenotypic markers, CD45RA, CD27 and CCR7, previously discussed in 
chapter 4, were measured. 
 
In the total (non-specific) CD4 T cell population, the proportion of cells 
expressing the naïve phenotype CD45RA+CCR7+CD27+ increased 
significantly over the first 3 months of ART (p<0.0001, Figure 5.12). This 
naïve population continued to increase to a median of approximately 60% by 
6 months, and remained at this level 12 months into ART. 
 
 
 
Figure 5.12: Non-specific naïve CD4 T cell population 
The CD45RA+CCR7+CD27+ naïve CD4 T cell population, determined by flow 
cytometry, significantly expanded during the first 12 months of ART. The Kruskal-
Wallis test (solid line) was used to analyse the overall change. Differences between 
time-points were analysed with the Wilcoxon matched pairs test (dashed line). A 
p<0.05 indicates significance. 
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Central memory cytokine producing Ag85B/TB10.4-specific CD4 T cells, 
which lack expression of CD45RA (CD45RA-CCR7+CD27+), did not change 
(p=0.301, Figure 5.13). The proportion of effector memory Ag85B/TB10.4-
specific CD4 T cells (CD45RA-CCR7-CD27+), decreased significantly from 
baseline to 13.34% (Figure 5.14 A), 3 months into ART. CD45RA-CCR7-
CD27- CD4 T cells also decreased significantly from baseline, to 3 months, 
(p=0.006, Figure 5.14 B). 
 
 
 
 
Figure 5.13: Ag85B/TB10.4-specific central memory CD4 T cells 
The CD45RA-CCR7+CD27+ central memory phenotype showed an increasing trend 
but this did not reach statistical significance. The Kruskal-Wallis test (solid line) was 
used to analyse the overall change. Differences between time-points were analysed 
with the Wilcoxon matched pairs test (dashed line). A p<0.05 indicates significance. 
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Figure 5.14: Ag85B/TB10.4-specific effector memory CD4 T cells 
Proportional decline of effector memory populations: (A) CD45RA-CCR7-CD27+ and 
(B) CD45RA-CCR7-CD27-, from baseline (T0) to 3 months of ART. This was 
sustained over 12 months of therapy. The Kruskal-Wallis test (solid line) was used to 
analyse the overall change. Differences between time-points were analysed with the 
Wilcoxon matched pairs test (dashed line). A p<0.05 indicates significance. 
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CD45RA+CCR7+CD27+-expressing naïve, non-cytokine producing CD8 T 
cells increased steadily, and showed a significant difference, 6 months into 
ART (p=0.020, Figure 5.15). Although at a lower rate than naïve CD4 T cells, 
the naïve CD8 T cells continued to increase 12 months into ART (p=0.002). 
 
 
 
 
 
 
 
 
Figure 5.15: Non-specific naïve CD8 T cell population 
The CD45RA+CCR7+CD27+ naïve CD8 T cell population, determined by flow 
cytometry, significantly expanded during the first 12 months of ART. The Kruskal-
Wallis test (solid line) was used to analyse the overall change. Differences between 
time-points were analysed with the Wilcoxon matched pairs test (dashed line). A 
p<0.05 indicates significance. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 138 
The Ag85B/TB10.4-specific CD8 T cell central memory population 
characterized by CD45RA-CCR7+CD27+ remained low throughout the first 12 
months of ART (data not shown). CD8 T cells expressing the effector memory 
phenotype CD45RA-CCR7-CD27+ or CD45RA-CCR7-CD27- significantly 
decreased 3 months into ART (p=0.003 and p=0.004, Figure 5.16 A and B, 
respectively). The significant decrease was sustained in the first 12 months of 
therapy. The terminally differentiated phenotype characterized by expression 
of CD45RA+CCR7-CD27- did not change in the first 12 months ART, 
(p=0.540, Figure 5.17). 
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Figure 5.16: Ag85B/TB10.4-specific effector memory CD8 T cells 
The effector memory CD8 T cell populations: (A) CD45RA-CCR7-CD27+ and (B) 
CD45RA-CCR7-CD27-, decreased significantly over the course of the 12 months of 
ART. The Kruskal-Wallis test (solid line) was used to analyse the overall change. 
Differences between time-points were analysed with the Wilcoxon matched pairs test 
(dashed line). A p<0.05 indicates significance. 
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Figure 5.17: Ag85B/TB10.4-specific terminally differentiated effector memory CD8 T  
cells 
There was no significant change in the percentages of terminally differentiated CD8 T 
cells. The Kruskal-Wallis test (solid line) was used to analyse the overall change. 
Differences between time-points were analysed with the Wilcoxon matched pairs test 
(dashed line). A p<0.05 indicates significance. 
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5.4.Discussion 
 
Tuberculosis (TB) remains a leading cause of death for children in TB 
endemic countries, especially in children with HIV infection. ART has 
completely transformed both life expectancy and quality of life for HIV-infected 
individuals, by reducing the immunodeficiency characteristic of AIDS. 
However, there is heterogeneity in the extent to which immune recovery is 
realised. Little is known about reconstitution of the mycobacteria-specific T 
cell memory response in children during ART. This study provides the first 
detailed analysis of these T cell sub-populations in children on ART. We 
assessed the longitudinal changes in mycobacteria-specific CD4 and CD8 T 
cell responses in HIV-1-infected children on ART. Three main findings 
emerged from these data: 1. mycobacteria-specific CD4 and CD8 T cell 
frequencies declined on ART; 2. effector memory specific CD4 and CD8 T cell 
populations decreased during ART; 3. non-specific naïve CD4 and CD8 T 
cells increased dramatically during ART. 
 
Overall Ag85B/TB10.4-specific CD4 and CD8 T cells declined in frequency 
during the first year of ART. PPD-specific responses remained unchanged 
and ESAT-6- specific responses remained very low before and during the first 
year of ART. However, most children retained their ability to respond to SEB, 
a superantigen with potent cytokine-inducing potential. This suggests a 
selective defect in the response to recall antigens, while responses to the 
superantigen are maintained. Although the inter-individual responses varied 
greatly, the overall percentages of effector memory specific CD4 and CD8 T 
cell populations had significantly declined by 3 months of ART. The decrease 
was observed in Ag85B/TB10.4-specific IFN-! producing CD4 and CD8 T 
cells. Mycobacteria specific responses were not uniform among participants. 
The staining, acquisition and analysis of longitudinal samples, of individual 
patients were performed in batch. The gating strategy used was the same for 
all samples and was consistent across all time-points for each individual. 
Furthermore the changes in the responses in some individuals at 3-9 months 
could not be explained by differential cell viability or assay variability, since 
the consistent response to the positive control (shown in Figure 5.2) does not 
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support this hypothesis. The data presented here suggest that once HIV has 
induced depletions within the T cell pool, ART does not result in an immediate 
and complete restoration of mycobacteria-specific responses. The changes in 
CD8 responses appeared more dramatic than the changes in the CD4 
responses. A discrepancy in the rate of replacement of these two subsets 
could have contributed to this. However, we did not address this 
experimentally, since we did not include assays to detect recent thymic 
emigrants (Douek et al., 1998; De Rossi et al., 2002) in our cohort of HIV-
infected children. 
 
The extent of immune reconstitution was assessed in HIV-infected children in 
the first year of ART. We observed significantly increased CD4 T cell 
percentages and decreased viral load as early as three months after initiation 
of treatment. This was sustained during the first year of follow-up and likely 
reflects the early effect of ART on immune restoration. Previous studies in 
adults and children have shown that recovery of CD4 cells on ART is 
associated with significant expansion of naïve CD4 T cell populations (Autran 
et al., 1997; De Rossi et al., 2002; Wilkinson et al., 2009). 
 
Consistent with the previous studies, increased proportions of CD4 T cells 
were of a ‘naïve’ CD45RA+CCR7+ phenotype, during ART. These T cells are 
not antigen experienced, and do not possess the capacity to respond quickly 
to antigen re-exposure. Therefore they do not produce IFN-! in response to 
mycobacteria. Two mechanisms have been suggested for this high recovery 
in the naïve populations: greater thymic output of naïve T cells or higher 
peripheral T cell turnover. The rise in CD4 T cells in children on ART is 
predominantly confined to CD45RA+ cells (Bohler et al., 1999). Thymic output 
of T cells is recognised to be greater in children compared with adults (Ometto 
et al., 2002). T cells recently generated in the thymus are quantified by 
measuring T cell receptor excision circles (TRECs) (Ribeiro and de Boer, 
2008). Studies quantifying thymic output using TREC assays confirm that a 
high proportion of cells are recent thymic emigrants (Douek et al., 1998; De 
Rossi et al., 2002). Immune reconstitution using ART might also lead to an 
expansion in the periphery of existing resting/naïve T cells, as shown in adults 
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(Emery and Lane, 1997; Lange et al., 2002), but the timing and extent have 
not yet been fully established. 
 
The early effects of ART have previously been described in HIV-infected 
children and adolescents (Bohler et al., 1999). In the study by Böhler et al., 
ART caused a significant increase in absolute lymphocyte and CD4 T cell 
counts and a decrease in activation-induced apoptosis of CD4 and CD8 T 
cells to near-normal levels, even in patients without complete suppression of 
viral replication. Resting/naïve cells contributed significantly to the rise in CD4 
T cells especially in infants and young children. An early rise in resting/naïve 
CD4 T cells (and, to a lesser extent, also in CD8 T cells) during ART was 
observed in these patients. It is well known that routine childhood vaccinations 
do not appear to elicit equally long lasting memory responses in children with 
HIV compared to HIV-negative children. It is therefore recommended to 
revaccinate HIV-infected children once ART has established successful 
immune reconstitution (Moss et al., 2007; Sutcliffe and Moss, 2010). 
 
ART treated individuals with substantially restored CD4 T cells may still have 
impaired antimycobacterial immunity. This might be caused by the failure of 
ART to restore central memory T cell populations (Elrefaei et al., 2004), which 
are capable of rapid expansion in response to antigen re-stimulation, and are 
critical for the development of T cell memory. Care must therefore be taken 
when following-up latently infected individuals on ART because they are at a 
high risk of TB reactivation or disease development. During latency 
mycobacteria are sequestered within the granuloma and are poised for 
uncontrolled replication in conditions of immunosuppression. Wilkinson et al. 
showed a significant increase in the central memory population in HIV-
infected adults on ART (Wilkinson et al., 2009). In addition, the potential for 
early ART to preserve antimycobacterial immune responses should be 
explored. Jansen et al. demonstrated that early introduction of ART in acute 
HIV-1 infection resulted in higher numbers of HIV-specific IFN-! and IL-2-
producing CD4 T cells (Jansen et al., 2005). Central memory cells are 
associated with long-term immunological memory. There was no change in 
proportions of central memory cells in children in the first 12 months of 
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therapy. It is likely that the dynamics of T cell turnover differ between adults 
and children with HIV starting ART, with the initial changes in children 
primarily associated with naïve T cells (De Rossi et al., 2002). 
 
The study by Wilkinson et al. reported that frequencies of PPD-specific IFN-!-
producing effector cells, measured by ICS, proportionally declined as CD4 T 
cell numbers recovered during ART (Wilkinson et al., 2009). However, the 
number of IFN-!-producing cells, measured by ELISpot assay (spot forming 
cells, SFC) increased with increasing numbers of absolute CD4 T cells 
(Wilkinson et al., 2009). A discrepancy between ICS and ELISpot can be 
observed because ICS reports the data as a frequency of CD4 T cells. So, 
changes in T cell numbers are not taken into account by ICS. By contrast, 
ELISpot assays report data as SFC per million PBMC, so if the relative 
proportion of CD4 cells out of a million PBMC increases during ART, this may 
be detected as an increase in responses. Our results are in concordance with 
the flow cytometric measurements of this work in adults, since we also 
observed a significant decrease in the effector memory populations, 
accompanied by a decrease in IFN-! production after stimulation with 
Ag85B/TB10.4. This is attributed, to the effector cell population proportionally 
declining within the expanding naïve CD4 T cell pool (Wilkinson KA, 2009). 
Due to limited volumes of blood available, unfortunately, we could not confirm 
the relative expansion of IFN-! producing effector CD4 T cells, measured by 
ELISpot, as described by Wilkinson et al. 
 
We were also interested in the quality of the T cell pool in both the CD4 and 
CD8 T cell compartment, since polyfunctional cells have been linked to 
protective immunity against Leishmania major (Darrah et al., 2007) and M. 
tuberculosis (Forbes et al., 2008). IFN-!+IL-2+ T cells produced significantly 
increased amounts of cytokine compared with cells producing only one 
cytokine. However, no significant qualitative differences were found under 
ART. ART leads to a decline in susceptibility to disease with M. tuberculosis. 
A clear correlation with polyfunctional T cell responses has not yet been 
demonstrated. Kalsdorf et al. observed lower frequencies of cells co-
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expressing IFN-!, TNF-" and IL-2 in HIV-1-infected adults than in uninfected 
controls (Kalsdorf et al., 2009). However, another paper from the same group 
illustrated the lack of a correlation between polyfunctional T cells and 
protection against TB in BCG-vaccinated infants. Infants who developed TB 
were compared with age-matched controls who did not develop TB (Kagina et 
al., 2010). No difference in the frequencies of polyfunctional T cells was found 
between the two groups. Further studies are required to elucidate the role of 
these polyfunctional T cells in immunity to TB. 
 
We conducted further analysis to determine changes in the quality of the 
antigen-specific response, by analysing changes in proportions of effector cell 
populations and also the median fluorescent intensity (MFI). The MFI 
indicates the amount of cytokine produced on a per cell basis (Darrah et al., 
2007). These parameters were not significantly different. Wilkinson et al used 
IFN-! Elispot assay to determine qualitative changes. We were not able to 
assess effector function using this assay as well, due to constraints on blood 
volumes in children. 
 
A limitation of this study is the absence of healthy control samples to compare 
the mycobacteria response at 12 months of ART. A second limitation is the 
absence of non-tuberculous antigens to rule out global impairment of the T 
cell response during ART (Sutherland et al., 2006). For example, 
cytomegalovirus-specific (CMV) CD4 T cells with IFN-!-secreting capacity 
have been detected in patients who controlled cytomegalovirus disease after 
ART initiation (Jacobson et al., 2001). 
 
In conclusion, ART results in significant immune restoration in HIV-infected 
children, but the degree of antigen-specific restoration may be limited. It was 
interesting to note that most changes in immunity were detected in the first 
three months of ART and were then maintained. Phenotypic and functional 
analysis of CD4 T cells might help to guide decisions regarding 
discontinuation of prophylactic medication against opportunistic infections in 
patients with undetectable viral load under ART. The availability of a larger 
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population of naïve T cells under ART is encouraging in the context of 
vaccination of HIV-infected children, since antigen-specific effector and 
memory T cells can be generated from this pool of T cells. This has important 
implications for the timing of vaccination in HIV-infected children. 
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CHAPTER 6 
 
Effects of ART on mycobacterial growth inhibition in HIV-
infected children 
 
6.1 Introduction 
 
6.2 Methods 
 
6.3 Results 
6.3.1 Participant follow-up 
6.3.2. Increased mycobacterial growth inhibition in children on ART 
6.3.3 Correlation of mycobacteria-specific T cell responses with mycobacterial  
 growth inhibition 
 
6.4.Discussion 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 148 
6.1 Introduction 
 
Exposure to mycobacterial pathogens results in no infection, containment of 
infection or progression to active disease (acute or chronic) (Kaufmann and 
McMichael, 2005). A better understanding of the immunological determinants 
of these outcomes of mycobacterial exposure would be valuable in the 
development of new vaccines. A cell-mediated immune response (CMI) is 
essential for control of M. tuberculosis infection (Cooper and Flynn, 1995). 
Containment of mycobacterial growth can be measured in animal models, 
enumerating CFU in target organs. However, quantification of mycobacterial 
load in humans is very difficult. Although assays that measure host cell-
mediated immunity to mycobacteria exist (such as ELISA, Elispot, ICS and 
proliferation assays), these do not measure antigen load or mycobacterial 
survival. 
 
HIV infection can be understood as a model of impaired ability to contain 
mycobacterial infection. HIV-infected individuals have increased risk of TB 
disease as a consequence of their impaired cell-mediated immune responses, 
resulting in insufficient ability to contain the growth of M. tuberculosis 
(Imperiali et al., 2001; Bezuidenhout et al., 2009), more rapid progression of 
clinical symptoms (Daley et al., 1992), and high mortality (Harries et al., 
2001). Introduction of ART improves CD4 cell numbers and dramatically 
decreases viral load, resulting in reduced incidence of TB disease in HIV 
infected patients (Kirk et al., 2000; Girardi et al., 2000; Badri et al., 2002). 
Most studies of antigen-specific immune reconstitution during ART have 
concentrated on measuring lymphoproliferative responses or the specific 
production of cytokines in whole blood or PBMC, measured via ELISA, RNA 
expression or ICS (Imami et al., 1999; Lange et al., 2002). However, these 
assays measure the host immune response and do not provide a read-out of 
the effect on mycobacterial growth. 
 
Kampmann et al. developed an in vitro model that measures the growth of 
reporter-gene tagged mycobacteria (bacillus Calmette-Guérin; BCG lux) in 
whole blood as a functional read-out of antimycobacterial immune responses 
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(Kampmann et al., 2000). In our previous studies using this model we have 
established an association between in vitro growth of mycobacteria and 
observations of anti-mycobacterial host immune response. For example, 
tuberculin skin test (TST)-positive individuals are better able to restrict 
mycobacterial growth compared to TST-negative individuals (Kampmann et 
al., 2000). Further, increased inhibition of mycobacterial growth is related to 
the production of IFN-! and the presence of antigen-experienced CD4 T cells. 
Anti-mycobacterial growth inhibition is enhanced following BCG vaccination in 
adults (Cheon et al., 2002; Hoft et al., 2002) and children (Kampmann et al., 
2004). Children infected with HIV do not restrict growth of BCG as 
successfully as age-matched non-HIV infected children (Tena et al., 2003). 
Introduction of ART can improve growth restriction of BCG in this in vitro 
assay (Kampmann et al., 2006). 
 
Growth inhibition as a functional read-out of antimycobacterial immune 
responses is attractive as a tool to measure immunological correlates, 
including vaccine-induced immune responses. The whole blood M. 
tuberculosis luciferase (MTB lux) assay used in this study employs 
mycobacterial growth restriction in vitro as the final read-out of immunological 
effector functions. Our recent work using this model has shown that HIV-
infected children are more permissive of BCG growth in vitro than healthy 
children, reflecting the high susceptibility to tuberculosis in HIV infection (Tena 
et al., 2003). We have also shown that ART leads to rapid and sustained 
improvement of the ability to restrict growth of BCG in vitro (Kampmann et al., 
2006). We now wished to confirm the relevance of our earlier observations 
using the avirulent BCG lux strain with the virulent organism, M. tuberculosis 
H37Rv. 
 
In this chapter we describe findings from measuring M. tuberculosis growth 
inhibition in HIV-infected children using the virulent MTB H37Rv lux strain. We 
also examined the role of antigen-specific T cell responses on MTB inhibition. 
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6.2 Methods 
 
The MTB lux assay was performed in the same samples obtained from the 
cohort of HIV-infected children as described in chapter 4 and 5. The whole-
blood assay utilising luciferase-tagged MTB H37Rv has been described in 
chapter 2. Briefly, heparinised venous blood, diluted 1 in 2 with RPMI, was 
inoculated in triplicate with 1 x 107 RLU/ml of MTB lux and incubated for 96h 
with continuous mixing. An unstimulated control sample incubated with whole 
blood and RPMI only was included at each time point. Growth of MTB lux in 
mycobacterial culture medium only was also measured after 96h. 
Mycobacterial viability was measured before incubation at the time of 
inoculation (T0) and at 96h (T96) after the lysis of red blood cells, using a 
single tube luminometer (Turner Design 20/20, Germany). The growth ratio 
was calculated as follows: 
 
       RLU of BCG lux at T96 
 Growth ratio = 
       RLU of BCG lux at T0 
 
Mycobacterial growth inhibition was measured prior to ART and at 3, 6, 9 and 
12 months of therapy. All work was carried out in a BSL3 laboratory. 
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6.3 Results 
 
6.3.1 Participant follow-up 
 
The whole blood mycobacterial growth inhibition assay was performed on 
blood obtained from 19 of the 30 (63.33%), HIV-infected children enrolled into 
the longitudinal study. This was because the BSL3 unit was not available at 
the time of commencing enrollment. In 17/19 children the whole blood lux 
assay was completed at each time point (every 3 months) for the entire study 
duration of 12 months. Two children did not complete the study: one child died 
from septicaemia and the second child was lost to follow-up. To the best of 
our knowledge, none of the children had been exposed to acute tuberculosis 
in his or her household prior to commencing the study or during the follow-up 
visits. None of the children were receiving anti-TB treatment or any other 
forms of antibiotics known to be active against mycobacteria. 
 
6.3.2. Increased mycobacterial growth inhibition in children on ART 
 
Prior to commencing ART we established the baseline effect of HIV infection 
on mycobacterial immunity expressed in the whole blood assay. Table 6.1 
summarises the details of baseline CD4 cell percentage, age, log viral load 
and growth ratios. 
The median age of the HIV-infected children whose blood was obtained for 
the whole blood lux assay was 4 years (IQR: 1-7 years). The median log viral 
load was 5 log10 RNA copies/ml (IQR: 4.70-6.04 log10 RNA copies/ml) at 
baseline. The baseline median growth ratio was 8.94 (IQR: 6.92–12.21, 
Figure 6.1 A) and median CD4 T cell count was 17.30% (IQR: 13.00-23.40%, 
Figure 6.1 B). The age, viral load and CD4 percentage measurements were 
all similar to those obtained in the cross-sectional study. We observed 
significant negative correlation between the growth ratio and CD4% prior to 
ART (p=0.004) (Figure 6.2 A). There was no association between viral load 
and growth ratios at baseline (Figure 6.2 D). Age was also not correlated to 
growth ratios (data not shown). 
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Next we assessed the ability of whole blood from HIV-infected children on 
ART to inhibit growth of MTB lux. The introduction of ART was followed by 
reconstitution of anti-mycobacterial immune responses, measured as the 
decreased growth of mycobacteria (Figure 6.1 A). Mycobacterial growth 
inhibition increased significantly by 6 months of ART (p=0.001, Figure 6.1. A), 
continued to increase at 9 months and this growth ratio stayed the same at 12 
months into ART. We observed a strong association of the ability to inhibit 
mycobacterial growth and rising CD4 percentage during the first 12 months of 
ART. This is reflected in the highly significant restoration of CD4 T cell 
percentages as shown in Figure 6.1 B. There was substantial correlation 
between CD4 percentage and the ability to restrict growth at all time-points 
during the first 12 months of ART, (data shown for baseline, 6 and 12 months, 
Figure 6.2 A-C). 
 
In order to establish whether levels of HIV viral load before receiving ART 
were predictive of the growth ratios at any particular time-point, we calculated 
correlation coefficients between viral load at baseline and subsequent growth 
ratios. No correlations were found at any time-point (Figure 6.2 D-F). 
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Study ID 
Age 
(years) 
Viral load 
(log10 RNA 
copies/ml) 
CD4 Cell 
Count (%) 
Growth ratio 
MTB lux 
H1 0.42 6.28 32.10 5.16 
H2 4 5 7.34 13.58 
H3 2 N/A 18.00 8.00 
H4 4 6 18.10 7.48 
H5 0.42 4.79 12.20 6.85 
H6 11 8.08 20.80 6.92 
H7 0.58 6.48 13.00 6.78 
H8 5 5 10.50 12.21 
H9 1 3.37 19.10 7.71 
H10 4 2.83 14.00 12.48 
H11 5 2.58 24.50 6.07 
H12 2 4.96 14.50 12.12 
H13 8 6.08 17.30 11.19 
H14 0.67  n/a 23.40 8.94 
H15 6 4.60 17.10 11.67 
H16 12 4.97 15.20 12.98 
H17 7 5 7.76 15.25 
H18 8 5.91 19.00 10.81 
H19 4 4.85 34.60 7.26 
 
Table 6.1: Summary of patient details: study number, age, viral load, percentage  
CD4 T-cell count and growth of MTB lux in whole blood at the time of enrolment into  
the study, (N/A: not available) 
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Figure 6.1: Longitudinal changes in mycobacterial growth inhibition and CD4  
percentage 
(A) Growth of M. tuberculosis lux in whole blood was measured at time of enrolment 
and subsequently at 3-monthly intervals after the introduction of ART. (B) The 
percentage CD4 T-cell count was measured at the time of enrolment into the study 
(T0), and then at 3, 6, 9 and 12 months 
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Figure 6.2: Relationship between mycobacterial growth inhibition and CD4  
percentage or viral load 
There was a significant inverse correlation between growth ratios and CD4 
percentages at (A) baseline (n=19), (B) 6 (n=15) and (C) 12 (n=17) months into ART. 
There was no correlation between growth ratios and viral load at (D) baseline (n=19), 
(E) 6 (n=15) and (F) 12 (n=17) months into ART. The CD4 percentages and viral 
loads were not available for some children at 6 and 12 months. 
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6.3.3 Correlation of mycobacteria-specific T cell responses with mycobacterial 
growth inhibition 
 
In order to assess the effect of mycobacteria-specific T cells on the ability to 
control mycobacterial growth we compared functional CD4 and CD8 T cell 
responses (defined as those that produce IFN! and/or IL-2 in response to 
mycobacterial antigens) to growth ratios before ART (T0) and after 3, 6, 9 and 
12 months of therapy (only data for baseline and 12 months are shown). 
 
The frequency of functional subsets of mycobacteria-specific T cells was 
compared with their ability to restrict the growth of mycobacteria in vitro. 
Ag85B/TB10.4-specific total cytokine, or IFN-! or IL-2 producing CD4 T cells 
did not correlate with MTB lux growth inhibition prior to commencing ART 
(Figure 6.3 A-C). The antigen specific T cell response was then normalised to 
the CD4 percentage by multiplication of the antigen-specific response with the 
CD4% (in decimal format). However, there was still no association between 
the ability to inhibit mycobaterial growth and Ag85B/TB10.4-specific T cell 
response at T0 (Figure 6.3 D-F). This was also true when comparing 
Ag85B/TB10.4-specific T cell responses at 3, 6, and 9 months with growth 
ratios (Figure 6.4 A-E, only data obtained at 12 month is shown). However, 
there was a significant correlation between Ag85B/TB10.4-specific total IL-2 
expressing CD4 T cells and mycobacterial growth at 12 months of ART 
(Figure 6.4 F). 
 
PPD- specific total cytokine, or IFN-! or IL-2 producing CD4 T cells did not 
correlate with MTB lux growth inhibition before ART (Figure 6.5 A-C). There 
was no association between the baseline PPD-specific T cell response 
(normalised to the CD4 percentage) and mycobacterial growth (Figure 6.5 D-
F). There was also no association between the ability to inhibit mycobaterial 
growth and PPD-specific T cell response (Figure 6.6 A-F), whether 
normalised to CD4 percentage or not. 
 
ESAT-6 specific responses did not correlate with mycobacterial growth 
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restriction prior to commencing ART or at 3, 6, 9 and 12 months into ART 
(data not shown). This was also true for mycobacteria-specific CD8 T cell 
responses for all antigens tested (data not shown). 
 
 
 
Figure 6.3: Association between Ag85B/TB10.4-specific CD4 T cells and growth  
ratios before ART 
The relationship between (A) total cytokine+, (B) IFN-!+ or (C) IL-2+ Ag85B/TB10.4-
specific CD4 T cells and the ability to inhibit mycobacterial growth was assessed in 
HIV-infected children before commencing ART. There was no correlation between 
antigen specific CD4 T cells and growth ratios at baseline. There was also no 
association between the CD4 percentage normalised (D) total cytokine+, (E) IFN-!+ or 
(F) IL-2+ Ag85B/TB10.4-specific CD4 T cell response and the ability to inhibit 
mycobacterial growth. 
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Figure 6.4: Relationsip between Ag85B/TB10.4-specific CD4 T cells and growth  
ratios after 12 months of ART 
The correlation between (A) total cytokine+, (B) IFN-!+ or (C) IL-2+ Ag85B/TB10.4-
specific CD4 T cells and the ability to inhibit mycobacterial growth was assessed in 
HIV-infected children at 12 months of ART. There was no correlation between 
antigen specific CD4 T cells and growth ratios at 12 months. There also was no 
association between (D) total cytokine+ or (E) IFN-!+ Ag85B/TB10.4-specific CD4 T 
cells and the ability to inhibit mycobacterial growth, after normalizing the antigen 
specific response to CD4 percentages. However, there was significant correlation 
between the IL-2+ Ag85B/TB10.4-specific CD4 T cell response (normalized to CD4 
percentage) and mycobacterial growth at 12 months. 
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Figure 6.5: Relationship between PPD-specific CD4 T cells and growth ratios before  
ART 
The correlation between (A) total cytokine+, (B) IFN-!+ or (C) IL-2+ PPD -specific CD4 
T cells and the ability to inhibit mycobacterial growth was assessed in HIV-infected 
children before ART. There was no correlation between PPD-specific CD4 T cells 
and growth ratios at baseline. There was also no association between the CD4 
percentage normalised (D) total cytokine+, (E) IFN-!+ or (F) IL-2+ PPD-specific CD4 T 
cell response and the ability to inhibit mycobacterial growth. 
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Figure 6.6: Correlations between PPD-specific CD4 T cells and growth ratios after  
12 months of ART 
The correlation between (A) total cytokine+, (B) IFN-!+ or (C) IL-2+ Ag85B/TB10.4-
specific CD4 T cells and the ability to inhibit mycobacterial growth was assessed in 
HIV-infected children at 12 months of ART. There was no association between PPD-
specific CD4 T cells and growth ratios at 12. There also was no association between 
(D) total cytokine+, (E) IFN-!+ or (F) IL-2+ PPD-specific CD4 T cells and the ability to 
inhibit mycobacterial growth, after normalizing the antigen specific response to CD4 
percentages. 
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6.4.Discussion 
 
Cell-mediated immunity is of key importance to combat mycobacterial 
infections, such as M. tuberculosis (Orme et al., 1993; Cooper and Flynn, 
1995). However, the mechanisms of protection have not been fully described. 
Earlier in vitro studies have concentrated on antigen-specific 
lymphoproliferative responses, IFN-! production, and cytotoxic effector 
functions of immune cells (Andersen et al., 1991; Barnes et al., 1993; 
Tsukaguchi et al., 1995). Recently, Kampmann et al. developed a whole blood 
in vitro model to study human antimycobacterial immunity (Kampmann et al., 
2000). This functional whole blood reporter-gene assay (lux assay) measures 
the combined anti-mycobacterial immune response in whole blood and 
employs mycobacterial growth restriction as the read-out of the final effector 
function. The virulent MTB lux showed the same decreasing trend as with the 
avirulent BCG lux (Kampmann et al., 2006). The initial decline in 
mycobacterial growth was less rapid with the MTB lux compared to that 
previously observed with BCG lux (Kampmann et al., 2006), but was 
significant by 6 months and sustained from then on. The more delayed effect 
might be due to the more virulent strain of mycobacteria, which requires more 
vigorous immune responses than BCG. 
 
As our previous work with this assay has shown, it provides an additional and 
complimentary method to measurements of CMI by combining measurements 
of host responses with their effect on mycobacterial survival in vitro. It has 
potential use in the evaluation of TB vaccine candidates. In this study, we 
observed a significant reduction in the ability of virulent MTB lux to grow in the 
blood of HIV-infected children once receiving ART, which was maintained 
over the 12 months of observation. This was accompanied by a significant 
increase in absolute CD4 T cell numbers and percentages as well as by a 
significant decrease in the HIV viral load, due to ART. However, 
mycobacteria-specific T cell responses, (those that produce IFN-! and IL-2) 
did not correlate with the ability to restrict growth prior to and during the first 
12months of ART. Interestingly, the percentage of IL-2-producing numbers of 
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CD4 T cells did correlate with growth inhibition by 12 months. Mycobacterium 
tuberculosis has a broad repertoire of antigens. Thus, although highly 
recognized by the immune system, Ag85B and TB10.4 might not represent 
antigens associated with virulence, since they are also found in BCG and 
environmental mycobacteria. The responses to these selected antigens is 
likely to be different from the responses to the whole organism, which is what 
is measured in the lux assay. 
 
In agreement with our work with BCG lux this study also showed a significant 
correlation between CD4 T cell numbers and growth ratios when using MTB 
lux. Our previous work using this model has confirmed the critical role of CD4 
T cells in mediating this growth restriction, because the in vitro depletion of 
CD4 T cells using magnetic beads leads to enhanced growth of mycobacteria, 
in line with the in-vivo depletion of CD4 T cells in HIV-infected children 
(Kampmann et al., 2000; Tena et al., 2003) associated with the highly 
increased susceptibility to tuberculosis. Interestingly, the control of 
mycobacterial growth and reconstitution of CD4 T cell numbers did not result 
in increased levels of IFN-! in our previous study, using BCG lux, suggesting 
the involvement of additional pathways of TB immunity. We previously only 
measured secreted levels of IFN-! using ELISA technique, which cannot 
identify the source of the cytokine. In this study, we wished to additionally 
identify the source of the cytokine IFN-! and also measure antigen-specific IL-
2 as a marker associated with central memory. 
 
The extent of reconstitution of cellular immunity through ART is not fully 
understood (Lawn et al., 2005), and very few studies have been conducted in 
HIV-infected children on ART (Resino et al., 2003; Resino et al., 2004). Most 
of these studies have used non-specific antigens. Work in adults attributes 
antigen-specific immune recovery to the presence of memory CD4 T-cells. 
However, the scale of immune-recovery differs depending on the nadir CD4 
cell count and the antigens investigated (Lange et al., 2002; Wendland et al., 
1999). 
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As previously observed in our studies using the BCG lux model, ART 
reversed the CD4 T cell deficiency caused by HIV infection, but cytokine 
production by CD4 and CD8 T cells in response to mycobacterial antigens 
related poorly to the ability to control mycobacterial growth. This probably 
reflects the only partial recovery of the mycobacterial immune response after 
initiation of ART in HIV infection, or the time period of sustained viral 
suppression needed to achieve more comprehensive immune recovery is 
much longer than the 12 months of follow-up in our current study. The details 
of restoration of immune function in HIV-infected adults on ART are still poorly 
understood and even less data exist in children. It has been suggested that in 
order for the recall response to recover after initiation of ART, HIV viral load 
should remain persistently low for a prolonged period (Li et al., 1998). 
However, substantial decrease in HIV replication did not translate to 
increased antigen-specific responses in the HIV-infected children in our study. 
Only a small percentage of individuals show reactivity to tuberculin after 
initiation of ART (Wendland et al., 1999; Girardi et al., 2002).  
 
We did not conduct a tuberculin skin test in our population. Recovery of IFN-! 
production, a more common measure of lymphocyte responsiveness, is partial 
and delayed. Immune reconstitution using ART is likely to lead to a re-
expansion of surviving memory T cells, as shown in adults (Emery and Lane, 
1997; Lange et al., 2002), but the timing and extent have not yet been fully 
established. In contrast to adults, the increase in CD4 T cells in children in 
response to ART is seen predominantly with the CD45RA (naive) phenotype 
(De Rossi et al., 2002). Thymic output of T cells is recognized to be greater in 
children, and TCR excision circle assays confirm that a high proportion of 
cells are recent thymic emigrants. These T cells are not antigen experienced, 
and might not necessarily produce IFN-! in response to mycobacteria. This is 
in line with our flow cytometric measurements reported in chapter 5: the 
immune reconstitution we observed was largely due to naïve CD4 T cells and 
we did not see a significantly enhanced effector memory response. 
 
Interestingly though, the growth inhibition in the lux assay was maintained 
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throughout the study period and did correlate well with absolute CD4 counts 
and percentages, but not with antigen-specific T cell populations. However, 
growth inhibition did correlate with IL-2 producing CD4 T cells, when adjusted 
for total percentage number of CD4 T cells. As far as IFN-! is concerned, this 
observation can be interpreted in several ways: either the increasing numbers 
of naïve CD4 T cells made it impossible to appreciate the very small changes 
within the antigen-specific populations measurable by the flow cytometric 
technique, or antigen-specific T cell responses were not adequately reflected 
by enumerating IFN-! and IL-2 as the only intracellular cytokines. 
Alternatively, frequency of antigen-specific T cells correlate badly with growth 
inhibition and other immune mechanisms play a role, which we did not 
capture in our experimental set-up, beyond the total numbers of CD4 T cells. 
 
This is of some concern, since many investigators measuring “vaccine take” in 
vitro rely exclusively on measurements of th  increased induction of 
polyfunctional antigen-specific CD4 and CD8 T cell responses in their 
immuno-assays. However, our study did not show that such measurements 
correlate with the key effector function of growth inhibition in our model. 
 
However, the observation that by 12 months percentages of IL-2 producing 
CD4 T cells in response to Ag85/TB10.4 did show a correlation with growth 
restriction is in line with the anticipated recovery of the central memory 
compartment under ART. Wilkinson et al recently showed that although the 
relative percentages of cytokine-producing CD4 T cells decreased in HIV-
infected adults receiving ART, the absolute number of IL-2 secreting T cells 
increased, as measured via Elispot. Our data now illustrate a similar finding 
and relate this to anti-mycobacterial activity in vitro, which has not been 
shown previously. 
 
Our findings highlight the complex interplay of different mechanisms of 
immunity involved in the containment of mycobacteria and may reflect the 
differences in components of the immune response that are measurable in 
any of these assays and may vary according to time intervals. Individual 
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cytokines alone might not be good indicator of protective immunity. Rather a 
combination of factors including those that mediate reduced mycobacterial 
growth may better reflect this complexity. Researchers have reported IFN-!-
independent mechanisms of M. tuberculosis control in murine models in vitro 
and in vivo (Cowley and Elkins, 2003). Other mechanisms of growth inhibition 
could involve cytotoxic or apoptotic functions, mediated by granzymes/perforin 
and FAS/FAS ligand interactions, respectively (Oddo et al., 1998; Serbina et 
al., 2000). 
 
Future studies aiming to identify the “right” correlates of protection to be 
induced by novel TB vaccines should possibly use a combined approach of 
measurements of antigen-specific host responses as well as functional growth 
inhibition assays to identify the most suitable candidates to move forward in 
vaccine trials. Moreover, an in vitro system may also facilitate a systematic 
evaluation of mycobacterial antigen for their ability to induce effective in vitro 
immunity, and thus provide a screening method for evaluating vaccine 
candidates, as we had already shown for the BCG vaccine (Kampmann et al., 
2004). 
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CHAPTER 7: 
 
General discussion 
 
The findings of this thesis are relevant for the assessment of novel TB 
vaccines, as they provide background data of sensitization to mycobacterial 
antigens from a TB-endemic population of children with and without HIV-
infection. These are the types of cohorts in which current and future trials of 
novel TB vaccines are placed, and it is important to know about the existing 
background responses, which might play a role in the assessments of 
“vaccine take”. 
 
In this thesis, we show evidence of the successful development and 
application of the powerful tools of multiparameter flow cytometry to small 
whole blood samples collected from childhood populations. We were 
successful in the development of a complicated multi-colour, multiparameter 
panel for flow cytometric analysis of rare events, combined with the ability to 
phenotype the memory T cells. This panel took a long time to develop but is 
now in use by our own group and has inspired the use of similar 
fluorochromes by other users in the group. As always, the limitations lie with 
the still limited amount of parameters, which can be measured simultaneously 
when using flow cytometry, the long process of optimising the panel and the 
more complicated data analysis required when many parameters are 
included. This is an innate problem with flow cytometry, which is offset by the 
ability of the tool to characterise phenotype and function at the single cell 
level. 
 
We were able to measure all parameters in comparatively small volumes of 
blood, which are ideal for studies in children, as conducted for this thesis. 
By applying the flow cytometric methods in this study we found that a 
substantial proportion of children have mycobacteria-specific T cell 
populations, expressing IFN-! and/or IL-2, which potentially could be 
augmented by new vaccines in a heterologous boosting strategy. We have 
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examined these responses in 3 different groups of children and have found 
sizeable responses, even in HIV-infected individuals. Our data illustrate the 
enormous inter-individual variability between donors, which led to the 
observation that there were no significantly different responses measurable 
between HIV-infected children and healthy, HIV-negative children. This clearly 
differed from our hypothesis. A limitation is the study size and potentially age 
of the children, although the ages were carefully matched and no correlation 
was found between age and antigen-specific responses in either HIV-positive 
or negative children. It is likely that the antigen-specific responses mirror 
natural exposure and that the exposure is similar in all cohorts, as they reside 
in the same TB-endemic environment. 
 
Few studies have conducted careful phenotyping of mycobacteria-specific 
memory responses in children living in TB endemic settings to date. We have 
gathered data on antigen-specific and non-specific CD4 and CD8 populations, 
which show that the overall distribution of the memory phenotypes did not 
differ between the groups, but that the cytokine-producing CD4 and CD8 T 
cells had a clear effector memory phenotype. This confirms findings in adults 
and also in vaccine-induced responses. 
 
The additional experimental approach we chose was to combine the flow 
cytometric, single cell measurements with a functional assay of anti-
mycobacterial immunity, which we have previously used. Our previous results 
had already validated this model in the context of BCG vaccination and 
immune reconstitution in children receiving ART, but we now wished to test 
the model using the virulent H37Rv strain of M. tuberculosis (MTB lux), again 
genetically modified with the luciferase genes. 
 
We were able to show concordant results compared with the use of BCG lux. 
In addition we could correlate the mycobacterial growth restriction with total 
numbers of CD4 T cells, but not with antigen-specific or polyfunctional 
responses. The exception was the observation that at 12 months, 
mycobacterial growth restriction correlated with production of IL-2 by antigen-
specific CD4 T cells. This is encouraging, since the recovery of central 
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memory has been observed in adult HIV-infected patients receiving ART 
(Wilkinson et al., 2009), but this has not been correlated with functional ability 
to contain mycobacteria in vitro. This observation only occurred at the later 
time-point, possibly indicating the need for prolonged immune reconstitution 
with ART to achieve better immunological control. 
 
However, we did not observe a significant correlation between polyfunctional 
T cell responses and mycobacterial growth restriction, suggesting that 
polyfunctional T cells may not mediate a detectable in vitro protective effect. 
Polyfunctional T cells are frequently measured to gauge “vaccine take” or 
immunogenicity of candidate TB vaccines with the hypothesis that these cells 
may be the best estimate of protective T cell responses. Our data support a 
recent paper from our group that identified the lack of such a correlation 
between polyfunctional T cells and protection against TB in BCG-vaccinated 
infants, where infants who developed TB were compared with matched 
controls who did not develop TB (Kagina et al., 2010). No difference in the 
frequencies of polyfunctional T cells was found between the 2 groups. 
 
Unfortunately, we still do not know if measurable parameters routinely 
evaluated in TB vaccine development will correlate with lower risk of TB in 
children in either natural exposure or following vaccination. We acknowledge 
that we have not shown protection against tuberculosis in our studies, but it 
might still be important to include additional assays such as the lux assay, 
which have a functional read-out of anti-mycobacterial immunity in future 
studies of novel TB vaccines. 
 
In summary, this work has led to a comprehensive characterisation of 
mycobacteria-specific CD4 and CD8 responses in HIV-infected and 
uninfected children, including the assessment of memory, functional anti-
mycobacterial capabilities and the impact of ART. We hope that in the future, 
safe, novel TB vaccines are tested rapidly in HIV-infected children, since they 
remain particularly vulnerable to developing TB. The best time to vaccinate 
this group might indeed be prior to depletion of their cellular immune 
responses and again after ART-induced recovery of their naïve and central 
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memory populations. This group of children might also benefit from 
revaccination, as ART might not fully restore vaccine-induced immunity 
established before the start of therapy. However, levels of immunity or 
memory to pathogens might need to be monitored and some children might 
need additional vaccine doses to restore or maintain immunological memory 
to pathogens. 
We believe that our work has contributed to knowledge in this field. 
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